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Introduction
injuries where there is a risk of transmission of infection frequently present in emergency 
departments, occupational health departments and primary care settings. Bloodborne virus 
(BBV) infections  such as hepatitis B (HBV), hepatitis C (HCV) and human immunodeficiency 
virus (HiV) are of particular concern because of the potential long-term health effects 
for people who become infected, the anxiety experienced by the injured persons,  and 
the increase in their prevalence in the population in recent decades. the appropriate 
management of such injuries, in the emergency and follow-up periods, has important 
implications in terms of minimising the risk of transmission of BBVs and in allaying the 
psychological impact on the injured person.
Many emergency departments and occupational health departments throughout ireland 
have developed guidelines for the management of injuries where there is a risk of BBV 
transmission. However, these guidelines differ in their scope (eg all BBVs versus HiV; all 
exposures versus occupational or sexual), their level of detail, and recommended actions, 
such as testing schedules and the use of post-exposure prophylaxis (PEP). the development 
of these guidelines was prompted by the idea of having standardised guidelines on the 
management of these injuries that could be used in all relevant settings throughout the 
country and that would be based on best available evidence and expert opinion.
Purpose and scope
the purpose of these guidelines is to provide comprehensive guidance on the appropriate 
management of injuries where there is a risk of transmission of BBVs and other infections. 
the guidelines are intended for use as follows:
Setting: Any medical setting where the patient first presents with the injury, for example, a 
hospital emergency department or occupational health department, a general practice, a 
dental practice, a Garda occupational health department, a clinic for sexually transmitted 
infections or a sexual assault treatment unit (SAtU).
Patient population: Members of the public in a healthcare or community setting; healthcare 
workers (HCW) or other workers (eg members of the Garda or defence forces) in an 
occupational setting; adults and children; both recipients and sources of injuries.
Type of injury: Needlestick or other sharps injury, sexual exposure, human bites, exposure 
of broken skin or of mucous membranes. these guidelines do not cover injuries where the 
source is an animal.
Time: Emergency management on first presentation, and also arrangements for any 
necessary follow-up.
Content
the guidelines cover the following aspects of management: first aid, risk assessment, 
testing, treatment (including PEP for HBV and HiV), counselling and follow-up, records and 
documentation. Although the focus is mainly on BBVs, the management of other risks is 
also covered in brief.
BaCkGround to the GuIdelInes
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The main questions covered by the guidelines are:
• What first aid treatment should be administered?
• Is the exposure significant?
o What materials are significant for BBVs?
o What injuries are significant for BBVs?
• How to assess the risk of transmission of BBVs?
o What is the level of risk of HBV, HCV or HIV?
o What factors in the injury increase the risk of transmission?
• How should the source be investigated?
• How should the recipient be investigated?
• What blood tests should be done and when?
•  Who should receive HBV vaccine and/or hepatitis B specific immunoglobulin (HBIG)?
•  When is HIV PEP indicated and what treatment protocol should be used?
•  How should HCV exposure be managed?
•  What reassurance can be given to the recipient?
•  What precautions are advised?
•  What follow-up is needed?
the content is arranged as follows:
1. Main body of text – a summary protocol for case management from presentation to 
discharge.
2. Appendices – stand-alone flow charts and tables; data collection forms; template 
letters and information leaflets; detailed discussion and evidence base for specific 
aspects of assessment or treatment.
Methods
Working group
the working group that developed the guidelines is a sub-committee of the Scientific 
Advisory Committee (SAC) of the Health Protection Surveillance Centre (HPSC), and 
included professionals with the relevant expertise and experience, and target users of the 
guidelines. the disciplines represented were dentistry, emergency medicine, infection 
prevention and control nursing, infectious diseases, medical microbiology, occupational 
medicine (hospital and Garda), and public health medicine. the members were chosen 
to represent a professional body or because of their individual expertise. the irish College 
of General Practitioners (iCGP) was unable to provide a representative but agreed to be 
available for consultation during the course of the guidelines development. the members of 
the working group and the organisations they represented are listed on page 10.
Search protocol
in developing the recommendations in these guidelines various sources of guidance were 
reviewed. initially, existing guidelines for the management of needlestick injuries, bites, 
and other blood and sexual exposures were reviewed. these included policies and standard 
operating procedures from emergency departments, occupational health departments, 
infectious diseases services and community health care settings in ireland. Guidelines from 
several Uk services were also reviewed. Existing irish guidelines on immunisation and the 
prevention of transmission of bloodborne viruses were included in this review. international 
documents were also examined, eg National institute for Health and Clinical Excellence 
(NiCE) guidelines, Centers for Disease Control and Prevention (CDC) sources and reviews 
from the Cochrane Database of Systematic Reviews. information which was deemed 
relevant for the purpose of developing these guidelines was extracted from these sources by 
working group members, and then discussed at the working group meetings to ensure that 
the guidance selected was appropriate for use in various settings throughout ireland. 
eMI Guidelinestool
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in order to provide information for patients and their practitioners on the possible risk of 
transmission following different exposures, comprehensive reviews of reliable published 
resources were conducted by the working group members. A new detailed systematic review 
was not considered necessary, as it was felt by committee members that this would only 
replicate reviews which have already been published elsewhere, and would not have been 
feasible within the time allowed for the development of these guidelines. instead, available 
published resources were thoroughly reviewed, and their recommendations were appraised 
by the working group in terms of the reliability of the source, as well as their applicability 
and operability within irish healthcare settings. 
Where insufficient evidence or guidance was available from these sources, or where there 
were discrepancies in the information or recommendations from several reliable sources, 
evidence was sought from original research published in journal articles. Searches were 
conducted using appropriate MeSH search terms to find the available evidence, and this 
was further appraised by the working group. the MeSH headings included: hepatitis B; 
hepatitis B virus; hepatitis C; hepatitis C virus; HiV; transmission; needlestick injuries; 
bites, human; mucous membrane; sexually transmitted diseases; viral. We searched in 
MEDliNE, and Embase, and conducted detailed searches in the BMJ, the lancet, and other 
core journals relevant to the transmission of HiV, HBV and HCV eg AiDS, Clinical infectious 
Diseases, infection Control and Hospital Epidemiology, occupational Medicine, American 
Journal of Epidemiology, Journal of the American Dental Association. Articles relating to 
perinatal or vertical transmission were excluded, as were articles not in English, and articles 
which were not available in full for review. 
A recognised limitation during the development of these guidelines was that, in some areas, 
clear evidence from research was not available. Where discrepancies or gaps existed in the 
available guidance and evidence, expert opinion was sought, both from within ireland, and 
abroad. For example, in considering the risks from exposure to saliva following an injury 
such as a human bite, extensive consultation with international oral health experts was 
conducted. 
Consultation
the consultation exercise was carried out as follows:
the draft document was sent to the HPSC SAC in october 2011 and to key stakeholder 
groups and individuals for consultation in December 2011
the draft document was placed on the HPSC website for general consultation in December 
2011. A notice about this posting appeared in the HPSC monthly on-line bulletin, Epi-
insight, in January 2012
eMI Guidelines tool
k
it
eMI Guidelines
-7-
t
o
o
l
k
it     
eMI Guidelines
the following are the groups to which the draft document was sent for consultation:
Academy of Medical laboratory Science
An Bord Altranais
Consultants in Emergency Medicine
Consultant Microbiologists 
Consultant Paediatricians
Cork University Dental School and Hospital
Department of Health and Children, CMo’s office
Directors of Public Health
Dublin Dental University Hospital
Health information and Quality Authority 
Health and Safety Authority
HSE infection Control Nurses
HSE integrated Services Directorate 
infection Prevention Society
infectious Diseases Consultants 
infectious Disease Society of ireland
irish Blood transfusion Service
irish College of General Practitioners
irish Dental Association
irish Faculty of Primary Dental Care
irish Patients’ Association
irish Prison Service
irish Society of Clinical Microbiologists
National AiDS Strategy Committee (NASC) 
occupational Health Nurses Association of ireland 
occupational Medicine Consultants 
RCPi Faculty of occupational Medicine 
RCPi Faculty of Paediatrics
RCPi Faculty of Pathology
RCPi Faculty of Public Health Medicine
RCSi Faculty of Dentistry
Royal College of Physicians of ireland
Royal College of Surgeons in ireland
Sexual Assault treatment Units 
Specialists in Public Health Medicine
 
t
o
o
l
k
it
eMI Guidelines
-8-
t
o
o
l
k
it
Acknowledgements
the working group is very grateful to the following people and organisations who assisted in the 
development of the guidelines or provided feedback on the consultation document:
Dr Doron J Aframian, Hebrew University-Hadassah School of Dental Medicine, Jerusalem
Professor Jeremy Bagg, University of Glasgow Dental School, Scotland
Ms orla Bannon, Health Protection Surveillance Centre
Professor David Brown, Virus Reference Department, Health Protection Agency, london
Dr Donal Collins, Garda Siochána occupational Health Department
Dr Jeff Connell, National Virus Reference laboratory, UCD
Professor Esmonde Corbet, University of Hong kong
Ms Patricia Coughlan, infection Prevention and Control Nurse, HSE South
Professor Stephen Cusack, Emergency Medicine, Cork University Hospital
Dr Eoghan De Barra, Mater Misericordiae University Hospital, Dublin
Ms Sheila Donlon, Health Protection Surveillance Centre
Professor Stephen Flint, Dublin Dental School and Hospital
Dr Wendy Ferguson, Rotunda Hospital
Mr Steve Gruninger, American Dental Association
Dr Julie Heslin, Department of Public Health, HSE South East
irish Antimicrobial Pharmacists Group, on behalf of the Hospital Pharmacists Association of ireland
Professor Mike lewis, School of Dentistry, Cardiff University
Dr Shay keating, Drug treatment Centre Board
Dr Jean lane, Daughters of Charity Services for People with intellectual Disability
Dr Jean long, Alcohol and Drug Research Unit, Health Research Board
Dr therese long, organization for Safety, Asepsis and Prevention, Maryland, USA
Ms kirsty Mackenzie, Health Protection Surveillance Centre
Ms Marie Mahon, Mayo General Hospital, HSE West
Dr Ellen McSweeney, irish Blood transfusion Service
Dr Daniel Malamud, NYU College of Dentistry
Professor Antonio Mata, Faculty of Dentistry, University of lisbon, Portugal
Ms Nuala Moore, irish Blood transfusion Service
Ms Niamh Murphy, Health Protection Surveillance Centre
Ms Frances Nangle o’Connor, irish Prison Service
Dr Cliona Ni Cheallaigh, Mater Misericordiae University Hospital, Dublin
Professor Brian o’Connell, Dublin Dental School and Hospital
Ms Anne Maria o’Connor, Health and Safety Authority
Dr Aidan o’Hora, Health Protection Surveillance Centre
Dr John o’keefe, Canadian Dental Association
organization for Safety, Asepsis and Prevention (oSAP), USA
Dr Patrick o’Sullivan, Department of Public Health, HSE Mid West
Ms Grainne Parker, Communicable Disease Control Nurse, HSE South East
Mr Mick Quinlan, Gay Men’s Health Service, HSE
Dr Fiona Ryan, Department of Public Health, HSE South 
Dr Gerard Sonder, Department of infectious Diseases, Public Health Service, Amsterdam
Professor Arie van Nieuw Amerongen, Academic Centre for Dentistry, Amsterdam
Mr Pete Wedderburn, Veterinary Surgeon, Bray, Co. Wicklow
Members of the HPSC Scientific Advisory Committee
eMI Guidelines tool
k
it
eMI Guidelines
-9-
t
o
o
l
k
it
eMI Guidelines
in developing the EMi guidelines, the working group reviewed existing guidelines that were in 
use in many healthcare settings throughout the country. the working group would like to thank 
all those who kindly shared these documents with us and allowed us to use extracts from the 
documents:
•  Beaumont Hospital, Dublin - Occupational Health Department
•  Cork University Hospital – Emergency Department
•  Galway University Hospital – Emergency Medicine and Occupational Health Departments
•  Garda Siochána – Occupational Health Department
•  HSE Dublin North East – Occupational Health Department
•  HSE West (Mid-West) – Occupational Health Department
•  Mater Misericordiae University Hospital, Dublin – Departments of Infectious Diseases, 
Emergency Medicine, Risk Management, occupational Health, and Pharmacy
•  Our Lady’s Children’s Hospital, Crumlin – Infectious Diseases and Emergency Departments
•  Rotunda Hospital, Dublin – Sexual Assault Treatment Unit
•  St James’s Hospital, Dublin – GUIDE Clinic and Emergency Medicine, in association with the Gay 
Men’s Health Service, HSE
•  St Vincent’s University Hospital, Dublin – Occupational Health and Emergency Departments
•  Waterford Regional Hospital – Emergency Department
t
o
o
l
k
it
t
o
o
l
k
iteMI Guidelines
-10-
Members of the guidelines working group (and organisations they 
represented)
Dr Anthony Breslin, Specialist in Public Health Medicine, HSE North West (Faculty of Public Health 
Medicine, Royal College of Physicians of ireland).
Dr tomás Breslin, Consultant in Emergency Medicine, Mater Misericordiae University Hospital 
(irish Association for Emergency Medicine).
Dr Susan Clarke, Consultant in infectious Diseases, St James’s Hospital (infectious Diseases 
Society of ireland).
Dr Brendan Crowley, Consultant Clinical Microbiologist, St James’s Hospital (irish Society of 
Clinical Microbiology).
Dr tom Feeney, Dental Practitioner, Blackrock, Co. Dublin (irish Dental Association).
Dr Deirdre Fitzgerald, Specialist Registrar in occupational Medicine, AMNCH Hospital (Medical 
Secretary to group from January 2011).
Ms Mary Clare kennedy, infection Prevention and Control Nurse, St luke’s General Hospital, 
kilkenny (infection Prevention Society).
Dr Una kennedy, Consultant in Emergency Medicine, St James’s Hospital (irish Association for 
Emergency Medicine).
Dr Jack lambert, Consultant in infectious Diseases, Mater Misericordiae University Hospital.
Dr oghenovo oghuvbu, occupational Health Physician, Garda Siochána occupational Health 
Department.
Dr Coilín Ó hAiseadha, Specialist Registrar in Public Health Medicine, HSE South East (Medical 
Secretary to group until December 2010).
Dr Alex Reid, occupational Health Physician, AMNCH Hospital, (Faculty of occupational Medicine, 
Royal College of Physicians of ireland).
Dr lelia thornton, Specialist in Public Health Medicine, Health Protection Surveillance Centre 
(Chair). 
Ms Aoibheann o’Malley, Health Protection Surveillance Centre, was administrative secretary to 
the group.
t
o
o
l
k
it
t
o
o
l
k
it eMI Guidelines
-11-
the GuIdelInes
t
o
o
l
k
it
t
o
o
l
k
it
-12-
the GuIdelInes
1. Introduction
1.1   these guidelines are intended for use in emergency medical settings where a patient first presents 
with an injury (including needlestick or other sharps injury, sexual exposure, human bite, exposure 
of broken skin or of mucous membranes) where there is a risk of transmission of infection, in 
particular bloodborne viruses (BBV). these guidelines are relevant to injuries occurring to members 
of the public in a community setting and also to injuries sustained occupationally (such as to 
healthcare workers (HCW) or members of the Garda).
1.2   the terms “recipient” and “source” will be used throughout these guidelines:
 Recipient: the person who sustains the injury
  Source: the source of the potentially infected material, eg the person on whom the sharp was used, 
the person who bites, or the source of the blood or body fluid.
1.3    the BBVs considered in these guidelines are hepatitis B virus (HBV), hepatitis C virus (HCV) and 
human immunodeficiency virus (HiV).
2. Initial assessment
See appendices 1-6: 
• Patient management form
• Flow chart for management of injuries
• Algorithm for needlestick/sharps exposure
• Algorithm for mucous membrane exposure
• Algorithm for sexual exposure
• Algorithm for human bite exposure
Note: If the recipient is a healthcare worker (HCW), they should not manage the incident 
themselves. Another appropriate health professional should take over responsibility.
2.1   Urgent first aid treatment should be administered if required. Urgent assessment should be made 
regarding the need for HiV post-exposure prophylaxis (PEP). (See appendix 7 for HiV PEP) 
2.2  Initial wound care
 2.2.1  For contaminated needlestick injuries, sharps injuries or human bites:
   Encourage the wound to bleed.
   the recipient should not suck the injury site.
    irrigate the wound thoroughly with running water and soap. A nailbrush should not be used.
   Dry, and cover the wound with a waterproof dressing if necessary.
 2.2.2  For contamination of the conjunctiva or mucous membranes:
    immediately irrigate the area with copious amounts of normal saline or water. For a splash to 
the eye, this irrigation should be done before and after removal of contact lenses.
 2.2.3  Full clinical assessment should be carried out
    Examine for signs of infection, foreign bodies, damage to blood vessels, nerves, tendons, 
joints or bones (this is particularly important for human bites).
   Assess whether the injury has broken the skin.
2.3 Complete the Patient Management Form (appendix 1):
•  Document who was injured, how, when and the type of injury.
•  Record vaccination status (hepatitis B, tetanus), underlying medical conditions including 
immunosuppression, medications, and allergies.
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2.4 Decide if a significant exposure has occurred.
 2.4.1  Assessment of significance of exposure
   A significant exposure involves both a high-risk material and a significant injury.
 2.4.2  High-risk materials (ie significant risk of transmission of BBVs):
    Blood, body fluids containing visible blood, semen and vaginal secretions represent a risk of transmission 
of HBV, HCV or HiV, if the source is infected.1
   (See appendices 21-27 for information about HBV, HCV and HiV)
    outside the body, HCV and HiV significantly decline in infectivity within a few hours. HBV can remain 
infectious for a week or more.
 2.4.3  Low-risk materials (ie no significant risk of transmission of BBVs):
    Contamination with faeces, nasal secretions, saliva*, sputum, sweat, tears, urine, and vomitus, unless they 
contain blood, represents a negligible risk of HBV, HCV or HiV transmission. 
    *if the injury is serious (eg extensive or deep tissue bite) HBV transmission may be a risk, even if there is 
no visible blood in the saliva. in this situation, HBV vaccine with or without HBiG may be indicated (see 
appendix 6 for algorithm for human bite exposure, appendix 8 for HBV PEP and appendix 18 for discussion 
of human bite injuries and saliva).
 2.4.4  Other materials:
   the risk of transmission of BBVs from exposure (eg splash) to the following fluids is unknown:
    Cerebrospinal fluid, synovial fluid, pleural fluid, peritoneal fluid, pericardial fluid, breast milk and amniotic 
fluid. if the source has a high blood viral load, the viral load in other fluids, such as amniotic fluid, is also 
likely to be high.
 2.4.5  Significant injuries include: 
    •  Percutaneous injuries 
   •  Human bites which break the skin, ie involving a breach of the epidermis, not just bruising or indentation 
of the skin (see appendix 18 for discussion of human bite injuries). 
   •  Exposure of broken skin to blood or body fluids.
   •  Exposure of mucous membranes (including the eye) to blood or body fluids, eg by splashing.
   •  Sexual exposure (unprotected). 
 2.4.6  Non-significant injuries include:
   •  Superficial graze not breaking the skin.
   •  Exposure of intact, undamaged skin to blood or body fluids.
   •  Exposure to sterile or uncontaminated sharps.
 2.4.7  Non-significant exposure
    if the incident involves exposure to a low-risk material or a non-significant injury, no further testing or 
examination is required. The patient should be reassured and discharged. the patient should be given 
an information leaflet (appendix 28) and a discharge letter (appendix 36) to give to their GP, indicating 
that no significant exposure occurred, outlining any testing or treatment carried out, and indicating if any 
follow-on care is needed, such as HBV vaccination or wound care.
The following sections relate only to 
significant exposures
eMI Guidelines
t
o
o
l
k
it
-14-
The remainder of the guidelines relate 
only to significant exposures
3. Assessing the risk of transmission of infection
3.1  Risk assessment - bloodborne viruses
  (See appendices 21 to 27 for information about HBV, HCV and HiV)
  Where a significant exposure has occurred, a risk assessment should be carried out to 
estimate the risks of transmission of HBV, HCV and HiV. this should take account of the 
following:
 •  the infectious status (HBV, HCV, HiV), if known, of the source.
 •  if the source is unknown or refuses testing, information may be available about whether the 
source has risk factors for BBVs (such as: injecting drug user (iDU), prisoner, commercial 
sex worker (CSW), men who have sex with men (MSM), born in an endemic country (see 
appendices 22, 24, 26 for maps), sexual partner with a risk factor). 
 •  knowledge of the background prevalence of BBVs in the population and in risk groups 
may be helpful. knowledge of the prevalence of iDUs in the local population may also be 
helpful.
 •  the nature of the exposure, including the type of injury and the type of material involved.
 •  the HBV vaccination status of the recipient.
 •  the infectious status (HBV, HCV, HiV), if known, of the recipient.
3.2  Factors increasing the risk of transmission of BBV infection:
 •  Deep percutaneous injuries
 •  Visible blood on injuring device
 •  Hollow needle from source patient artery or vein
 •  large bore needle
 •  Visible blood (of the biter) in mouth of biter 
 •  Blood containing a high viral load of HBV, HCV or HiV
 •  the presence of HBeAg in source
 •  Higher volume of material
 •  Personal protective equipment, eg gloves, goggles, not worn (HCWs)
 • Sexual exposure due to aggravated sexual intercourse
 • Sexual exposure in men who have sex with men
 • Sexual exposure in the presence of concurrent STIs.
3.3  Investigation of source
 (See Appendix 30: Checklist: Testing of source person or recipient)
  in the case of a significant exposure, every effort should be made to ascertain the HBV, HCV 
and HiV status of the source.
 3.3.1    If the source is known
  Where the incident occurred in a hospital and the source is a patient in the hospital, the 
consultation with the source should be carried out by a member of his/her treating team. 
When the incident occurred outside the hospital, the consultation and blood testing of the 
source should be carried out by another suitably qualified health professional eg primary 
care provider, prison healthcare team.
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 Explain to the source in simple language exactly what has happened.
 Ask if they are known to be infected with HBV, HCV or HiV.
  Ask if they have risk factors for BBVs, eg iDU, CSW, MSM, born in an endemic country (see 
maps in appendices 22, 24, 26), sexual partner with a risk factor.
 Ask if they are immunocompromised.
  if their BBV status is unknown, request permission from the source, either directly or through 
their doctor, to take a blood sample for testing for: HBV (hepatitis B surface antigen - HBsAg), 
HCV (antibody to hepatitis C - anti-HCV) and HiV (HiV antigen/antibody - Ag/Ab). if the 
recipient is known to be HBV immune, then the source need not be tested for HBV. if the 
source is HBsAg positive, then hepatitis B e-antigen (HBeAg), antibody to HBeAg (anti-HBe) 
and HBV viral load should be carried out to estimate the risk of transmission. if the source is 
anti-HCV positive, a HCV ribonucleic acid (RNA) test, and viral load if RNA positive, should be 
carried out as soon as possible. if the source is HiV Ag/Ab positive, a HiV viral load should be 
done to estimate the risk of transmission. 
  if the source is likely to be in the window period for infection with a BBV, a repeat sample 
should be requested at 3 months. 
  informed consent must be obtained for this testing (see below). Explain why the tests are 
being done, exactly what tests will be carried out, and the implications for them if a test result 
is positive. the source must be informed that they are free to refuse to provide a sample or to 
have this testing carried out. An information leaflet should be provided (appendix 31). if the 
source refuses consent, this fact should be recorded by the health professional.
  the source should be told that the result will be provided by the testing laboratory to their 
nominated doctor (general practitioner (GP) and/or consultant) and that the recipient will 
also be told the result. the confidential nature of the testing process should be emphasised. 
if, as a result of the outcome of this testing, follow-up care is necessary for the source person 
(eg referral to an infectious diseases consultant), this is the responsibility of the hospital 
consultant if the source is a patient in hospital, or the source person’s GP. if the source is not 
registered with a GP, then it is the responsibility of the doctor who ordered the test to ensure 
that appropriate follow-up is arranged.
  the laboratory should be advised to expect an urgent blood sample and asked to provide the 
results as soon as possible. the sample may need to be sent by courier.  the sample (10mls 
of clotted blood) should be marked “Urgent. Possible bloodborne virus exposure – source” 
and should indicate to whom results should be sent. if an RNA test is required, arrangements 
should be made with the testing laboratory. A second blood sample will be required. Results 
of source blood tests should be available from the laboratory to allow a decision to be made 
as soon as possible. in some situations, the urgency with which the blood test is taken and 
sent to the laboratory is dictated by the circumstances and risk assessment. if a delay is likely 
and the source is high-risk, consider whether HiV PEP should be started while waiting for the 
HiV test result. the laboratory should be asked to retain part of the sample for storage for two 
years. 
 3.3.2 Informed consent         
  the components of a legally valid consent are that it must be given by a person with the 
capacity to consent, it must be given voluntarily and not under any duress or coercion and the 
person must be given sufficient information to allow them to make a decision. Fully informed 
consent requires a clinician to disclose to the person the reason for the test or procedure, the 
benefits and all of the material risks associated with the test or procedure together with the 
consequences of having or not having the test or procedure and the person understands the 
information that has been provided, and has been given an opportunity to consider and weigh 
it up in order to make a decision.  
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 3.3.3 If the source is unknown or known but refuses testing 
  Assess the risk based on any available information, including the circumstances of the 
exposure and the epidemiological likelihood of BBV in the source (prevalence of BBVs 
in the population, known risk environment such as prison, or risk behaviours if source is 
known). the use of HiV PEP is unlikely to be justified in the majority of such exposures 
but HBV immunisation may be appropriate.
  Consent is required by a clinician who treats, examines, tests or operates on a 
person and to do so without that person’s consent would result in that clinician/
nurse committing an unlawful act.  there are exceptions to this principle, usually in 
exceptional or emergency cases where the treatment is necessary to save the life of or 
preserve the health of a person. to ensure the greatest level of protection to persons 
taking samples, where consent is not forthcoming, an application to Court should be 
made. this can be made at very short notice.
  
  If a blood sample from the source is available to be tested (eg it may have been taken 
for another purpose previously), is it acceptable to test it for bloodborne viruses, even if 
the source has refused consent or is unconscious or deceased?
  Under irish law, informed consent to testing should be obtained from the source prior 
to carrying out the test. Where this is not available, the permission of the Court to test 
should be obtained, save in exceptional circumstances where the treatment is necessary 
to save the life of or preserve the health of a person and there would not be sufficient 
time in which to make an application to Court. An application can be made to Court at 
very short notice.
  if a decision is taken to test the sample, the source person should be informed unless to 
do so would, in the doctor’s opinion, be harmful to the individual’s mental or physical 
health.
  If the source person is unconscious, is it acceptable to take a blood sample from them 
for testing?
  Under irish law, informed consent to testing should be obtained from the source prior 
to carrying out the test. Where this is not available, the permission of the Court to test 
should be obtained, save in exceptional circumstances where the treatment is necessary 
to save the life of or preserve the health of a person and there would not be sufficient 
time in which to make an application to Court. An application can be made to Court at 
very short notice.
  if a sample is taken from an unconscious person, they should be informed as soon as 
they regain consciousness unless to do so would, in the doctor’s opinion, be harmful to 
the individual’s mental or physical health.
  If the source person is deceased, is it acceptable to take a blood sample from them for 
testing?
  the position in relation to taking a sample from a deceased person is unclear. if consent 
from the next of kin is not forthcoming and in order to ensure the greatest level of 
protection to the person taking a sample, an application should be made to the Court for 
permission to take the sample. this can be made at very short notice
3.4  Assessing the recipient
 (See Appendix 30: Checklist: Testing of source person or recipient)
  in the case of a significant exposure:
  obtain details of HBV immunisation status if possible, including number of doses, dates, 
post-vaccination anti-HBs level.
  Ask if they have a HBV vaccination record card (HCWs, Garda and prison personnel are likely 
to have these).
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  Ask if they know their infectious status in relation to HBV, HCV or HiV.
  Explain why the tests are being done, exactly what tests will be carried out, and the 
implications for them if a test result is positive.
  informed consent should be obtained and documented before testing is carried out (see 3.3.2). 
An information leaflet should be provided (appendix 29).
  Give the recipient the option of having the blood tested at this time, or of having it held in the 
laboratory for possible testing at a later time. if testing is being carried out, request HBsAg, 
antibody to hepatitis B core antigen (anti-HBc), anti-HCV and HiV Ag/Ab. if the recipient 
is documented to have an adequate response to HBV vaccine, it is not necessary to test for 
HBsAg. See appendix 9 for testing schedule, including baseline tests and follow-up testing at 
6 weeks and 3 months as indicated.
  
  if the recipient was previously vaccinated but the anti-HBs level post-vaccination is unknown, 
and hepatitis B immunoglobulin (HBiG) administration (in addition to vaccine booster) is now 
being considered, it may be helpful to do an antibody to HBsAg (anti-HBs) test. if the anti-
HBs level is ≥10miU/ml, HBiG is not indicated. if anti-HBs is <10miU/ml, the result is of no 
assistance in making the decision about administering HBiG, as antibody level declines over 
time after vaccination but the person may still be protected due to immune memory. in this 
situation, assessment of other factors such as the severity of the exposure may assist in making 
the decision about HBiG.
  Some of the sample should be retained in the laboratory for storage for two years.
  if the source tests negative for HBV, HCV and HiV, the recipient can be reassured and testing 
of the recipient is not required (unless the source is at significantly high-risk for recent BBV 
infection – discuss with infectious diseases specialist if in doubt).
  See appendix 10 for interpretation of HBV results.
4. Treatment of recipient following a significant exposure
4.1  the actions to be taken will depend on the outcome of the risk assessment. 
  if the source blood test results are available and indicate that the source is negative for HBsAg, 
anti-HCV and HiV Ag/Ab, and the investigation has identified no obvious risk factors for BBVs 
in the source (ie unlikely that source is in window period for infection), then no further follow-
up of the recipient is required. they can be reassured and discharged. 
  However, even if it is deemed that there has been no risk from the current incident, if the 
recipient has not completed a course of HBV vaccination and may be at risk of HBV infection in 
the future, they should be encouraged to be vaccinated. 
  if the source test results are negative but significant risk factors for recent acquisition of BBVs 
have been identified in the source, they may be in the window period for infection and the 
incident may have to be managed as if potentially infectious.
  testing of the source may not be possible or may be delayed. Some actions (below) may need 
to be taken immediately and without having the results of source testing. 
  The following actions should be considered when the source is infected or potentially 
infected with a BBV:
4.2 Hepatitis B post-exposure prophylaxis
  Post-exposure, HBV vaccine is highly effective at preventing infection, provided that the vaccine 
is administered preferably within 48 hours but up to 7 days post-exposure. Due to the safety 
profile of HBV vaccine and the infectivity of HBV, a low threshold for initiating HBV vaccination 
is recommended (appendices 8 and 11 –  HBV PEP and Hepatitis B vaccine).2 in general, HBV 
vaccination should be offered to all patients who have had a significant exposure, unless they 
are already immune due to vaccination or past infection. 
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  the first dose of vaccine should be given in the health care setting where the person 
first presents. Give the patient a HBV vaccination record card with the first dose entered 
(appendix 12). Arrangements should be made for further doses of vaccine to be delivered 
either by the GP, occupational health service, Sti/GUM clinic or infectious diseases clinic as 
appropriate. if the GP has any queries with regard to such follow-up, they should seek advice 
from their department of public health or infectious diseases service.
  HBiG, in addition to HBV vaccine, may be used in limited circumstances to confer passive 
immunity after exposure to HBV (appendix 13). HBiG provides short-term protection (3-6 
months). HBiG should generally only be given to non-immune patients who have had 
a significant exposure to a known HBsAg positive patient or to a known non-responder 
to vaccine who has had exposure to a HBsAg positive source or to an unknown source, 
following a risk assessment (appendix 8). HBiG should ideally be given within 48 hours of 
exposure but not later than 1 week after exposure.
 the recipient should be tested for HBsAg at baseline, 6 weeks and 3 months (appendix 9).
  if the recipient was previously vaccinated, with a documented post-vaccination anti-HBs 
level of ≥10miU/ml, they are likely to have long-term protection against HBV infection. No 
further action is required from the point of view of HBV PEP and no follow-up testing is 
required (appendix 8). 
4.3  Hepatitis C
  Currently there is no recommended post-exposure prophylaxis for HCV.3 However, treatment 
of early infection has been shown to be successful, therefore follow-up monitoring for 
evidence of HCV infection should be carried out (see appendix 14 for treatment of acute 
hepatitis C).
  if a significant risk of exposure to HCV has occurred, ie the source is known or likely to be 
HCV positive, testing of the recipient for HCV Ag or RNA, and for anti-HCV should be carried 
out at 6 weeks and 3 months (appendix 9). if the recipient HCV Ag or RNA test is positive, the 
patient should be referred immediately to an appropriate specialist for assessment.
4.4 HIV post-exposure prophylaxis
  HiV PEP should only be considered in patients who present within 72 hours with a 
significant exposure to either a known HiV positive person or a suspected high-risk source.
  PEP should not be offered where testing has shown that the source is HiV negative, or if the 
risk assessment has concluded that HiV infection of the source is unlikely.
  if the HiV status of the source is unknown, a careful risk assessment should be carried out. 
PEP is unlikely to be justified in the majority of such exposures.4
  if the source is known to be HiV infected, and the exposure is significant, the recipient should 
be commenced on PEP as soon as possible, ideally within an hour of exposure.4  PEP should 
not be offered if more than 72 hours has elapsed since the exposure. A 3-5 day starter pack 
of antiretroviral medications should be supplied to the patient. An urgent referral should 
be arranged to an appropriate clinician specialising in HiV treatment or a clinician with 
significant experience in managing HiV PEP. Ensure that the first appointment is scheduled 
before the finish of the PEP starter pack. An information leaflet should be given to the 
patient (appendix 32). All emergency departments and occupational health departments 
should have arrangements in place for timely access to starter packs of PEP. if the source is 
known to be HiV positive and on anti-HiV medication, or has a resistant HiV virus, the case 
should be managed in consultation with a HiV specialist. the total duration of HiV PEP is 28 
days.
  local arrangements should be put in place so that relevant information on the source can be 
made available to the clinician caring for the recipient.
  PEP should be discontinued immediately if a HiV test on the source is found to be negative 
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(unless the risk assessment indicates that there is a high likelihood that the source is in the 
window period). See appendix 7 for detailed protocol for HiV PEP.
4.5 Tetanus
  Depending on the circumstances of the injury, tetanus immunisation should be considered. 
  See appendix 15 re risk assessment for the use of tetanus vaccine and tetanus 
immunoglobulin (tiG).
4.6 Antibiotic treatment
  Prophylactic antibiotics are not routinely recommended for needlestick injuries, although 
each wound should be assessed individually. Antibiotic prophylaxis may be indicated after 
human bites, especially to the hand (see appendices 6 and 18). 
5.  Specific injuries and settings
5.1  Occupational exposure
  See appendices 3 and 4 for algorithms for management of needlestick and mucous 
membrane exposures, and appendix 17 for discussion of occupational exposure.
5.2 Sexual exposure
  if a sexual assault has occurred, the recipient should be referred as soon as possible to the 
nearest sexual assault treatment unit (SAtU) for further management. 
  in cases of sexual exposure which do not involve assault, the following actions should be 
taken in the emergency department:
  •  Assess the need for HiV PEP (see above and appendix 7)
  •  offer HBV vaccination unless known to be immune. Consider HBiG (see appendix 8)
  •  take blood for baseline BBV testing (see appendix 9), including syphilis
  •  Consider emergency contraception (appendix 16) and give information leaflet (appendix 33)
 •  Advise safe sex (ie condoms) for 3 months
  •  Arrange follow-up within 3-5 days in iD/genitourinary medicine (GUM) clinic or with other 
appropriate HiV treating clinician if HiV PEP starter pack commenced
  • Give the recipient an information leaflet (appendix 34)
 •  Refer to sexually transmitted infection (STI)/GUM clinic in 2 weeks time (appendix 35)
 See appendix 5 for algorithm for management of sexual exposure.
5.3 Human bites
  Following a human bite, an individual risk assessment is required, taking account of the 
extent of the injury, the HBV immunisation status of the recipient and the BBV status of the 
source and the recipient. With the exception of a deep bite wound sustained from a source 
who is infected or has risk factors for HBV, in a recipient who is not HBV immune, the risk of 
BBV transmission is negligible. A recipient of a bite that breaches the skin but with no visible 
source blood does not require any follow-up from the point of view of HiV and HCV. 
  HBV vaccination should be advised for an unvaccinated recipient following a percutaneous 
or mucous membrane exposure to saliva from a source who is HBV infected or high-risk but 
of unknown sero-status (see appendix 8). HBiG may also be indicated, depending on the risk 
assessment, but generally only if the source is HBV positive. HiV PEP would almost never be 
indicated except in extreme circumstances.
  See appendix 6 for algorithm for management of human bites and appendix 18 for a detailed 
discussion of the risks of human bites.
5.4 Community acquired needlestick injury
  injuries from discarded needles and syringes in public places create considerable anxiety 
regarding the possible transmission of bloodborne pathogens. While these injuries pose 
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less of a risk than that resulting from a needlestick injury in health-care settings, the perception 
of risk often results in the necessity for evaluation, testing and counselling of the injured person.2  
Management of such injuries includes acute wound care and consideration of the need for 
prophylactic management, based on a detailed risk assessment.
  HBV is the most stable of the major bloodborne viral pathogens and can survive in the environment 
for 1 week or longer. it is advisable to administer a full course of HBV vaccine to those susceptible 
to HBV infection. HBiG is not usually required unless the needle comes from a known HBV positive 
source and a risk assessment identifies a significant risk of HBV transmission (appendix 8). the 
likelihood of transmission of other bloodborne viruses such as HCV or HiV is very remote.2 
  in general PEP for HiV is not recommended but should be considered in high-risk situations – based 
on location (eg prisons) and likely source (eg iDU, insulin injection), the presence of fresh blood, the 
amount of blood, the type of needle involved (eg large bore, hollow), and depth of penetration.5,6,7
  See appendix 3 for algorithm for needlestick/sharps exposure and appendix 19 for a detailed review 
of community needlestick injuries.
5.5 Injury in dental practice
  Protocols should be in place in the dental setting to prevent avoidable exposures and to minimise 
risk. these protocols should include the safe use of equipment, the use of personal protective 
equipment, training, re-training and induction, the need for vaccination, the need for documentary 
evidence of immunity and what to do in case of an accident.  A responsible person should be 
appointed to manage such incidents. it is vitally important that the practice identifies in advance 
an appropriate unit to which to refer an injured person. the legislation which covers this area is the 
Safety, Health and Welfare at Work Act 2005 (and 2007 Regulations). 
 Emergency management of an injury
 1.  immediate wound hygiene should be carried out.
 2.  if a significant exposure has occurred, ie a bite, or an injury from a used needle or from a used 
sharp, immediate referral should take place to the appropriate unit (emergency department or 
infectious disease specialist or occupational health specialist) where a definitive risk assessment 
is carried out.
 3.  the management of the recipient (injured party) is directly based on risk assessment of the 
source. the information to assist the appropriate unit in making this assessment should 
be provided by the practice using the on-Site Assessment Form (Appendix 20) which is 
downloadable from the iDA website (www.dentist.ie). Copies of this form should be readily 
available in all practices to facilitate speedy referral.  
 4.  the source must be informed before they leave the practice that an injury has occurred and the 
on-Site Assessment Form should be completed in their presence. the source should be asked 
if they have any relevant medical history or risk factors for bloodborne viruses. they should be 
asked if their medical history and contact phone number can be passed on to the medical team 
that will treat the recipient. the source should also be informed that they may be contacted by 
the recipient’s treating doctors and asked to provide a blood test. they should be reassured that 
all information will be treated with strict confidentiality by the recipient’s treating doctors, and 
that where necessary appropriate follow-up care will be offered to them. the source should be 
informed that the results of their blood tests may have to be disclosed to the recipient.
 5.  the use of information put on the on-Site Assessment Form must comply with data protection 
legislation. 
 6.  Contact details of the responsible person (from the dental practice) both during and after hours 
must be made available to the appropriate unit. 
5.6 Injury in primary care medical practice
  the management of injuries in the primary care medical practice setting should be dealt with 
broadly along the same lines as in a dental practice. Where there is relevant expertise within a 
medical practice then it may be more appropriate to deal with the injury and follow-up within that 
practice.
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6.  Information and follow-up of recipient
6.1 Information
  All recipients, whether or not the exposure is significant, should receive appropriate 
information. if no significant exposure has occurred, no follow-up is required and no 
precautions need be taken. the patient should be reassured, given an information leaflet 
and discharged (appendix 28). 
  if a significant exposure has occurred, the recipient should receive information about the 
level of risk, the testing required, the implications of a positive result, the implications of 
treatment, the precautions required and the arrangements for follow-up. An information 
leaflet should be given (appendix 29). if the recipient has particular concerns, formal 
counselling may be arranged.
6.2 Precautions
  if a significant exposure has occurred, the recipient should be advised to take certain 
precautions, depending on the exposure and actions taken: 
  •  Adopt safe sex practices (ie use condoms) for 3 months
  •  If planning to donate blood, tissue, breast milk, sperm or organs, the person should 
inform the relevant donation agency about the exposure incident and follow their 
recommendations 
  •  Seek expert advice regarding pregnancy or breast-feeding
  •  In the absence of infection, healthcare and other workers need not be subject to any 
modification of their work practices
  •  No restrictions are necessary in relation to participation in contact sports
  •  Do not share toothbrushes, razors or needles
  these precautions should be outlined in written form, eg a leaflet (appendix 29).
6.3  Follow-up
  Where a significant exposure has occurred, follow-up may be required for the following:
  •  Blood tests and feedback of results
  •  Monitoring for clinical evidence of HBV, HCV or HIV infection. If evidence of infection 
occurs, an urgent referral should be made to an appropriate specialist.
  •  Completion of HBV vaccination course
  •  HIV PEP
  •  Ongoing counselling
  •  STI screen
  Arrangements should be made for follow-up by the appropriate service and the recipient 
clearly advised about this. this will depend on the circumstances of the incident and the 
type of injury.
  if the person has been started on HiV PEP, they should be monitored by a clinician  
specialising in HiV treatment or a clinician with significant experience in managing HiV 
PEP. An urgent referral should be made to ensure that they are first seen by this specialist 
before the starter pack of antiretroviral medication is finished. the referral pathway to this 
specialist should be clearly defined in each region and a written note given to the patient 
clearly stating where they should go (appendices 32, 35).
  For recipients not prescribed HiV PEP:
  •  Healthcare staff who have received an occupational injury should be referred to their 
occupational health department for follow-up. if they have no occupational health 
department, they should go to their own GP for follow-up if required (appendix 36).
  •  Members of the public should be referred to their own GP, an STI/ID/GUM/SATU service 
or their own occupational health service (appendix 36).
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 7.  Records/documentation
7.1  Patient management form
  All parts of the patient management form should be completed (appendix 1) and the form 
retained in the service where the consultation took place.
7.2  Recording of medication
  Details of all medications prescribed, administered and supplied (eg PEP, antibiotics, 
vaccines) should be recorded in the appropriate patient record (eg hospital chart, 
occupational health department medical record). For vaccines and immunoglobulin products, 
the batch number and expiry date should be recorded.
7.3  Notifiable diseases
  HBV, HCV and HiV are notifiable diseases and should be notified by the attending doctor 
to the director of public health (DPH)/medical officer of health (MoH) (see Appendix 37 re 
details of DPHs). A notification form may be downloaded from: http://www.hpsc.ie/hpsc/
NotifiableDiseases/NotificationForms/
7.4  Occupational exposures
  if the injury occurred in the workplace setting, the appropriate report forms should be 
completed and management informed.
  if, as a result of a work related injury, the employee is absent from work for more than 3 
consecutive days, the employer must report the injury using the iR1 form available from the 
Health and Safety Authority (HSA).
  Under the Safety, Health and Welfare at Work (Biological Agents) Regulations 1994 and 
amendment Regulations 1998, the employer must inform the HSA of any work related 
accident or incident which may have resulted in the release of a biological agent and 
which could cause severe human infection/human illness eg a percutaneous injury with a 
contaminated sharp where the source patient is known or found to be positive for hepatitis B, 
hepatitis C or HiV. the iR3 Report of Dangerous occurrence Form may be used to report the 
incident to the HSA, available at www.hsa.ie.
7.5  Risk management forms for hospital
  Where the injury relates to an incident that occurred in a hospital setting, appropriate risk 
management forms should be completed.
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Glossary of abbreviations and terms 
Abbreviations
Ab  Antibody
Ag Antigen
AiDS  Acquired immunodeficiency Syndrome
Alt  Alanine aminotransferase
Anti-HBc  Antibody to hepatitis B core antigen
Anti-HBe  Antibody to hepatitis B e antigen
Anti-HBs  Antibody to hepatitis B surface antigen
Anti-HCV  Antibody to hepatitis C virus
BBV  Bloodborne virus. eg HiV, HBV, HCV
CANSi  Community acquired needlestick injury
CDC  Centers for Disease Control and Prevention (Atlanta, USA)
CoHP  Country of high prevalence
CSW  Commercial sex worker
DtaP  Diphtheria, tetanus and acellular pertussis vaccine
DPH  Director of public health
DNA  Deoxyribonucleic acid
ECDC  European Centre for Disease Prevention and Control
EiA  Enzyme-linked immunoassay
EPP  Exposure-prone procedure
EU  European Union
GP  General practitioner
GUM  Genitourinary medicine
HAARt  Highly active antiretroviral therapy
HBeAg  Hepatitis B e antigen
HBiG  Hepatitis B specific immunoglobulin
HBsAg  Hepatitis B surface antigen
HBV  Hepatitis B virus
HCC  Hepatocellular carcinoma
HCV  Hepatitis C virus
HCW  Healthcare worker
Hib Haemophilus influenzae b
HiV  Human immunodeficiency virus
HPSC  Health Protection Surveillance Centre
HSE  Health Service Executive
iBtS  irish Blood transfusion Service
iCGP  irish College of General Practitioners
iD  infectious diseases
iDU  injecting drug use oR injecting drug user
iPV inactivated polio virus vaccine
iM  intramuscular
iU  international units
MoH  Medical officer of health
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MSM  Men who have sex with men
n/a  not available; not applicable
NiAC  National immunisation Advisory Committee
NiCE  National institute for Health and Clinical Excellence
NVRl  National Virus Reference laboratory
oHD  occupational Health Department
oHP  occupational Health Physician
PCR  Polymerase chain reaction
PEP  Post-exposure prophylaxis
PEPSE Post-exposure prophylaxis for sexual exposure
RCPi  Royal College of Physicians of ireland
RNA  Ribonucleic acid
Roi  Republic of ireland
SAtU Sexual Assault treatment Unit
StD  Sexually transmitted disease
Sti  Sexually transmitted infection
SVR  Sustained virological response
td tetanus, low-dose diphtheria
tdap tetanus, low dose diphtheria and low-dose acellular pertussis vaccine
tiG  tetanus immunoglobulin
UNAiDS  Joint United Nations Programme on HiV/AiDS
UPSi  Unprotected sexual intercourse
WHo  World Health organization
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Terms
•   Endemic: The constant presence of a disease or infectious agent within a given geographic area 
or population group; may also refer to the usual prevalence of a given disease within such area 
or group.
•   Exposure incident: A specific exposure to the eye, mouth, other mucous membrane, nonintact 
skin, or parenteral exposure to blood or other potentially infectious materials. Examples of 
an exposure incident include blood spattering into the eyes, splashing into the mouth or a 
puncture by a blood-contaminated needle.
•   Fight bite: A fight bite or closed fist injury is a laceration to the “knuckle” (MCP joint) of the 
hand of someone who punches another person in the mouth.
•   Parenteral: Piercing the skin barrier or mucous membranes eg by needlestick.
•   Percutaneous: An exposure through the skin (eg a needlestick or cut with a sharp object) 
or contact of non-intact skin (eg exposed skin that is chapped, abraded, or afflicted with 
dermatitis) with blood, tissue, or other body fluids that are potentially infectious.
•   Post-exposure prophylaxis (PEP): The administration of a drug to prevent the development 
of an infection after the patient has been exposed to the infection, eg HiV PEP involves 
administration of antiretroviral drugs to HiV-negative persons who have been exposed to HiV in 
an effort to prevent establishment of infection. HBV PEP involves the administration of hepatitis 
B vaccine and/or hepatitis B specific immunoglobulin after exposure.
•   Recipient: The person who sustains the injury. In the case of a bloodborne virus exposure 
incident, the recipient is exposed to blood or body fluids of someone else, who is known as the 
source.
•   Risk factors: An aspect of personal behaviour or lifestyle, an environmental exposure, or an 
inborn or inherited characteristic that is associated with an increased occurrence of disease.
•   Seroprevalence: The level of a pathogen in a population, as measured in blood serum.
•   Sharps: Any items that have the potential to puncture the skin and inoculate the recipient with 
infectious material.
•   Source individual: The source of the potentially infectious material, eg the person on whom the 
sharp was used, the person who bites, or the source of the blood or body fluid.
•   Standard Precautions: Standard Precautions are the minimum infection prevention practices 
that apply to all patient care, regardless of suspected or confirmed infection status of the 
patient, in any setting where healthcare is delivered. Standard Precautions include: 1) hand 
hygiene, 2) use of personal protective equipment (eg gloves, gowns, masks), 3) safe injection 
practices, 4) safe handling of potentially contaminated equipment or surfaces in the patient 
environment, and 5) respiratory hygiene/cough etiquette.
•   Sustained virological response (SVR) (for hepatitis C treatment): The absence of detectable 
hepatitis C RNA in the serum as shown by a qualitative hepatitis C RNA assay with lower limit 
of detection of 50 iU/ml or less at 24 weeks after the end of treatment.
•   Toxoid: is a modified bacterial toxin that has been rendered non-toxic but has the ability to 
stimulate the formation of antitoxin.
•   Window period: The time interval after infection during which serological assays for antigen 
and/or antibody are negative.
t
o
o
l
k
iteMI Guidelines
-27-
aPPendICes
t
o
o
l
k
it eMI Guidelines
t
o
o
l
k
it
-28-
eMI Guidelines - Appendix 1  Patient management form
Bloodborne Virus Exposure • Patient Management Form
Reporting time:          __ __ : __ __ Reporting date:            __ __ / __ __  / __ __
Doctor name: Doctor signature:
 
Details of injury (date, time, place etc.)
 
Nature of material (e.g. blood, saliva, semen etc.)
if Not blood, was fluid blood stained  Yes   No  
HEALTHCARE ExPOSURES (Consider using local form if applicable)
Area where exposure occured
Was this an ‘exposure prone procedure’?  Yes   No  
Were gloves worn at the time of the injury?  Yes   No  
instrument (if any) which caused the injury
What was the instrument originally intended for?
Did the instrument have a safety mechanism?  Yes   No 
Was the safety mechanism activated ?   Yes   No 
Past Medical History (incl. immunosuppression)
Is recipient known to have HBV, HCV, or HIV?  No   Yes   Detail below  
Medications
Allergies
if female Pregnant   Breastfeeding  
Hepatitis B Vaccination
1 dose 2 doses Full course Year
Antibody result if known
Tetanus
Date of last vaccination       __ __ / __ __  / __ __    Number of doses
  
RECIPIENT DETAILS
ASSESSMENT OF ExPOSURE RISK
Name
Address
Gender  M ¨  F ¨ Date of birth     __ __ / __ __  / __ __
MRN
tel no. Mobile
occupation
Work address
  GP name and address and telephone number
Needlestick/sharp injury 
 Hollow bore needle    Solid Needle 
 Visible blood present 
 Device had been directly in source artery or vein 
 other sharp      Describe___________________________________
Severity of needlestick or sharp injury
 Superficial - source scratch, no blood appeared 
 Moderate - penetrated skin and blood appeared 
 Deep - puncture, with or without blood appearance 
Human bite    Skin breached    
Splash 
 intact skin    Non-intact skin 
 Mucous membrane    Eye 
Sexual exposure 
Receptive anal  insertive anal 
Receptive oral   insertive oral 
Receptive vaginal    insertive vaginal 
Condom used/ condom intact   Ejaculated 
if sexual assault, consider referral to a sexual assault treatment
unit or social worker 
other injury   (describe in “Details of injury” box)
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eMI Guidelines - Appendix 1  Patient management form 
  
  
  
Overall, is exposure significant? (see section 2.4, page 13)      Yes ¨  No ¨
if exposure is considered significant
Is source known?  Yes   No 
if yes, iD number    e.g. source hospital MRN or laboratory number
(Health care institution to assign an iD number by which the recipient and source can be confidentially linked)
  
  
  
  
  
  
DECISION
RECIPIENT MANAGEMENT CHECKLIST
FOLLOW-UP ARRANGEMENTS
If exposure is considered significant, proceed.
If unsure how to proceed, discuss with senior 
doctor in the Emergency Department or in 
Infectious Diseases.
 
if no, no further follow up is required
Reassured 
Patient information leaflet provided (appendix 28)  
Discharged 
First aid given  Yes    No   (see section 2, page 12)
Recipient bloods taken (appendix 9) Yes    No 
For testing         For storage only  
Appropriately labeled “Possible BBV exposure - Recipient”  
 test Date  Result
HBsAg  ______________  _______
Anti-HBc ______________ _______
Anti-HCV ______________ _______
HiV Ag/Ab ______________  _______
Syphilis (sexual exposures only) ______________ _______
Pregnancy  ______________ _______
informed consent received for testing   Yes    No  
(see Checklist, appendix 30)
Following sexual assault  Yes
Social worker referral    
Sexual assault unit referral   
Emergency contraception  
Garda notification if patient agrees   
Treatment record, including PEP  Yes
HBV vaccination given (appendices 8 & 11)   
HBiG required (appendix 8)   
HBiG given   
HiV PEP offered (appendix 7)   
HiV PEP accepted (HiV PEP should be discontinued 
immediately if the source is found to be HiV negative)  
Considered interactions between PEP and other medication 
(Consult BNF, pharmacist, www.hiv-druginteractions.org,   
product insert)   
HiV PEP information leaflet given (appendix 32)   
Baseline bloods taken (FBC, lFts, Renal, Bone profile)  
Urinalysis for proteinuria (in renal impairment, give first dose of 
truvada and discuss with an iD consultant. kaletra can be given)  
time between exposure and starting HiV PEP    ______  hours
Number of days of HiV PEP given     ______   days
HiV PEP drugs prescribed (name of drugs) _________________________
____________________________________________________________________
tetanus vaccine given (appendix 15)   
tetanus immunoglobulin (tiG)   
Examined wound for infection  
Antibiotics prescribed  
Note: Record details of medication/ vaccines in patient’s chart
    
  
  
Precautions advised during follow-up period – 3 months
(appendix 29)
Avoid unprotected sexual practices   
Seek expert advice regarding pregnancy or breastfeeding   
Discussed
Compliance with medication   
Possible adverse reactions and how to manage them   
No modification to work practices   
No restrictions to sports   
importance of advising relevant agency if donating blood,  
blood products, organ donation, other donation  
Follow-up referral for:  Name of service
(Please use the standard referral forms—  
appendices 35 &36)
test results  _________________
Further testing (6/52, 3/12) (appendix 9)  _________________
Vaccinations _________________
HiV PEP (urgent, in 3-5 days — appointment to be
arranged in iD or HiV clinic, or in the occupational
health department (if appropriate)). _________________
Counselling _________________
Sti screen  _________________
Patient information leaflet regarding significant exposures 
provided (appendix 29)   
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  Do not give this part of the form to the recipient if it contains confidential information that the recipient has not 
themselves provided.
in these circumstances, local plans must be made so that the form can be forwarded to the iD clinic when the recipient is being referred
iD number      e.g. source hospital MRN or laboratory number
(Health care institution to assign an iD number by which the recipient and source can be confidentially linked)
Source: Any risk factors for BBV?  Yes    No    Unknown  
iDU  
Prisoner   
Born in an endemic country            
(Refer to maps in appendices 22, 24, 26)
Recipient of blood/ blood products   (pre August 1973 HBV, pre oct 1985 HiV, pre oct 1991 HCV)
High risk sexual behaviour
 MSM (men who have sex with men  
 CSW (commercial sex worker)  
 Multiple sexual partners  
 Partner with BBV  
Was source consent received for testing?  Yes      No  
implications of testing discussed with source  Yes     No  
Consent sought from source to disclose test results to recipient  Yes      No  
Source information leaflet provided (appendix 31)  Yes      No  
Reason for not testing source person serology (if applicable)
Unknown source    Refused    Dead    Unable to give consent  
Discharged/ not available    Next of kin not available   
  
  
  
  
ASSESSMENT OF SOURCE INFECTIVITY (SEE SECTION 3.3, PAGE 14)
INFORMATION ON SOURCE
Is source immunosuppressed?   Yes      No     Unknown   
HBV 
HBsAg:  Positive       Negative       Unknown   
if positive:  HBeAg positive     Viral load_________
if negative:  Date of last negative test________ 
HCV 
Anti-HCV:  Positive       Negative       Unknown    
if positive:  RNA positive     Viral load_________ 
if negative:  Date of last negative test__________
HiV 
HiV Ag/Ab:  Positive       Negative       Unknown   
if positive:  Viral load________   CD4 count__________ 
What ART now?_____________________
if negative: Date of last negative test_________
if unknown serology, test the following:   Date sent  Result:
HBsAg
if HBsAg positive:  HBeAg
 Anti-HBe
 Viral load
Anti-HCV
if Anti-HCV positive:  RNA
 Viral load
HIV Ag/Ab
if HiV Ag or Ab positive: Viral load
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Management of injuries where there is risk of 
bloodborne virus (BBV) transmission
Exposure incident
needlestick, sharps, bite, 
splash, sexual 
(algorithms - appendices 3-6)
Initial wound management
Wound: Encourage bleeding, 
wash, don’t scrub, cover. 
Eye splash: irrigate with water
Is exposure significant?
ie high risk material AND 
significant injury (see side panel)
Assess BBV status of source 
(HBV, HCV, HIV – appendices 
21-27)
No further action. 
Reassure and 
discharge
(information leaflet 
appendix 28)
Source known: test 
for BBVs or confirm 
previous results, with 
consent 
(Section 3.3.1)
(appendices 30 and 31)
Source unknown or 
does not consent: 
assess risk based on 
circumstances and 
likelihood of BBV 
(Section 3.3.3)
Assess BBV status of recipient 
History of HBV vaccination, 
previous tests for BBVs. 
take blood to test for BBVs or 
store (appendices 9 and 30 )
Clinical management of 
recipient based on risk 
assessment 
(appendices 7 & 8)
Information and follow-up
level of risk, precautions, follow-up 
for tests, vaccination, PEP, 
information, Sti screen
(information leaflet appendix 29)
High risk materials: 
blood, semen, vaginal 
secretions, body fluids with 
visible blood
Low risk materials:  
urine, nasal secretions, 
saliva*, sputum, faeces, 
vomit, sweat, tears – unless 
visible blood
Significant injury: 
percutaneous, human bite* 
with skin broken, exposure 
of broken skin or mucous 
membrane to blood or body 
fluids, sexual exposure 
(unprotected) 
*if human bite with no visible 
blood, only risk is HBV.
Non-significant injury: 
superficial graze, exposure of 
intact skin, exposure to sterile 
sharps
Source testing:   
HBsAg, anti-HCV, HiV Ag/
Ab. if HBsAg positive, test 
HBeAg, anti-HBe and viral 
load. if anti-HCV positive, test 
HCV RNA and viral load. if 
HiV positive, test viral load
Recipient testing:  
HBsAg, anti-HCV, HiV Ag/Ab, 
± anti-HBs
Clinical management 
of recipient may include: 
HBV PEP (vaccine ± HBiG); 
HiV PEP; Emergency 
contraception; tetanus; 
antibiotics
Follow-up/referral may be: 
GP, occupational Health, iD, 
SAtU, Sti/GUM
No
Yes
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Inform
ation and Follow
-up 
level of risk, precautions, follow
-up for further testing (appendix 9), vaccination, PEP. G
ive inform
ation leaflet (appendices 29 and 32)
N
o risk of H
B
V/H
CV/H
IV
 
transm
ission. R
eassure.
G
ive patient inform
ation 
leaflet (appendix 28) 
and discharge letter 
(appendix 36). 
A
dvise G
P/occupational 
health follow
-up
N
O
YES
  See H
BV PEP table 
(appendix 8)
 there is currently no PEP 
available for H
CV, but if 
seroconversion occurs, 
early treatm
ent is highly 
effective (appendix 14)
W
ound (or eye, m
outh) irrigation 
W
as the fluid a high risk m
aterial? (Section 2.4)
A
ssess B
B
V
 risk of source (Section 3.3). If source know
n, test for B
B
Vs or confirm
 previous results (w
ith 
consent).  If source unknow
n or does not consent, assess risk based on circum
stances and likelihood of B
B
V
A
ssess B
B
V
 status of recipient (H
B
V
 vaccination, previous B
B
V
 tests, baseline bloods 
(Section 3.4 &
 appendix 9).  Clinical m
anagem
ent of recipient based on risk assessm
ent (Section 4)
H
iV PEP should only be considered w
here the follow
ing criteria are m
et:
•  Injury  w
ithin the past 72 hours
•  Splash from
 high risk m
aterial to non-intact skin, eye or m
outh
•  Source is know
n H
IV-positive w
ith a detectable viral load
if these criteria are not m
et, H
iV PEP is N
o
t indicated
See appendix 7 (H
iV PEP)
H
IV
M
anagem
ent of B
B
V
 risk follow
ing exposure of m
ucous m
em
brane or broken skin 
in occupational or com
m
unity setting
Com
plete patient m
anagem
ent form
 (appendix 1)
H
B
V
H
CV
t o o l k i t
t
o
o
l
k
it
eMI Guidelines - Appendix 5   Algorithm for sexual exposure
-34-
In
fo
rm
at
io
n 
an
d 
Fo
llo
w
-u
p
A
dv
is
e 
pa
tie
nt
 to
 a
tt
en
d 
G
U
M
/i
D
 c
lin
ic
 in
 a
pp
ro
x 
2/
52
 fo
r S
ti
 s
cr
ee
n 
an
d 
fu
rt
he
r f
ol
lo
w
-u
p.
 S
af
e 
se
x 
ad
vi
se
d 
un
til
 a
ft
er
 th
e 
w
in
do
w
 p
er
io
d.
 G
iv
e 
in
fo
rm
at
io
n 
le
afl
et
s 
(a
pp
en
di
ce
s 
29
 &
 3
4)
N
o 
ri
sk
 o
f H
B
V/
H
CV
/H
IV
 
tr
an
sm
is
si
on
. R
ea
ss
ur
e.
 
N
o 
fu
rt
he
r f
ol
lo
w
-u
p 
re
qu
ir
ed
. G
iv
e 
pa
ti
en
t i
nf
o 
le
afl
et
 (a
pp
en
di
x 
28
) a
nd
 
di
sc
ha
rg
e 
to
 G
P
 (a
pp
en
di
x 
36
)
N
O
  th
er
e 
is
 c
ur
re
nt
ly
 n
o 
PE
P 
av
ai
la
bl
e 
fo
r H
CV
, 
bu
t i
f s
er
oc
on
ve
rs
io
n 
oc
cu
rs
, e
ar
ly
 
tr
ea
tm
en
t i
s 
hi
gh
ly
 
ef
fe
ct
iv
e 
(a
pp
en
di
x 
14
)
Se
e 
H
BV
 P
EP
 ta
bl
e 
(a
pp
en
di
x 
8)
 
Fo
llo
w
 a
pp
en
di
x 
7 
fo
r d
et
ai
ls
 
on
 H
iV
 P
EP
 a
nd
 u
se
 th
e 
m
an
ag
em
en
t c
he
ck
lis
t i
n 
th
e 
pa
tie
nt
 m
an
ag
em
en
t 
fo
rm
 (a
pp
en
di
x 
1)
. o
ut
si
de
 
of
 th
es
e 
re
co
m
m
en
da
tio
ns
, 
H
iV
 P
EP
 s
ho
ul
d 
no
t 
be
 p
re
sc
rib
ed
 w
ith
ou
t 
di
sc
us
si
on
 w
ith
 a
n 
iD
/H
iV
 
sp
ec
ia
lis
t, 
w
he
re
 it
 m
ay
 b
e 
co
ns
id
er
ed
 in
 ra
re
 e
xt
re
m
e 
ca
se
s.
Co
ns
id
er
 n
ee
d 
fo
r e
m
er
ge
nc
y 
co
nt
ra
ce
pt
io
n 
(a
pp
en
di
x 
16
) /
 S
A
TU
 re
fe
rr
al
 (a
pp
en
di
x 
37
)/
ri
sk
 o
f o
th
er
 S
TI
s
W
as
 th
e 
ex
po
su
re
 s
ig
ni
fic
an
t?
 (i
e 
ex
po
su
re
 to
 b
lo
od
/s
em
en
/v
ag
in
al
 s
ec
re
ti
on
s)
A
ss
es
s 
B
B
V
 ri
sk
 o
f s
ou
rc
e 
(S
ec
tio
n 
3.
3)
. I
f s
ou
rc
e 
kn
ow
n,
 te
st
 fo
r B
B
Vs
 o
r c
on
fir
m
 p
re
vi
ou
s 
re
su
lt
s 
w
it
h 
co
ns
en
t.
 
If 
so
ur
ce
 u
nk
no
w
n 
or
 d
oe
s 
no
t c
on
se
nt
, i
s 
it
 li
ke
ly
 th
at
 th
ey
 a
re
 fr
om
 a
 h
ig
h 
ri
sk
 g
ro
up
 e
g 
ID
U
/M
SM
/C
SW
/e
nd
em
ic
 
co
un
tr
y?
 (S
ec
tio
n 
3.
1)
A
ss
es
s 
B
B
V
 s
ta
tu
s 
of
 re
ci
pi
en
t (
H
B
V
 v
ac
ci
na
ti
on
, p
re
vi
ou
s 
B
B
V
 te
st
s,
 b
as
el
in
e 
bl
oo
ds
 (S
ec
tio
n 
3.
4 
an
d 
ap
pe
nd
ix
 9
))
Cl
in
ic
al
 m
an
ag
em
en
t o
f r
ec
ip
ie
nt
 b
as
ed
 o
n 
ri
sk
 a
ss
es
sm
en
t (
Se
ct
io
n 
4)
H
IV
 - 
P
EP
 
Ta
bl
e 
ad
ap
te
d 
fr
om
 B
A
SH
H
 2
0
11
D
o 
no
t g
iv
e/
co
ns
id
er
 P
EP
 if
 m
or
e 
th
an
 7
2 
ho
ur
s 
si
nc
e 
th
e 
ex
po
su
re
M
an
ag
em
en
t o
f B
B
V
 ri
sk
 fo
llo
w
in
g 
se
xu
al
 e
xp
os
ur
e 
Co
m
pl
et
e 
B
BV
 p
at
ie
nt
 m
an
ag
em
en
t f
or
m
 (a
pp
en
di
x 
1)
YE
S
Ex
P
O
SU
R
E 
TY
P
E
H
IV
 p
os
it
iv
e 
vi
ra
l l
oa
d 
de
te
ct
ab
le
H
IV
 p
os
it
iv
e 
vi
ra
l l
oa
d 
un
de
te
ct
ab
le
U
nk
no
w
n 
fr
om
 h
ig
h 
pr
ev
al
en
ce
 g
ro
up
/a
re
a
U
nk
no
w
n 
fr
om
 lo
w
 
pr
ev
al
en
ce
 g
ro
up
/a
re
a
R
EC
EP
TI
VE
 A
N
A
L 
SE
X
R
EC
o
M
M
EN
D
R
EC
o
M
M
EN
D
R
EC
o
M
M
EN
D
N
o
t 
R
EC
o
M
M
EN
D
ED
 
IN
SE
R
TI
VE
 A
N
A
L 
SE
X
R
EC
o
M
M
EN
D
N
o
t 
R
EC
o
M
M
EN
D
ED
Co
N
Si
D
ER
*
N
o
t 
R
EC
o
M
M
EN
D
ED
R
EC
EP
TI
VE
 V
A
G
IN
A
L 
SE
X
R
EC
o
M
M
EN
D
N
o
t 
R
EC
o
M
M
EN
D
ED
Co
N
Si
D
ER
*
N
o
t 
R
EC
o
M
M
EN
D
ED
IN
SE
R
TI
VE
 V
A
G
IN
A
L 
SE
X
R
EC
o
M
M
EN
D
N
o
t 
R
EC
o
M
M
EN
D
ED
Co
N
Si
D
ER
*
N
o
t 
R
EC
o
M
M
EN
D
ED
FE
LL
AT
IO
 W
IT
H
 
EJ
A
CU
LA
TI
O
N
Co
N
Si
D
ER
*
N
o
t 
R
EC
o
M
M
EN
D
ED
N
o
t 
R
EC
o
M
M
EN
D
ED
N
o
t 
R
EC
o
M
M
EN
D
ED
FE
LL
AT
IO
 W
IT
H
O
U
T 
EJ
A
CU
LA
TI
O
N
N
o
t 
R
EC
o
M
M
EN
D
ED
N
o
t 
R
EC
o
M
M
EN
D
ED
N
o
t 
R
EC
o
M
M
EN
D
ED
N
o
t 
R
EC
o
M
M
EN
D
ED
SP
LA
SH
 O
F 
SE
M
EN
 IN
TO
 
EY
E
Co
N
Si
D
ER
*
N
o
t 
R
EC
o
M
M
EN
D
ED
N
o
t 
R
EC
o
M
M
EN
D
ED
N
o
t 
R
EC
o
M
M
EN
D
ED
CU
N
N
IL
IN
G
U
S
N
o
t 
R
EC
o
M
M
EN
D
ED
N
o
t 
R
EC
o
M
M
EN
D
ED
N
o
t 
R
EC
o
M
M
EN
D
ED
N
o
t 
R
EC
o
M
M
EN
D
ED
H
B
V
H
CV
*D
is
cu
ss
 w
ith
 iD
/H
iV
 s
pe
ci
al
is
t
toolkit
t
o
o
l
k
it
-35-
eMI Guidelines - Appendix 6  Algorithm for human bite exposure
Inform
ation and Follow
-up 
level of risk, precautions, follow
-up for further testing (appendix 9), vaccination, PEP. G
ive inform
ation leaflets (appendices 29 &
 32)
N
o risk of H
CV/H
IV
 
transm
ission. N
o 
further follow
-up 
required for H
CV
 or 
H
IV. H
B
V
 follow
-up 
as per H
B
V
 P
EP
 table 
(appendix 8) as it is 
theoretically possible 
that H
B
V
 can be 
transm
itted through a 
deep tissue bloodless 
bite.  M
anage as per 
table and  patient w
ill 
need H
B
sA
g (but not 
H
IV/H
CV
) level at 6 
w
eeks and 3 m
onths if 
not H
B
V
 im
m
une.
N
O
YES
Follow
-up 
required for H
B
V, 
H
CV
 and H
IV
 
O
ral antibiotic (A
ugm
entin if not penicillin allergic)  + w
ound irrigation (If ‘fight bite’ – refer for w
ashout) + tetanus prophylaxis (appendix 15)
W
as biter (source) bleeding from
 m
outh prior to bite?
Consider risk to biter if bitten person’s blood gets in biter’s m
outh
to date there have only been a handful of reports of B
BV transm
ission from
 hum
an bites and few
 of these w
ere 
convincing. A
ll cases involved deep bites w
here there w
as blood in the m
outh of the biter, and w
here the biter had high 
viral loads. thus the absolute risk is not know
n - deem
ed to be possible but extrem
ely rare.
H
IV
M
anagem
ent of B
B
V
 risk follow
ing hum
an bite breaching skin – or ‘fight bite’ (closed fist injury-
see appendix 18)  There is no risk of B
B
V
 transm
ission if the skin is not breached. Com
plete B
B
V
 patient m
anagem
ent form
 (appendix 1)
A
ssess B
BV risk of source (Section 3.3). if source know
n, test for B
BVs or confirm
 previous results (w
ith consent).  
if source unknow
n or does not consent, is it likely that they are from
 a high risk group eg iD
U
/M
SM
/CSW
/endem
ic 
country (Section 3.1)?
H
iV PEP should only be prescribed w
here all the follow
ing criteria are m
et: 
1. it is w
ithin 72 hours of the injury
2. there w
as deep tissue injury
3. the biter w
as, w
ith com
plete certainty, bleeding from
 their m
outh prior to the bite
4. the biter is know
n to have H
iV infection. (Every effort should be m
ade to determ
ine the H
iV viral load of the 
source and their treatm
ent regim
en).
if all 4 criteria are m
et, H
iV PEP is indicated. Follow
 the m
anagem
ent steps for H
iV PEP prescription as 
outlined in the m
anagem
ent checklist on the patient m
anagem
ent form
 (appendix 1), and in appendix 7 (H
iV 
PEP). o
utside of this, H
iV PEP should not be prescribed w
ithout discussion w
ith an iD
/H
iV specialist, w
here it 
m
ay be considered in rare extrem
e cases.
A
ssess B
BV status of recipient (H
BV vaccination, previous B
BV tests, baseline bloods (Section 3.4 and appendix 9))
Clinical m
anagem
ent of recipient based on risk assessm
ent (Section 4)
  See H
epatitis B
 PEP table 
(A
ppendix 8). 
  there is currently no 
PEP available for H
CV, 
but if seroconversion 
occurs, early treatm
ent 
is highly effective 
(appendix 14)
H
B
V
H
CV
t o o l k i t
t
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hIV Post-exPosure ProPhylaxIs (PeP)
Key points
1. only consider PEP if within 72 hours of exposure
2. Assess risk based on type of exposure and what is known about source (consider risk of HBV and HCV also – see 
relevant appendices)
3. test source if feasible
4. Discuss with senior doctor in emergency medicine or infectious diseases if unsure how to proceed
5. if PEP indicated:
a. Counsel
b. test blood and urine
c. Prescribe starter pack
d. Arrange iD clinic appointment before starter pack runs out
e. Advise no unprotected sex for 3 months
6. Complete the patient management form  (appendix 1) – it will serve as a checklist 
Introduction
the use of post-exposure prophylaxis (PEP) against HiV infection dates back to the early 1990s, when only limited 
antiviral treatment for chronic infection was available. Prophylaxis was primarily used after occupational exposures.1 
A case–control study published in 1997 showed that health care workers who received zidovudine after needlestick 
exposures were 81% less likely to undergo seroconversion to positivity for HiV.2 Generally, combination therapies are 
prescribed nowadays, so current HiV PEP may be more effective. However, PEP is not a guarantee of protection.
After exposure to HiV through sexual contact or injecting drug use, antiretroviral therapy may also be administered 
for prophylaxis against infection. No efficacy data are available for this strategy, but substantial safety and feasibility 
data have led to its widespread acceptance.1 
General principles
HiV PEP should only be considered in patients who present within 72 hours with a significant exposure from either a 
known HiV positive person or a suspected high risk source.
PEP should not be offered where testing has shown that the source is HiV negative, or if the risk assessment has 
concluded that HiV infection of the source is unlikely.
if the HiV status of the source is unknown, a careful risk assessment should be carried out. PEP is unlikely to be 
justified in the majority of such exposures.3
Risk assessment
the risk of an individual acquiring HiV following an exposure is dependent upon the risk that the source is HiV-
positive where unknown, and the risk of infection following a specific exposure from an HiV-positive individual.4
Risk of HiV transmission = risk that source is HiV-positive x risk of exposure*
(*including co-factors such as sexually transmitted infections, high HiV viral load and bleeding).4
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Table 1 Risk of HIV transmission following an exposure from a known HIV-positive individual 
(Adapted from BASHH Uk Guideline for use of HiV PEPSE 20114 – source references omitted from table)
type of exposure Estimated median (range) risk of HiV 
transmission per exposure (%)
Receptive anal intercourse 1.11 (0.042-3.0%)
insertive anal intercourse 0.06 (0.06-0.065%)
Receptive vaginal intercourse 0.1 (0.004-0.32%)
insertive vaginal intercourse 0.082 (0.011-0.38%)
Receptive oral sex (giving fellatio) 0.02 (0-0.04%)
insertive oral sex (receiving fellatio) 0
Blood transfusion (one unit) (90-100%)
Needlestick injury 0.3 (95% Ci 0.2-0.5%)
Sharing injecting equipment 0.67
Mucous membrane exposure 0.63 (95% Ci 0.018-3.47%)*
Human bite† Very low risk. Case reports only
NB: All sexually related risk probabilities are for unprotected sexual exposure; it is assumed similar risks will exist where condom 
failure has occurred
*the (BASHH) writing committee has concern regarding the risk estimate following mucous membrane exposures, which is derived 
from a single study including only small numbers of health-care workers exposed to HiV following mucous membrane exposures. this 
is likely to significantly overestimate the risk
†Not contained in BASHH Guidelines table
the table above is simply a guide. there are a number of factors that may increase the risk of 
transmission such as high viral load in the source, and intercurrent Stis, eg syphilis. 
the overall number of HiV cases in the Uk diagnosed in HCWs following occupational exposures is 
five documented cases and 31 probable cases, eight of these probable cases being diagnosed prior to 
1997.5
Table 2  Estimated risk of HIV transmission by type of exposure where source HIV status is 
unknown
type of exposure Population group 
(% HiV prevalence) 
Risk of HiV transmission - 
source HiV status unknown 
Rounded off estimated 
risk per exposure 
(compared with risk if 
source known HiV+) 
Receptive anal sex 
MSM* 
MSM in ireland 
(10%)6
0.1x1.11%=0.111% 1/900 (1/90) 
insertive anal sex 
MSM* 
MSM in ireland 
(10%)6
0.1x0.06%=0.006% 1/16,666 (1/1667) 
Receptive oral sex 
MSM* 
MSM in ireland 
(10%)6
0.1x0.02%=0.002% 1/50,000 (1/5000) 
Receptive vaginal sex Heterosexuals in 
ireland (0.2%)7 
0.002x0.1%=0.0002% 1/500,000 (1/1000)
NSi† from unknown 
non high risk hospital 
pt 
Heterosexuals in 
ireland (0.2%)7
0.002x0.3%=0.0006% 1/166,667 (1/333) 
NSi† from community 
source 
iDU‡ in ireland
(5 to10%)8,9,§ 
0.05x0.3%=0.015 to
0.1x0.3%=0.03% 
1/6,667 to
1/3,333 (1/333)
*MSM=men who have sex with men
†NSi=needlestick injury
‡iDU=injecting drug user
§Personal communications: Dr Shay keating, Drug treatment Centre Board and Dr Jean long, Alcohol and Drug Research Unit, 
Health Research Board.
It is generally recommended that HIV PEP is only offered when the estimated transmission risk is 1 
in 1000 or greater, but all cases are considered on a case-by-case basis.4 PEP can be considered in 
those with a risk of between 1 in 1,000 and 1 in 10,000 only in very exceptional circumstances.
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Table 3 HIV PEP recommendations by type of exposure and source status 
(Adapted from BASHH Uk Guideline 20114 – modified to take account of higher prevalence of HiV in iDU population in ireland compared to 
Uk**. the last two rows are not contained in the BASHH Guideline table**)
Source HIV status
HIV-positive Unknown, from high 
prevalence group/
area*
Unknown, from 
low prevalence 
group/area
Viral load 
detectable
Viral load 
undetectable
Receptive anal sex Recommend Recommend Recommend Not recommended
insertive anal sex Recommend Not 
recommended
Consider† Not recommended
Receptive vaginal sex Recommend Not 
recommended
Consider† Not recommended
insertive vaginal sex Recommend Not 
recommended
Consider† Not recommended
Fellatio with ejaculation ‡ Consider Not 
recommended
Not recommended Not recommended
Fellatio without ejaculation‡ Not recommended Not 
recommended
Not recommended Not recommended
Splash of semen into eye Consider Not 
recommended
Not recommended Not recommended
Cunnilingus Not recommended Not 
recommended
Not recommended Not recommended
Sharing of injecting 
equipment
Recommend Not 
recommended
Consider Not recommended
Human bite§ Consider** in 
very limited 
circumstances (see 
Bite algorithm, 
appendix 6)
Not 
recommended
Not recommended Not recommended
Needlestick from a discarded 
needle in the community
Consider in very limited 
circumstances** (see 
Needlestick/Sharps 
algorithm, appendix 3)
Not recommended
Needlestick direct from 
source**
Recommend Not 
recommended
Consider Not recommended
Blood splash to non-intact 
skin, eye or mouth**
Consider Not 
recommended
Not recommended Not recommended
* High prevalence groups within this recommendation are those where there is a significant likelihood of the source individual being HiV-
positive. Within ireland at present, this is likely to be men who have sex with men, and individuals who have immigrated from areas of high 
HiV prevalence (particularly sub-Saharan Africa) (See map of global HiV prevalence, appendix 26)
† More detailed knowledge of local prevalence of HiV within communities may change these recommendations from consider to recommend in 
areas of particularly high HiV prevalence
‡PEP is not recommended for individuals receiving fellatio, i.e. inserting their penis into another’s oral cavity
§A bite is assumed to constitute breakage of the skin with passage of blood
**Denotes parts of table that differ from BASHH Guideline
Estimating probability that source is HIV positive
in the case of a significant exposure, every effort should be made to ascertain the HiV status of the source.
If the source is known, the exposure should be outlined to the source and consent requested for blood to test 
for HiV Ag/Ab (and HBsAg, anti-HBc and anti-HCV)(appendices 30 & 31).
•  The source is considered HIV negative if there is a recent HiV negative result within the past 3 months plus 
no clinical indication of a retroviral/ seroconversion-like illness, and source is not considered to be at high 
risk of infection. 
•  The source is considered HIV positive if they have a positive HiV result, or a physician has diagnosed HiV or 
the source self-reports a diagnosis of HiV. A low or undetectable HiV viral load greatly diminishes but does 
not completely eliminate the risk of transmission. PEP should be discussed with the treating iD consultant 
if the source is on anti HiV medication. if not contactable, commence standard PEP. 
 
If the exposure involves a source person with either unknown HIV status or unknown identity it is not 
possible to give reassurance that the risk of HiV infection is zero. However, it may be possible to estimate 
risk, eg is the source from a high risk group such as IDU, MSM or from a country of high prevalence (COHP)? 
(See appendices 25 & 26 on HiV epidemiology and risk of transmission, and maps of global HiV prevalence 
and prevalence in iDUs).
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Counselling
if the risk of HiV is estimated to be high and PEP is being considered, the recipient should receive 
counselling on the risks and benefits of PEP. the counselling should cover:
•  The estimated HIV risk.
•   The potentially serious adverse reactions to PEP which must be balanced against the risk of HIV 
infection.
•   The possible requirement to inform insurer of a positive test result, as is applicable for an existing 
policy or for a new application 
•   The benefits of early identification versus the implications of a positive result.
•   The window period.
Give the recipient an information leaflet about significant exposures (appendix 29).
Decision not to give PEP
if PEP is not to be given, explain why. Arrange for follow-up to be carried out by a GP, occupational 
health service or Sti clinic as appropriate (appendix 36). 
Decision to give PEP
if a decision is taken to prescribe PEP, the recipient should be advised:
•   How to take the medication.
•   The importance of adhering to the prescribed medication.
•   The expected side effects.
•   That only a starter pack is being prescribed.
Give the recipient a HiV PEP information leaflet (appendix 32)
Baseline investigations of recipient prior to prescribing HIV PEP
Baseline investigations prior to prescribing PEP are outlined in table 4. Blood samples should be 
labelled “Possible BBV exposure – recipient”.
Table 4  Baseline recipient investigations prior to prescribing PEP 
Safety bloods FBC, U&E, LFTs, Bone profile Must be reviewed 
prior to discharge 
home
Pregnancy test Urine strip
Urinalysis Dipstick for proteinuria
HiV testing HiV Ag/Ab
Hepatitis HBsAg, anti-HBc, anti-HCV 
Syphilis if sexual exposure
Prescribing HIV PEP 
Key points
•  Discuss with senior doctor in emergency medicine or infectious diseases if unsure how to proceed. 
•  Only start PEP within 72 hours of the risk event. 
•  The first dose of PEP should be given as soon as possible. It is not necessary to wait for blood results 
on the recipient (table 4) or the source.
•  Ensure baseline safety bloods are within normal limits before discharge. If there is renal impairment or 
proteinuria, see special prescribing situations below.
•  PEP should be discontinued immediately if a HIV test on the source is found to be negative, unless the 
source is at high risk of recent infection.
•  It is important to note that antiretrovirals are unlicensed in Ireland for PEP. However, there are no 
licensed alternatives and they are widely used internationally and accepted as best practice.
Drug Interactions
Antiretroviral medications may have potentially serious drug-drug or drug-disease interactions, 
affecting patient safety and the effectiveness of prophylaxis. therefore, a full medication history 
(including herbal remedies) should be completed and reviewed with the patient’s blood results, medical 
history and the reference sources detailed below before HiV PEP is prescribed. HiV PEP can reduce the 
effectiveness of the oral contraceptive pill. 
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information in the area of HiV therapeutics changes rapidly, so it is important to use up-to-date 
reference sources:
•  Product insert of the medicinal product
•   British National Formulary (BNF)
•   http://www.hiv-druginteractions.org/
•  www.medicines.ie
Medications - Adults
Standard regimen: is truvada® (tenofovir/emtricitabine) one blue tablet daily, plus kaletra® (lopinavir/
ritonavir) four yellow tablets once daily,3,10,11,12 a total of 5 tablets/day. the tablets should be taken 
with food as this improves tenofovir absorption and may reduce nausea. if patients have difficulty in 
swallowing, truvada® can be dispersed in approximately 100ml of water or orange juice and taken 
immediately. kaletra® tablets, however, should be swallowed whole and not chewed, broken or crushed 
(see table 6 for further details about kaletra®). 
treatment duration is 4 weeks. A starter pack (3-5 days) of medication only should be provided in 
emergency care. it is important that the patient not miss any dose. 
 
Truvada Kaletra
Once daily
Side effects: Gi side effects are common and may be relieved by domperidone and/or loperamide. 
these are available without prescription. they may be included in the PEP pack and the patient should 
be counselled on their use to minimise side effects. Headache is common. Severe side effects are 
uncommon, but include renal impairment and hepatotoxicity. See tables 5 and 6 for details of common 
side effects.
All medications must be reviewed by an iD/HiV specialist or by a clinician with significant experience in 
managing HiV PEP before the starter pack runs out. A leaflet explaining the contents of the pack, the 
possible side effects and brief advice on how to deal with them should be provided for future reference 
by the patient (appendix 30). 
Special prescribing situations 
if the source is known to be HiV positive and on antiretroviral drugs: Discuss with iD/HiV specialist. if not 
contactable, commence standard regimen and ensure follow up with iD/HiV specialist urgently. 
Renal impairment or proteinuria: Give first dose of truvada® and discuss with iD/HiV specialist regarding 
the need for dose adjustment. kaletra® can be given.
Pregnancy: if indicated, commence same PEP. Ensure urgent specialist follow up.
Breastfeeding: Breastfeeding is generally not recommended while taking PEP. if the patient is currently 
breastfeeding or considering breastfeeding, this should be discussed with an obstetrician or an iD/HiV 
specialist.
Patients unable to tolerate 3-drug PEP: in exceptional circumstances the regimen can be switched to 
truvada® alone. this should always be discussed first with an iD/HiV specialist.
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Medications - Children 
the risk assessment should be as per adults. the treatment is outlined below.
Counsel and advise the family.  
Regimens 
Accurate weight and height measurements should be used to calculate doses.
Surface area calculation:
Children under 40kg (and adolescents >40kg unable to swallow tablets): triple therapy with 
zidovudine, lamivudine and kaletra®.13
Children and adolescents over 40kg (able to swallow tablets): triple therapy with truvada® 
(tenofovir and emtricitabine) and kaletra®. An alternative for truvada®, for a child with renal 
insufficiency, is Combivir® (zidovudine and lamivudine).13
Paediatric starter packs are not in use and not recommended as drugs are dispensed according 
to the individual’s body surface area. it is recommended that all centres with paediatric units 
should have paediatric HiV PEP preparations in stock or have formal arrangements in place 
whereby the drugs can be promptly sourced from another centre.
Table 5  HIV PEP preparations, dosing and side effects, for children (see table 6 for kaletra) 
(Adapted from CHiVA Guidelines 201113) 
Drug Formulation Dose Side Effects*
Zidovudine (AZt, 
ZDV) 
(for child <40kg)
Cap: 100mg (white 
with blue line)/ 250mg 
(White/Blue) 
Liq: 10mg/ml
180mg/m2 /per dose BD to 
a maximum dose of 250mg 
BD
Granulocytopenia and/
or anaemia, nausea, 
headache, myopathy, 
hepatitis, nail pigmentation, 
neuropathy.
lamivudine 
(3tC) 
(for child <40kg)
Cap: 100mg (orange), 
150mg (white)  
Liq: 10mg/ml
4mg/kg/per dose BD to a 
maximum dose of 150mg 
BD
Peripheral neuropathy, 
nausea, diarrhoea, 
headache.
Combivir® (3tC, 
ZDV) (for child 
>40kg)
Combined tablet: ZDV 
300mg/3tC 150mg 
(white)
oNE (1) tablet BD As for ZDV and 3tC
truvada® 
(tDF+FtC) (for 
child >40kg)
Combined tablet: 
tenofovir 245mg & 
emtricitabine 200mg 
(blue)
oNE (1) tablet oD Headache, diarrhoea, 
nausea, vomiting, renal 
tubular dysfunction, bone 
demineralization 
Do not use if known renal 
impairment
*this list of side effects is not exhaustive – refer to product datasheet for detailed information on side effects, interactions with 
other medicines and other cautions for use.
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Table 6  Kaletra® preparations and dosing for adults and children 
(Adapted from CHiVA Guidelines 201113)
Drug Formulation Dose Side effects
kaletra® 
(lopinavir/
ritonavir)
Liq: lopinavir 80mg/ml + 
ritonavir 20mg/ml 
Paediatric tablet: 
lopinavir 100mg & 
ritonavir 25mg (pale 
yellow)    
Adult tablet: lopinavir 
200mg & ritonavir 50mg 
(deep yellow) 
          
Kaletra® Liquid**:
Child: (≥2 yrs): 230mg/m2 BD
OR 
(0.6 - 0.8m2): 200mg BD; 
(0.8 - 1.2m2): 300mg BD; 
(1.2 - 1.7m2): 400mg BD; 
(≥1.4m2): 400mg BD
                                                       
Dose in mls = 230 x BSA/80         
Max dose: 5ml BD
Kaletra® Tablets 100/25mg (Paed):
0.5 - <0.9m2: 2 x 100/25mg  tablets 
BD    
0.9 - <1.4m2: 3 x 100/25mg  tablets 
BD  
≥1.4m2: 4 x 100/25mg  tablets BD
(or 2 adult tablets 
(2 x 200/50mg) BD)  
Adult: 800mg once daily, equivalent 
to:
• 4 Adult tabs once daily
• 8 Paed tabs once daily
• 10ml Paed solution once daily 
  
**All doses based on Lopinavir**
NB:kaletra® tablets MUSt Not be 
cut or crushed
Diarrhoea, abdominal 
pain, nausea, vomiting, 
headache.
in addition, an anti-emetic such as domperidone and an anti-diarrhoeal such as loperamide 
should be prescribed for use as required in the event of Gi side effects (see BNFC). 
Precautions
Advise the recipient to adopt safe sex practices (ie use condoms) for 3 months. See section 6.2 of 
main guidelines regarding precautions.
Follow-up
A recipient started on HiV PEP should be monitored by a clinician specialising in HiV treatment 
or a clinician with significant experience in managing HiV PEP. An urgent referral should be 
made to ensure that this visit takes place before the starter pack runs out (appendix 35). the 
doctor should complete the patient management form (appendix 1). this will serve as a referral 
form for the specialist clinic. Follow-up arrangements should be recorded in the patient’s notes.
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eMI Guidelines - Appendix 9   Testing of recipient for bloodborne viruses
testInG of reCIPIent for 
BloodBorne VIruses
1. this section does not cover testing of the recipient for the purpose of monitoring HiV PEP 
treatment.
2. if a significant exposure has occurred, BBV testing of the recipient at baseline and over 
a period of follow-up may be indicated. if no significant exposure has occurred, then no 
recipient testing is required.
3. if test results on the source are available and show that the source is negative for HBV, HCV 
and HiV, and the source is not considered to be at high-risk for recent infection, then testing of 
the recipient is not required.
4. informed consent should be obtained from the recipient before any testing is carried out 
(appendices 29 &30).
5. if recipient testing is considered to be appropriate, the recipient should be given the option 
of having the baseline sample tested now, or retained for possible testing at a later time. 
Baseline testing is to reflect the recipient’s current status - not to test for infection related to 
the current exposure. 
BBV testing of recipient where a significant exposure has occurred
Time of test Status of source
1. BBV status unknown OR
2. Negative but high-risk OR
3. Positive for HBV, HCV or HIV
Negative for HBV, HCV 
and HIV AND not high-
risk
Baseline* HBsAg†
Anti-HBc
Anti-HCV
HiV Ag/Ab
testing of recipient not 
required
6 weeks HBsAg†
Anti-HCV 
HCV Ag or RNA
HiV Ag/Ab
3 months HBsAg†
Anti-HCV 
HCV Ag or RNA
HiV Ag/Ab‡
*Recipient to be given option of testing now, or retaining blood for possible testing later
† if recipient documented to have an adequate response to HBV vaccine, it is not necessary to test for HBsAg
‡ if HiV PEP is taken by the recipient, the final HiV Ag/Ab test should be at 3 months from completion of PEP instead of 3 months 
after the exposure
Anti-HBs testing: 
if the recipient was previously vaccinated but anti-HBs level post-vaccination is unknown, and 
HBiG administration (in addition to vaccine booster) is now being considered, it may be helpful to 
do an anti-HBs test at baseline. if the anti-HBs is ≥10miU/ml, HBiG is not indicated. if anti-HBs 
is <10miU/ml, the result is of no assistance in making the decision about administering HBiG, 
as antibody level declines over time after vaccination but the person may still be protected due 
to immune memory. in this situation, assessment of other factors such as the severity of the 
exposure may assist in making the decision about HBiG.
if recipient initiates a course of HBV vaccination, an anti-HBs test should be carried out 2 months 
after completion of the course of vaccination.
Sample and accompanying information
the sample required is 10mls of clotted blood. the request form should include the following 
information:
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•  label: “Possible BBV exposure – recipient”
•  test and retain for 2 years OR retain only
•  list the tests requested (as per table)
•  Give the details and contact number (preferably mobile number) of the healthcare 
professional to whom the results should be sent
if an RNA test is being done, a second sample is required. this should be transported to the 
laboratory without delay. Arrangements should be discussed with the testing laboratory.
Negative test results
if all these tests are negative, no further testing is needed.
Positive test results
if any of the test results are positive, a referral to an appropriate specialist should be made 
(appendix 35).
Testing of needles
testing of needles or sharps for the presence of BBVs is not recommended.
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eMI Guidelines - Appendix 10  Interpretation of HBV Results
InterPretatIon of hBV results
(Adapted from immunisation Guidelines for ireland. 2008 Edition. National immunisation Advisory Committee, RCPi)
HBsAg HBeAg Anti-HBe Anti-HBc 
IgM
Total anti-
HBc
Anti-HBs Interpretation
Negative Negative Negative Negative Negative Negative Susceptible to HBV
Positive Positive Negative Negative Negative Negative Acute HBV infection
Positive Positive Negative Positive Pos/Neg Negative Acute HBV infection
Negative Negative Negative Positive Positive* Negative Recent HBV infection 
(HBsAg window)
Positive Positive Negative Weak Pos/
Neg
Positive Negative Chronic HBV 
infection**
Positive Negative Pos/Neg Weak Pos/
Neg
Positive Negative HBeAg neg chronic 
infection***
Negative Negative Pos/Neg Negative Positive Pos/Neg Resolved HBV infection
Negative Negative Negative Negative Negative Positive Response to HBV 
vaccine
*Anti–HBc detected in 2 assays
** Follow–up sample required to confirm chronic HBV infection
*** Follow-up sample required and also HBV DNA viral investigations may be required 
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eMI Guidelines - Appendix 11  Hepatitis B vaccine
hePatItIs B VaCCIne
HBV vaccine contains recombinant HBsAg, derived from yeast cells, adsorbed onto aluminium hydroxide 
adjuvant. the vaccine is effective at preventing infection in individuals who produce specific antibodies to 
HBsAg (anti-HBs). However, around 10-15% of adults fail to respond or have a poor response to 3 doses 
of vaccine. Poor response is associated with age over 40 years, male gender, obesity and smoking. lower 
seroconversion rates have also been reported in those with alcoholic liver disease. Patients who are 
immunocompromised or have chronic renal failure may respond less well and may require larger or more 
frequent doses of vaccine.
HBV vaccine is used for pre-exposure and post-exposure protection and provides long-term protection. 
Pre-exposure prophylaxis: Since 2008, all infants are offered HBV vaccine as part of the routine childhood 
immunisation schedule at 2, 4 and 6 months of age. in addition, HBV vaccine is recommended for those who 
are at increased risk of infection because of their occupation, close contact with cases, medical conditions, or 
lifestyle factors such as injecting drug use, and sexual behaviour.
Vaccine efficacy studies have shown that 90-100% of vaccinated persons who develop anti-HBs ≥10miU/ml 
after a primary series are protected from HBV infection. 
Post-exposure: HBV vaccine is highly effective at preventing infection, provided that the vaccine is 
administered preferably within 48 hours but up to 7 days post-exposure. 
Specific hepatitis B immunoglobulin (HBiG) is available for passive protection and, when indicated, is 
normally used in combination with HBV vaccine to confer passive/active immunity after exposure. it should 
be administered according to the manufacturer’s guidelines and should ideally be given within 48 hours of 
exposure but not later than a week after exposure. HBiG provides short-term protection (3-6 months) (see 
appendix 13)
Schedule and dosage:
the basic HBV immunisation schedule consists of three doses of vaccine at 0, 1 and 6 months. Alternative 
accelerated schedules exist (eg 0, 1 and 2 months; 0, 7 and 21 days – see manufacturer’s guidelines) if more 
rapid protection is required. these should be followed by a dose of vaccine at 12 months to complete the course.
Currently licensed vaccines contain different concentrations of antigen. the appropriate manufacturer’s dosage 
should be adhered to. Higher doses of vaccine should be used for adult patients with chronic renal failure, and 
considered for other immunosuppressed adults.
Administration: the vaccine is given intramuscularly in the deltoid region and not in the gluteal region. in the 
case of infants, the vaccine may be given in the anterolateral thigh. 
Contraindications: the vaccine is contraindicated in a person who has had an anaphylactic reaction to 
preceding doses of a HBV-containing vaccine or any of its constituents. 
Pregnancy and breastfeeding: Pregnancy is not a contraindication to HBV vaccination. No adverse effect 
on the developing foetus has been observed when pregnant women have been immunised against HBV. 
Breastfeeding is not a contraindication to HBV immunisation. 
Adverse reactions: HBV vaccine is generally well tolerated. the commonest reactions are soreness and redness 
at the injection site. Fever, rash, malaise and influenza-like symptoms are less commonly reported after 
vaccination.
Post-vaccination testing: Routine post-vaccination testing for anti-HBs is recommended 2 months after 
completing the course of vaccination for persons who are at continuing risk of HBV exposure. Following primary 
vaccination, it is preferable to achieve anti-HBs levels above 100miU/ml although levels above 10miU/ml are 
generally accepted as protecting against infection. Anti-HBs titre often declines post-vaccination but a rapid 
anamnestic response develops after exposure to the virus.
Reference
Royal College of Physicians of ireland, National immunisation Advisory Committee. immunisation Guidelines for ireland 2008 . Available 
from: http://www.immunisation.ie/en/HealthcareProfessionals/immunisationGuidelines2008/.
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eMI Guidelines - Appendix 12  Hepatitis B vaccination patient record card
hePatItIs B VaCCInatIon 
PatIent reCord Card
Patient Record Card
Patient MRN: 
Patient Name: 
Healthcare Facility: 
Vaccine 1 Date: 
Next vaccine dose due: 
Vaccine 2 Date: 
Next vaccine dose due: 
Vaccine 3 Date: 
Return for Blood test on:  
Post Vaccination Anti-HBs titre level:
It is important that all doses of vaccine are administered
Please keep safe and bring card with you for hospital appointments 
A downloadable version of this card can be found at www.emitoolkit.ie
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eMI Guidelines - Appendix 13  Hepatitis B immunoglobulin (HBIG)
hePatItIs B IMMunoGloBulIn (hBIG)
if HBiG is indicated (see appendix 8 re HBV PEP), it should be administered according to the 
manufacturer’s guidelines. it should ideally be given within 48 hours of exposure but not later than 1 week 
after exposure.
Hepatect CP® (Biotest Pharm GmbH) 50 units/ml is the HBiG product available in ireland. 
the dose for post-exposure prophylaxis in adults is 500 units (10 ml). For children, the dose is 8 units (0.16 
ml)/kg. 
Hepatect CP® should be infused intravenously at an initial rate of 0.1 ml/kg/hour for 10 minutes. if 
tolerated, the rate of administration may gradually be increased to a maximum of 1 ml/kg/hour.
Do not dilute Hepatect CP® or mix Hepatect CP® with any fluid.
the first dose of HBV vaccine can be given on the same day as HBiG but at a different site.
theoretical risk of infection
According to the  Hepatect CP® Summary of Product Characteristics (SPC) (http://www.imb.ie/images/
uploaded/swedocuments/licenseSPC_PA0592-005-004_19072010150738.pdf):
 “Standard measures to prevent infections resulting from the use of medicinal products prepared from 
human blood or plasma include selection of donors, screening of individual donations and plasma pools 
for specific markers of infection and the inclusion of effective manufacturing steps for the inactivation/
removal of viruses. Despite this, when medicinal products prepared from human blood or plasma are 
administered, the possibility of transmitting infective agents cannot be totally excluded. this also applies 
to unknown or emerging viruses and other pathogens.
the measures taken are considered effective for enveloped viruses such as HiV, HBV and HCV. the 
measures taken may be of limited value against non-enveloped viruses such as HAV and parvovirus B19.
there is reassuring clinical experience regarding the lack of hepatitis A or parvovirus B19 transmission 
with immunoglobulins and it is also assumed that the antibody content makes an important contribution 
to the viral safety.
it is strongly recommended that every time that  Hepatect CP® is administered to a patient, the name and 
batch number of the product are recorded in order to maintain a link between the patient and the batch of 
the product.”
Reference
Royal College of Physicians of ireland, National immunisation Advisory Committee. immunisation Guidelines for ireland 2008 . 
Available from: http://www.immunisation.ie/en/HealthcareProfessionals/immunisationGuidelines2008/.
t
o
o
l
k
it
-51-
eMI Guidelines - Appendix 14  Treatment of acute hepatitis C
 treatMent of aCute hePatItIs C
Currently there is no recommended post-exposure prophylaxis for HCV. However, treatment 
of early infection has been shown to be successful.
A review of 17 published studies on therapy of acute hepatitis C was carried out by Alberti et al.1  
Almost all of these studies were small in size, uncontrolled and highly heterogeneous in respect 
of patient features, dose and duration of treatment, follow-up evaluation, and criteria used 
to define efficacy and safety. However, the authors concluded that the pooled results strongly 
support the benefit of interferon therapy in reducing chronicity of acute hepatitis C, a finding 
that was confirmed by a formal meta-analysis of several randomised controlled trials of acute 
hepatitis C treatment. the pooled data from 17 studies showed a sustained virological response 
(SVR) of 62% (range 37-100%) in the treated patients, compared with 12% (range 0-20%) in 
untreated individuals. 
in the United kingdom, the surveillance system for occupational exposures to BBVs in healthcare 
workers (HCWs)has reported that, of 10 HCWs who received treatment for acute HCV, all had 
achieved an SVR.2  
in a review article on acute hepatitis C, Maheshwari et al state that, despite the absence of large 
randomised trials, it is reasonable to conclude that early treatment could reduce the chronicity 
of HCV infection.3 However, several issues of therapy are unresolved, such as: which patients to 
treat, when to start treatment and what regimen is optimal.
Recommendation:
it is essential that patients who develop acute hepatitis C infection are diagnosed as soon as 
possible to allow for early treatment. therefore, a HCV Ag or HCV RNA test on the recipient is 
carried out at six weeks and three months after the exposure incident. the recipient should also 
be counselled for symptoms suggestive of acute infection, eg fever, abdominal pain, vomiting, 
dark urine, yellow eyes. A person with symptoms suggestive of hepatitis, or a positive HCV RNA 
or Ag result, should be evaluated immediately by an infectious diseases physician.
References    
1. Alberti A, Boccato S, Vario A, Benvegnu l. therapy of acute hepatitis C. Hepatology 2002;36:S195-S200.
2. Health Protection Agency Centre for infections, National Public Health Service for Wales, CDSC Northern 
ireland and Health Protection Scotland. Eye of the Needle. Surveillance of significant occupational exposure to 
bloodborne viruses in healthcare workers. November 2008.
3. Maheshwari A, Ray S, thuluvath PJ. Acute hepatitis C. lancet 2008;372:321-32
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eMI Guidelines - Appendix 15  Tetanus
tetanus  
(Adapted from Royal College of Physicians of ireland, National immunisation Advisory Committee. 
immunisation Guidelines for ireland 2008 . Available from: http://www.immunisation.ie/en/
HealthcareProfessionals/immunisationGuidelines2008/.)
Prophylaxis for tetanus-prone wounds
the following wounds are considered tetanus-prone:
•  Wounds contaminated with soil, faeces, saliva or foreign bodies
•  Puncture wounds*, avulsions, burns or crush injuries
•  Wounds or burns requiring surgical treatment which is delayed for more than 6 hours
•  Compound fractures
Note: occasionally, apparently trivial injuries can result in tetanus.
*Needlestick injuries in healthcare settings are unlikely to pose a risk of tetanus.
Risk assessment of wounds for use of tetanus immunoglobulin (TIG) (1)
Age Immunisation status Clean wound Tetanus prone wound
<4 years <3 doses or unknown
3 or more doses
DtaP/iPV+/- Hib(2)
Nil
tiG, DtaP/iPV +/- Hib(3)
Nil
Consider  tiG(1)
>4 to 9 years <3 doses or unknown
3 doses only, >5 years 
since last dose
3 or more doses, <5 
years since last tetanus 
toxoid
4 or more doses, >5 
years since last dose
DtaP/iPV
DtaP/iPV
Nil
Nil
tiG plus DtaP/iPV
DtaP/iPV
Consider tiG(1)
Nil
Consider tiG(1)
DtaP/iPV, consider tiG(1) 
10 years and over <3 doses or unknown
3 or more doses, >10 
years since last dose
3 or more doses, <10 
years since last dose
td
td
Nil
tiG plus td/iPV
td, consider tiG(1)
Consider tiG(1)
(1) Consider tiG if wound contaminated with stable manure, or if extensive devitalised tissue. Give tiG if 
HiV positive, irrespective of vaccine status.
(2) if last tetanus containing vaccine <1 month previously, defer for 1 month
(3) if child is >1 year, the follow-up vaccine(s) will be DtaP/iPV or DtaP/iPV/Hib (only one dose of Hib is 
required >1 year).
tiG tetanus immunoglobulin
DtaP/iPV/Hib  Diphtheria, tetanus and acellular pertussis vaccine/inactivated polio virus vaccine/ 
haemophilus influenzae b vaccine
DtaP/iPV Diphtheria, tetanus and acellular pertussis vaccine/inactivated polio virus vaccine
td/iPV  tetanus, low-dose diphtheria/inactivated polio virus vaccine 
tdap  tetanus, low-dose diphtheria and low-dose acellular pertussis vaccine
Important:
If both TIG plus a vaccine are to be given, administer at separate sites.
Refer to GP for follow-up vaccines.
Batch numbers and expiry dates must be recorded for all vaccines given.
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eMI Guidelines - Appendix 15  Tetanus
This information MUST be communicated to the patient’s GP so that:
•  Duplication of vaccination does not occur
•  Full records may be passed onto the relevant agencies in order that a full nationwide 
database is kept of batch numbers and expiry dates of vaccines given to children.
Specific anti-tetanus immunoglobulin
Indications
(1) those with tetanus-prone wounds who have not received at least 3 doses of tetanus toxoid 
and their last dose within 10 years ( see table above)
(2) Patients with impaired immunity who suffer a tetanus-prone wound – may in addition 
require anti-tetanus immunoglobulin
(3) Patients who have suffered a high-risk wound, regardless of vaccine history.
Dose and route of administration
Prevention
250 units intramuscularly into the anterolateral thigh.
the single dose of tiG is doubled to 500 units (2ml) when any of the following situations exist:
•  The injury occurred more than 24 hours previously
•  The patient weights more than 90kg
•  The wound is heavily contaminated
•  The wound is infected or involves a fracture
Treatment
150 units/kg given in multiple sites. Specific anti-tetanus immunoglobulin is available in 1ml 
ampoules containing 250 units.
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PresCrIBInG InforMatIon for 
leVonorGestrel 
(eMerGenCy ContraCePtIon)
Please note that the provision of family planning services is not considered within the normal 
remit of the Emergency Department. However, there are situations where emergency hormonal 
contraception is considered appropriate.
When should emergency hormonal contraception be considered? 
1)  in females presenting for post-exposure prophylaxis (or consideration of same) following 
potential sexual exposure to HiV. 
2) in females presenting for assessment following sexual assault. 
Please note that insertion of a copper iUD is a more effective form of emergency contraception 
than levonorgestrel (levonelle™). Copper iUDs are available at Family Planning and Well 
Woman Clinics. Advice on how to obtain an iUD should be offered to all women attending for 
emergency contraception even if presenting within 72 hrs of unprotected sexual intercourse 
(UPSi).
How does levonorgestrel prevent pregnancy? 
the exact mode of action of levonorgestrel in preventing pregnancy following UPSi is not known. 
if taken in the preovulatory phase it will usually inhibit ovulation for 5-7 days, by which time 
any sperm in the upper reproductive tract have lost their fertilising ability. it may also cause 
endometrial changes that discourage implantation.
it is important to remember that women must not consider themselves protected against 
pregnancy for the rest of their cycle following a dose of levonorgestrel. this is particularly 
important if levonorgestrel has the effect of delaying ovulation. 
Results from a recent clinical study1 showed that a 1500 microgram single dose of levonorgestrel 
(taken within 72 hours of UPSi) prevented 82% of expected pregnancies. 
When can it be given? 
levonorgestrel should be given as soon as possible after UPSi. it is most effective when given 
within 72 hours of UPSi. Efficacy is reduced after this time. 
Use of levonorgestrel between 73 and 120 hours post UPSi may be associated with a reduced 
expected pregnancy rate and may be considered. Use of levonorgestrel after 72 hours is outside 
of the product licence. Women should be informed about the limited evidence of efficacy, that 
such use is outside product licence and should consider attending a family planning clinic for 
insertion of an iUD. 
there is no data on the effect of levonorgestrel after 120 hours post UPSi. 
What is the dose? 
the usual dose of levonorgestrel is 1.5mg stat, given as soon as possible after UPSi. 
it is not necessary to give prophylactic antiemetics routinely with levonorgestrel. Antiemetics can 
be reserved for women who give a history of vomiting when they have taken levonorgestrel in the 
past or where a woman is receiving a second dose because of vomiting within 3 hours of taking 
levonorgestrel (see below). 
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the metabolism of levonorgestrel is enhanced by concomitant use of liver enzyme inducers. 
Drugs suspected of having the capacity to reduce the efficacy of levonorgestrel containing 
medication include barbiturates (including primidone), phenytoin, carbamazepine, herbal 
medicines containing Hypericum perforatum (St. John’s Wort), rifampicin, ritonavir, rifabutin, 
griseofulvin. 
Medicines containing levonorgestrel may increase the risk of cyclosporin toxicity due to possible 
inhibition of cyclosporin metabolism. For further information on drug interactions check with a 
pharmacist or consult  the British National Formulary, BNF.
in women taking liver enzyme inducers the current recommendation from the Faculty of Family 
Planning is that the women take 3mg levonorgestrel stat.2 they should also be referred to a 
family planning clinic for insertion of an iUD. 
Please note that this increased dose does not apply to women who are just about to initiate a 
liver enzyme inducing drug as part of HiV post-exposure prophylaxis. 
Contraindications to using levonorgestrel 
1)  there is no age limit to the use of levonorgestrel, although there is little data on its use in 
females under 16 years of age. 
2)  the WHo Medical eligibility Criteria for Contraceptive use advises that there are no medical 
contraindications to levonorgestrel.3 the SPC (summary of product characteristics) for 
levonelle™ advises caution in women with severe hepatic dysfunction, hereditary problems 
of galactose intolerance, the lapp lactase deficiency or glucose-galactose malabsorption. 
Women with severe malabsorption syndromes (such as Crohn’s disease) may experience a 
reduction in efficacy of oral emergency contraception. 
3)  Any women known to have hypersensitivity to levonogestrel or any of the other components of 
the tablet should use levonorgestrel with caution. 
Please refer to the Faculty of Family Planning website (http://www.ffprhc.org.uk) or the 
Summary of Product Characteristics (http://www.medicines.ie/medicine/10951/SPC/
levonelle+1500/) for further information.
(Adapted from protocol of St James’s Hospital Emergency Department May 2010)
For information leaflet on emergency contraception, see appendix 33.
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oCCuPatIonal Blood or Body fluId 
exPosure
this section relates to workplaces where a risk assessment has indicated that blood and body fluid exposures 
are an occupational hazard. Such occupations include, but are not limited to, the healthcare sector, members 
of An Garda Siochana, and prison personnel.
Each occupational health service should have a local policy for the prevention and management of blood and 
body fluid exposures. this policy should take into account local expertise and local resources, which in turn will 
dictate whether the employee is managed at the initial stage in the occupational health department (oHD), 
local emergency department (ED) or elsewhere.  
in occupations where infectious exposures are recognized as potential hazards, a hierarchical approach to 
management is required and the focus should be on prevention.1 
Employees should be informed of the correct course of action to follow in the event of an occupational blood 
or body fluid exposure at commencement of their employment. Furthermore, employees should be reminded 
that they should not manage these exposures themselves but should report the exposure and follow local 
management arrangements.  
training of employees in the correct use of instruments (including personal protective equipment) is 
recommended.2, 3, 4 While this should reduce the frequency of exposures, unfortunately it will not completely 
eliminate blood and body fluid exposures. Where vaccination is available, it must be provided by the employer. 
At present, this is only available for hepatitis B (see appendix 11, Hepatitis B vaccine). Where an employee 
does not achieve an adequate protective antibody response, they should be counselled regarding the risk of 
exposures to hepatitis B infected blood and the recommended management of such exposures. this should be 
documented. 
the needlestick/sharps exposure algorithm (appendix 3) outlines the initial management of any employee 
who is exposed to blood or body fluids in the course of their work. Further details and relevant background 
information are included elsewhere in the guideline. local resources will dictate where the worker is managed 
at the initial stage i.e oHD, ED or other and where follow-up is carried out i.e. oHD, infectious diseases service.
in addition to the risk of disease transmission, blood and body fluid exposures are a recognised cause of 
distress among recipients, with potential medical and legal ramifications. Anxiety, insomnia and depression 
are frequently reported, while more extreme cases of post-traumatic stress disorder and panic attacks 
have also been described. to minimise this, clear and consistent information should be provided including 
the risks of disease transmission, details of the management and follow-up plan, symptoms suggestive of 
seroconversion illness, likely side effects and potential drug interactions of treatment (where relevant) and any 
workplace/life-style modification that may be indicated (see information leaflets, appendices 29 and 32).  
in all cases, the details of the injury, including the context of the injury and the nature of the device involved, 
should be recorded (appendix 1, patient management form). this information is required both in the initial 
assessment process (see Section 2 of the Guidelines) and to inform future decision making (e.g. purchasing 
policies, training, counselling requirements) regarding preventative measures. in addition, the oHD should be 
able to provide anonymous details of injuries to the Health & Safety Authority and for auditing purposes.
References
1.  Health and Safety Authority. Prevention of Sharps injuries in Healthcare. [online] March 2011. [Cited: 14 January 2012.] http://www.hsa.ie/eng/
Publications_and_Forms/Publications/information_Sheets/Prevention_of_Sharps_injuries_in_Healthcare.html.
2. official Journal of the European Union. CoUNCil DiRECtiVE 2010/32/EU of 10 May 2010 implementing the Framework Agreement on 
prevention from sharp injuries in the hospital and healthcare sector concluded by HoSPEEM and EPSU. [online] 1 June 2010. [Cited: 14 January 
2012.] http://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=OJ:L:2010:134:0066:0072:EN:PDF.
3.  office of the Attorney General. S.i. No. 146/1994 — Safety, Health and Welfare At Work (Biological Agents) Regulations, 1994. [online] 1994. 
http://www.irishstatutebook.ie/1994/en/si/0146.html.
4.  office of the Attorney General. S.i. No. 248/1998 — Safety, Health and Welfare At Work (Biological Agents) (Amendment) Regulations, 1998. 
[online] 1998. http://www.irishstatutebook.ie/1998/en/si/0248.html.
t
o
o
l
k
it
-57-
eMI Guidelines - Appendix 18  Human bite injuries, saliva and transmission of bloodborne viruses
huMan BIte InjurIes, salIVa and 
transMIssIon of BloodBorne 
VIruses
Summary of BBV transmission risk from exposure to saliva
the risk of BBV transmission from exposure to saliva is very low overall. it is related to the type of 
injury, the type of virus present, and the amount of blood in the saliva. Saliva cannot transmit BBVs 
unless blood is present, although blood can be present without being visible. the risk is increased if 
there is visible blood, poor oral hygiene, or if the source or recipient is immunocompromised. if there 
is a large amount of blood present in the saliva, the risk is similar to the risk from exposure to blood. 
 
With bite cases, an individual risk assessment is required, taking account of the extent of the injury, 
the HBV immunisation status of the injured person and the BBV status of the source and the injured 
person. With the exception of a deep bite wound sustained from a HBV infected, or high-risk, source, 
in a recipient who is not HBV immune, the risk of BBV transmission is negligible. the evidence 
suggests that the risk of transmission from a HiV positive or HCV positive source is minimal to non-
existent. A recipient of a bite that breaches the skin but with no visible source blood does not require 
any follow-up from the point of view of HiV and HCV. 
HBV vaccination should be advised for an unvaccinated recipient following a percutaneous or 
mucous membrane exposure to saliva from a source who is HBV infected or high-risk but of unknown 
sero-status (see appendix 8). HBiG may also be indicated, depending on the risk assessment, but 
generally only if the source is HBV positive. if HBiG is required, it should ideally be given within 48 
hours of exposure, but not later than a week after exposure. HiV PEP would not be indicated except 
in extreme circumstances.
Saliva and bloodborne viruses
Although composed mainly of water (99%), saliva is a complex secretion. Saliva can be considered 
as gland-specific saliva or whole saliva. Whole saliva (mixed saliva) is a mixture of oral fluids 
and includes secretions from both the major and minor salivary glands, in addition to several 
constituents of non-salivary origin, such as gingival crevicular fluid, expectorated bronchial and 
nasal secretions, serum and blood derivatives from oral wounds, bacteria and bacterial products, 
viruses and fungi, desquamated epithelial cells, other cellular components, and food debris. Saliva 
has protective properties and contains a variety of antimicrobial constituents and growth factors.  
in general, complete bloodborne viruses are not secreted into saliva, even though the bloodborne 
viruses HBV, HCV and HiV have all been detected by molecular techniques in saliva of infected 
patients. BBVs get there from blood leakage into the oral cavity, either from soft or hard tissue 
trauma or from periodontal bleeding. Salivary fluids exiting the glands mirror the composition of 
macromolecules in blood. Viral particles usually are too large to filter through the salivary glands 
and into saliva. However, individual components of unassembled viral particles can get through the 
glands, such as hepatitis B surface antigen or DNA, and appear in saliva without the presence of 
blood.  However, transmission can only occur if completely assembled HBV particles are in the saliva.  
No studies are available that prove that HBV is transmitted through saliva in the absence of blood.  
the same holds true for HCV and HiV. The bottom line is that saliva can only transmit BBVs to the 
extent that blood is present. 
However, even when blood is not visible, it can still be present in limited quantities in the saliva 
and therefore saliva is considered a potentially infectious material in any percutaneous or 
mucous membrane exposure by the US CDC and occupational Safety and Health Administration 
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(oSHA). A bite from someone known to have poor gum health, diabetes, immunocompromise, or on 
anticoagulant medication, may increase the risk. Dentists are occupationally exposed to saliva, and 
prior to 1982 when the HBV vaccine was not available and exam gloves were not routinely used, their 
seroprevalence of HBV markers of infection was about 15%. the HCV seroprevalence in dentists is 
about 0.5%, and for HiV it is under 0.025%. therefore, the risk of transmission from percutaneous or 
mucous membrane contact is proportional to the amount of blood in the saliva and the type of virus 
present.
 
Hepatitis B
HBV has been demonstrated in the saliva of HBV infected people and a high correlation has been 
shown between HBV DNA levels in serum and saliva.1,2,3 Saliva has been suggested as a vehicle for 
horizontal transmission of HBV among children. A study of paired saliva and plasma samples from 43 
children with chronic HBV infection found  high levels of HBV DNA (mean 33.9 x 103 iU/ml) in saliva 
of HBeAg positive children but HBV DNA was not detectable in the saliva samples from the HBeAg 
negative children.4
transmission of HBV by human bite has been described and definitively proven by genome sequencing 
of the virus in the carrier and in the bitten person.5
Hepatitis C
HCV has been shown to be frequently present in the saliva of HCV infected people.6,7,8 However, 
epidemiological studies show that infection by contact with contaminated saliva is rare.8 it may be 
that the specific and non-specific defence mechanisms present in saliva could attenuate or abolish 
the infective capacity of viral particles. Saliva of patients with chronic HCV infection contains specific 
igG and igA neutralising antibodies directed against the E1 and E2 surface glycoproteins which could 
block viral adhesion to the host cell.9 there is conflicting evidence about the relationship between the 
presence of the hepatitis C virus in the saliva and the viral load in the blood, with one review suggesting 
a direct relationship8; however, one study found that the presence of HCV in saliva is independent of the 
level of viral load.10
there have been no reports proving the direct transmission of HCV by saliva: the possibility of 
transmission of HCV by a human bite has not been confirmed by molecular studies.8 Data suggest 
that nosocomial transmission of HCV to dental HCWs is unlikely.11  A review of the evidence on HCV 
transmission by saliva8 found that the prevalence of HCV infection among dental health care workers 
exposed to saliva is similar to that for the general population. 
HIV 
Salivary proteins play a role in the inactivation of HiV and preventing its infectivity.12 HiV virus is 
detectable in saliva, especially in immune compromised patients as CD4 count declines and plasma 
viral load increases. in countries where HiV positive patients receive successful anti-viral therapy 
(HAARt), viral load is undetectable in most cases and the risk of oral transmission of HiV is probably 
low to non-existent.
Bite injuries represent a potential means of transmitting HiV. However, HiV transmission by this route 
has been reported rarely.13 the few documented cases of possible HiV transmission following bites were 
in adults exposed to blood-tinged saliva.14
transmission might theoretically occur either through biting or receiving a bite from a HiV-infected 
person. Biting a HiV-infected person, resulting in a break in the skin, exposes the oral mucous 
membranes to infected blood; being bitten by a HiV-infected person exposes non-intact skin to 
saliva. Saliva that is not contaminated with blood contains HiV in much lower titres and constitutes a 
negligible risk. A bite is not considered a risk exposure to either party when the integrity of the skin is 
not disrupted.
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A review of literature on human bites and HiV transmission15 concluded that it is possible for a bite from a 
HiV-infected individual to transmit HiV. the likely risk of transmission is increased if:
•  Blood is present in the oral cavity
•  The bite breaks the skin
•  The bite is associated with a previous injury
•  The biter is IgA deficient.
huMan BIte InjurIes 
(appendix 6, algorithm for management of human bites)
Background
Human bite wounds may result in infection such as cellulitis, osteomyelitis or septic arthritis. Current 
data suggest an infection rate from human bite wounds of the order of 10% to 50%, depending on the 
wound type and location. However, human bite wounds to the hand are associated with infection rates of 
almost 50%. A clenched-fist injury (“fight bite”) is considered the most serious of all human-bite wounds, 
with bites to feet, face, or skin overlying cartilaginous structures, or bites that penetrate deeper than the 
epidermal layer also significant. Human bites in other areas pose no greater risk than animal bites.
Human bites cause more serious infections than dog and cat bites because the human oral flora contains 
multiple species of bacteria. Human bite wound pathogens include aerobic bacteria (such as streptococci, 
s aureus and eikenella corrodens) and anaerobic bacteria (such as fusobacterium, Peptostreptococcus, 
Prevotella, and Porphyomonas spp.16 
Because individuals with human bite wounds have a high-risk of serious bacterial infections close 
assessment of any bite wound is necessary. overall, the risk of transmission of bloodborne viruses by 
human bites is likely to be low (see above). However, a significant risk of transmission must be considered 
following a human bite from a high-risk individual where a breach of the skin occurs and particularly if 
there is blood in the saliva. the risk is highest where the biter is HBV positive.
Pathophysiology
in a closed-fist injury (“fight bite”), forces sufficient to break the skin from striking an opponent’s tooth 
often inoculate the extensor tendon and its sheath. As the hand is flexed at the time of impact, the 
bacterial load is transferred caudally when the hand is opened and the tendon slides back to its relaxed 
state. Resulting contamination cannot be removed readily through normal cleansing and irrigation. 
When a finger is bitten, such as in a chomping-type injury, tendons and their overlying sheaths are 
in close proximity to the skin. the wound may appear to be a minor abrasion-type injury, but careful 
inspection is required to rule out deep injury.
When a tooth strikes the head, even a deep puncture wound may appear innocuous. Deep, subgaleal, 
bacterial contamination is possible. this is especially true in young children who have relatively thin soft 
scalp and forehead tissue.
Frequency, age and sex
in a 4-year retrospective review in the United kingdom, 421 (13%) human bites were identified out of 
3136 case notes in emergency medicine departments. the majority of those bitten were young males, 
with 44% of the males aged 16-25 years. the male-to-female ratio was 3:1. Closed-fist injuries are 
encountered almost exclusively in young males. toddlers frequently bite one another, but injuries usually 
are superficial and low-risk. 
Mortality/Morbidity
the primary concern with human bites of the hand is infection, which can be severe because of spread 
along tendon sheaths and deep into the hand. Surgical incision and drainage may be needed. Resultant 
scarring and tissue damage may compromise normal function of the hand. 
t
o
o
l
k
it
-60-
infection is also the major complication of bites in other areas of the body. Most can be treated 
adequately; however, infections of poorly vascularized structures, such as ear cartilage, may be difficult 
to treat. 
other serious infectious complications such as deep soft tissue infection, septic arthritis, osteomyelitis, 
infectious tenosynovitis, bacteraemia, necrotizing fasciitis, and osteomyelitis of the skull vault have 
been associated with human bites. 
Risk assessment following a human bite17, 18
History
· Circumstances of the injury
· time of injury (after three hours, the bacterial count in a wound increases dramatically)
· Past medical history, including immunocompromised state
· tetanus immunisation status
· Routine or recent medications (especially steroids, anticoagulants)
Examination
· Vital signs: temperature, blood-pressure and heart rate.
· Dimensions of wound, including depth 
· Assess for signs of infection, drainage or tissue loss
· Assess for vascular, neurological or tendon injury
· Photographic documentation (patient’s consent is required)
Special tests – to be considered
· labs: wound swab, blood culture and sensitivities, complete blood cell count with differential, 
HiV, HBV, HCV serological status.
· Cultures for both aerobic and anaerobic bacteria are recommended if the wound shows clinical 
evidence of infection.
· Radiographic: for wounds near a joint or bone - to evaluate for foreign bodies (eg tooth 
fragments).
Treatment of human bite wounds
Wound management plays a key role in prevention of infection. the surface should be cleaned and 
lacerations should be irrigated with sterile saline using pressure irrigation.19 Devitalized tissue should 
be debrided. the management of puncture wounds is more controversial. High pressure irrigation into 
a puncture wound should be avoided. 
Clinical findings which indicate infection of bite wounds include erythema, swelling, tenderness, 
purulent drainage, lymphangitis and fever. Wounds which are infected at presentation should 
be swabbed and cultured, and blood cultures should also be taken. infectious diseases/clinical 
microbiology advice should be sought regarding appropriate antimicrobial treatment, and surgical 
opinion should be sought regarding debridement and other surgical interventions. inpatient treatment 
with intravenous antibiotics and surgical input is often required. 
the use of prophylactic antibiotics after human bites to the hand has been shown to reduce the risk of 
infection.20 Prophylactic antibiotics should be given for human bites if any of the following are present: 
•  bite to hand (clenched fist injuries are particularly high-risk), foot, face or ear; 
•  bite through dermis or puncture wound; 
•  moderate-severe wound with crush injury; 
•  wound near bone or joint; 
•  wounds requiring closure; 
•  wounds in areas of impaired venous/lymphatic drainage including post-mastectomy; 
•  immunocompromised hosts (including patients with transplants, HIV, post-splenectomy, cirrhosis or 
diabetes mellitus). 
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 the recommended regimen for prophylaxis of infection is co-amoxiclav 625 mg tds for 3 to 5 days, with 
alternatives for penicillin allergic patients including doxycycline 100 mg bd plus metronidazole 400 mg 
po tds, or ciprofloxacin 500 to 750 mg bd plus metronidazole.19
HBV vaccination should be advised for all unvaccinated recipients of a human bite wound. HBiG may 
also be indicated, depending on the risk assessment, but generally only if the source is HBV positive (see 
appendix 8).
HiV PEP would almost never be indicated following a human bite except in extreme circumstances.
tetanus prophylaxis may be indicated (see appendix 15).
outpatient follow-up of patients with human bites is advised to monitor for any evidence of development 
of infection. 
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CoMMunIty aCquIred needlestICk 
InjurIes
Community acquired needlestick injuries (CANSis) have not been well described, and the evidence base 
on which to recommend management strategies is poor.1 CANSis cover a wide spectrum from criminal 
assault with blood filled syringes to children playing with discarded syringes in public parks.1 
Although community needlestick injuries are a common source of anxiety for the public and for the health 
care providers who treat them, transmission of BBVs in a non-clinical setting is exceedingly rare.2 CANSi 
due to deliberate assault with a blood filled syringe represents a higher risk than average.1 
in contrast to the situation with needlestick injuries in health care workers, the source of blood 
in discarded needles is usually unknown, injury does not occur immediately after needle use, the 
needle rarely contains fresh blood, any virus present has been exposed to drying and environmental 
temperatures, and injuries are usually superficial.3 
the risk of BBV transmission through a needlestick injury from a discarded needle/syringe is likely to 
depend on several factors. these factors include the prevalence of BBVs among iDUs in the particular 
setting, the type of injury sustained, the viability of the particular virus outside the body, how recently the 
needle/syringe has been used, the level of immunity (in the case of HBV) and the availability and use of 
PEP (in the case of HBV and HiV).4 
Reported cases of BBV transmission following a CANSI
there are currently few reported incidents of BBV infections thought to be secondary to a CANSi. A 
case of presumed acute HBV infection was reported in a 4 year old boy in Spain who did not receive 
post-exposure HBV vaccine or HBiG.5 in 2011, a case of acute HBV infection occurring 2 months after a 
CANSi was reported from Australia. the patient had a history of incomplete vaccination and HBV vaccine 
booster was delayed. He did not receive HBiG.2 three cases of HCV seroconversion in adults following 
needlestick injuries in the community have been reported.6, 7 No HiV infections have been reported after a 
CANSi.8
Case series
in a study in an emergency medicine department in Sydney, 124 cases of CANSi were identified over a 
6 year period, of which 120 were described. the median age was 26 years. there was a marked male 
predominance. injuries were work-related in 36% of cases, predominantly police officers and cleaners. 
68% of cases were as a result of exposure to discarded syringes. the source of the blood in the syringe 
was identifiable in only 12% cases. 54% of patients received HBV PEP and 8% received HiV PEP. At 6 
months post-injury there were no HBV, HCV or HiV seroconversions in the 10 patients for whom there was 
follow-up serology.1 
A large study in Montreal of 274 paediatric patients presenting with CANSi between 1988 and 2006 
found no seroconversions.8 of patients who were not known to be immune to HBV, 82.2% received HBiG 
and 92.6% received HBV vaccine. HiV chemoprophylaxis was given to 39% of patients who presented 
after 1997. the most common site of injury was the hand. Most of the injuries were superficial and blood 
was rarely visible on the needle or syringe.8
Several other studies reported the outcome of CANSis in children presenting to emergency departments 
in Edinburgh, Dublin, Melbourne and Birmingham. No cases of seroconversion for BBVs were detected. 
However, compliance with follow-up was generally poor.9, 10, 11, 12
A review of the literature up until September 2007 by the Canadian Paediatric Society yielded 12 case 
series from areas of high prevalence of bloodborne viruses. these involved a total of 483 children with 
follow-up for HiV, 452 for HBV and 265 for HCV. there were no infections. the majority of children 
received HBV prophylaxis, if it was indicated. 130 children received antiretroviral prophylaxis.3  
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Viability of BBVs in the environment
CANSis are likely to carry a considerably smaller risk of BBV transmission than injuries in the 
occupational setting as needles found in the community have been exposed to environmental 
temperatures and drying for an indeterminate period of time .8
Environmental HBV transmission is well documented and relates to its high concentration in blood and 
its ability to maintain infectivity on environmental surfaces.4 HBV has been demonstrated to survive 
in dried blood at room temperature on environmental surfaces for at least 1 week.1 HBV has been 
detected in discarded needles.3 
HCV is thought to be a fragile virus which would be unlikely to survive in the environment, but there 
are little data at this time.3 Support for the potential for environmental HCV transmission comes from 
studies that demonstrate high levels of HCV transmission in health care settings – particularly renal 
dialysis units and wards with immunocompromised patients.4
HiV is a relatively fragile virus and is susceptible to drying. However, survival of HiV for up to 42 days 
in syringes inoculated with the virus has been demonstrated, with duration of survival dependent 
on ambient temperature. one study found no traces of HiV proviral DNA in syringes discarded by 
intravenous drug users, while another study found HiV DNA in visibly contaminated needles and 
syringes from shooting galleries.3  However, the presence of viral DNA is not a direct demonstration of 
viable virus.
Risk of BBV transmission
the risk of transmission of BBVs following CANSis is difficult to estimate. HBV represents the highest 
risk. the likelihood of transmission of HCV or HiV is very remote. 
the risk of BBV transmission following needlestick injuries in the occupational setting has been 
estimated and may be of value in estimating the risk in CANSis:
the risk of acquiring HBV from an occupational needlestick injury when the source is hepatitis B 
surface antigen (HBsAg) positive ranges from 2% to 40%, depending on the source’s level of viremia.3 
the average incidence of anti-HCV seroconversion after accidental percutaneous exposure from a HCV 
positive source is 1.8%.1
the risk of acquisition of HiV from a hollow-bore needle with blood from a known HiV seropositive 
source is between 0.2% and 0.5%, based on prospective studies of occupational needlestick injuries. 
the risk is increased with higher viral inoculum, which is related to the amount of blood introduced 
and the concentration of virus in that blood. the size of the needle, the depth of penetration and 
whether blood was injected are also important considerations. in most reported instances involving 
transmission of HiV, the needlestick injury occurred within seconds or minutes after the needle was 
withdrawn from the source patient.3
Management of CANSI (see appendix 3, algorithm for needlestick exposure)
Risk assessment
Although the actual risk of infection from such an injury is very low, the perception of risk by patients 
results in much anxiety. Evaluation and counselling are needed. 
individualised risk assessment is essential for every case of CANSi as the source is rarely identified. 
However, if the source can be identified, then all attempts should be made to assess their risk factors 
and to test them for BBVs (see section 3.3 investigation of source). 
Post-exposure prophylaxis
hBV:  HBV vaccine with an accelerated schedule should be offered to non- and partially-immune 
recipients. HBiG may occasionally be indicated (see HBV PEP appendix 8).
hCV:  there is no effective post-exposure prophylaxis for HCV. However, treatment of early infection 
has been shown to be effective. Baseline and follow-up testing at 6 weeks and 3 months for HCV 
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would therefore enable early therapeutic intervention following HCV transmission4 (see 
appendix 14 treatment of acute hepatitis C).
hIV: HiV PEP remains an unresolved issue. No studies have directly measured the effectiveness 
of PEP in decreasing the risk of HiV transmission in non-occupational settings .12 the risk of HiV 
transmission, and risks and benefits of antiretroviral prophylaxis should be assessed on a case-
by-case basis, and guided by expert opinion.1  Antiretroviral prophylaxis should be recommended 
only in cases of high-risk.3, 8, 12 (See appendix 7, HiV PEP)
the factors associated with increased risk are:
•  the source is considered likely to have HIV
•  the injury was deep, penetrating
•  the needle was large-bore, hollow lumen
•  the incident involved a needle with visible blood (particularly fresh blood)
•  blood may have been injected. 
BBV testing and follow-up
Follow-up after any significant needlestick injury is essential. the clinician dealing with the 
initial incident should ensure that the patient understands the importance of follow-up, and that 
appropriate arrangements are made. Patients sometimes assume that if blood tests that are 
performed at the time of injury are negative, then there is no possibility of infection and no need 
for further testing.3 if a significant exposure has occurred, testing the recipient for BBVs should 
be carried out at baseline, 6 weeks and 3 months (see appendix 9 testing of recipient). 
Testing of needles and syringes
testing needles and syringes for viruses is not indicated. Results are likely to be negative, but a 
negative result does not rule out the possibility of infection.3
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injury in Dental Practice or Primary Care Medical Practice
Form to be given to the recipient’s treating doctor
on-site assessment form for incidents such as needlesticks and human bites where there is a risk of bloodborne virus (BBV) transmission
Reporting time: Reporting date:
Dentist name: Dentist signature:
Responsible person: Contact phone number:
  After hours number:
SOURCE DETAILS
Is the source known?  Yes   No  
Has the source been informed of incident?  Yes   No  
Has the source consented to medical history 
being passed on?    Yes   No  
Has the source consented to testing?  Yes   No  
If consent given, is there a relevant med history?  Yes   No  
if yes - details?  Yes   No  
RECIPIENT DETAILS
Name
Address
Gender  M    F  
Date of birth
telephone number
Mobile
occupation
Work address
  GP name and address and telephone number
ASSESSMENT OF ExPOSURE RISK
 Brief description of injury including date, time and place of injury
 
Nature of material e.g. blood, saliva
if Not blood, was fluid blood stained  Yes   No  
HEALTHCARE ExPOSURES
Area where exposure occured
Was this an ‘exposure prone procedure’?  Yes   No  
Were gloves worn at the time of the injury?  Yes   No  
instrument (if any) which caused the injury
What was the instrument originally intended for?
Did the instrument have a safety mechanism? Yes   No 
Was the safety mechanism activated ?   Yes   No 
Nature of injury
Needlestick  
 Hollow bore needle    Solid Needle 
 Visible blood present 
 Device had been directly in source artery or vein 
other sharps  
Describe
Severity of needlestick or sharp injury
 Superficial - surface scratch, no blood appeared 
 Moderate - penetrated skin and blood appeared 
 Deep - puncture, with or without blood appearance 
Human bite    Skin breached    
Splash 
 intact skin    Non-intact skin 
 Mucous membrane    Eye 
Medical History (incl. immunosuppression)
Specify if recipient known to be positive for HBV, HCV or HiV
Medications
Allergies
if female Pregnant   Breastfeeding  
Hepatitis B Vaccination
1 dose 2 doses Full course Year
Antibody result if known
Tetanus
Date of last vaccination Number of doses
Signed:  _______________________________________________________
Responsible Person
if consent to testing given:
Source first name:  ________________________________________________
Source mobile phone no.: _________________________________________
  
other injury  
Describe
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hepatitis B virus: epidemiology and 
transmission risks
Hepatitis B virus (HBV) infection is a serious and common infectious disease of the liver, affecting millions of 
people throughout the world. the incubation period for HBV is 45-180 days, most commonly 60-90 days.1
Clinical information
Acute infection is clinically recognised in only a small proportion of cases; less that 10% of children and 30-50% 
of adults show icteric disease. in those with clinical illness, the onset is usually insidious, with anorexia, vague 
abdominal discomfort, nausea and vomiting, sometimes arthralgia and rash, often progressing to jaundice. 
Following acute HBV infection, the risk of developing chronic infection varies inversely with age. Chronic HBV 
infection occurs among about 90% of infants infected at birth, 25-50% of children infected at 1-5 years of age 
and about 1-10% of persons infected as older children and adults. An estimated 15-25% of persons with chronic 
HBV infection will die prematurely of either cirrhosis or hepatocellular carcinoma.1
Vaccination
HBV can be effectively prevented by vaccination. A safe and effective vaccine has been available since the 1980s. 
the complete vaccine series induces protective antibody levels in more than 95% of infants, children and young 
adults. After age 40, protection following the primary vaccination series drops below 90%. Protection lasts 
at least 20 years and should be lifelong.2 Since 2008, hepatitis B vaccine has been included in the childhood 
immunisation programme in ireland, alongside the targeted immunisation programme for those individuals 
who are at increased risk of HBV because of their occupation, lifestyle or other factors. these include healthcare 
workers (HCW), prison and security personnel, contacts of cases, injecting drug users, people with certain 
medical conditions, clients in learning disability centres, people with multiple sexual partners, men who have sex 
with men, prisoners, and travellers to and immigrants from HBV endemic areas.3
Transmission
HBV has been found in virtually all body secretions and excretions. However, only blood, body fluids containing 
visible blood, semen and vaginal secretions represent a risk of transmission.4 HBV is transmitted by percutaneous 
and mucosal exposure to infective blood or body fluids. Major modes of HBV transmission include sexual or 
close household contact with an infected person, perinatal mother to infant transmission, injecting drug use and 
nosocomial exposure.1
Percutaneous exposures that have resulted in HBV transmission include transfusion of unscreened blood or 
blood products, sharing unsterilised injection needles for iV drug use, haemodialysis, acupuncture, tattooing and 
injuries from contaminated sharp instruments sustained by hospital personnel.5
HBV is stable on environmental surfaces for at least 7 days and is 100 times more infectious than HiV. 
Serological markers for HBV
HBsAg: Hepatitis B surface antigen is a marker of infectivity. its presence indicates either acute or chronic 
infection.
HBeAg: Hepatitis B e antigen is a marker of a high degree of infectivity and correlates with a high level of HBV 
replication.
Anti-HBs: Antibody to hepatitis B surface antigen is a marker of immunity, either an immune response to HBV 
infection or to vaccination.
Anti-HBc: Antibody to hepatitis B core antigen is a marker of HBV infection.
Prevalence of HBV infection in Ireland, Europe and the world
Ireland
the prevalence of HBV in the general population in ireland is low. However, HBV is more prevalent in certain sub-
groups of the population.6 the prevalence of HBV infection is generally lowest in the blood donor population, 
followed by the general population, then pregnant women, then high-risk groups. to determine the risk of HBV in 
migrant populations, it is necessary to look at data on their country of origin.
the World Health organization has classified ireland as a country of low prevalence for HBV, i.e. prevalence of 
HBsAg <2%.6 the European Centre for Disease Prevention and Control (ECDC) carried out a literature review 
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in 2010 of publications dated 2000-2009 on the prevalence of viral hepatitis in Europe.7 it reported that the 
HBsAg prevalence in the general population in ireland is estimated to be 0.1%. ireland and the Netherlands 
have the lowest prevalence of HBV infection in Europe. it also reported that the HBsAg prevalence rates in blood 
donors and pregnant women in ireland are among the lowest rates in Europe. 
low risk populations in Ireland
General population
A European HBV seroprevalence study using residual sera showed a low prevalence in irish samples collected 
in 2003 (anti-HBc 1.7%, HBsAg 0.1%).8 A national study of oral fluid samples collected by postal survey in 1998-
1999 estimated anti-HBc prevalence in ireland to be 0.51%.9
Blood donors
of 257,358 first time blood donors tested by the iBtS between 1997 and 2010, 30 (0.012%) were found to be 
HBsAg positive. (Personal communication, Dr Joan o’Riordan, iBtS, November 2011).
Pregnant women
Routine antenatal testing for HBsAg was introduced in the Rotunda Hospital in 1998. Uptake was almost 
100% and >16,000 pregnancies were screened between January 1998 and June 2000. this showed a HBsAg 
prevalence of 4.2% in non-EU women and 0.03% in irish women tested.10 Screening of >24,000 pregnant 
women in the West of ireland in 2004-2009 demonstrated a prevalence of HBsAg of 0.21%, and all positive 
women were thought to be of non-irish origin.11
high risk populations in Ireland
Prisoners
A national cross sectional survey of irish prisoners in 1998 showed a prevalence of anti-HBc of 8.7% total, and of 
18.5% in prisoners who were injecting drug users.12
injecting drug users
A cross-sectional study of 316 opiate users attending 21 addiction treatment centres in the HSE East was carried 
out between Dec 2001 and Jan 2002. the prevalence of HBsAg was 2% and of anti-HBc was 17%.13
Homeless people
Homeless people also have evidence of increased exposure to HBV, with a prevalence of anti-HBc of 9% in a 
study performed in Dublin in 1999-2000.3
Asylum seekers
Screening of asylum seekers in the HSE eastern region 1999-2003 found a prevalence of HBsAg of 5% .14
trends in hepatitis B infection in Ireland
Hepatitis B is a notifiable disease in ireland. there was a dramatic increase in annual HBV notifications between 
1997 (31 cases) and 2008 (919 cases), mostly attributable to large numbers of people immigrating to ireland 
from HBV endemic countries. Between 2000 and 2010, 95% of asylum applicants, and 73% of new work permit 
recipients, were from countries with intermediate or high HBV endemicity. immigration to ireland has decreased 
in recent years and this is likely to have contributed to the 30% decrease in HBV notifications in 2010 (645 
cases) compared to 2008. in 2010, 8% of cases were acute and 92% were chronic. For acute cases, where risk 
factor information was available, the majority were sexually acquired and half of these were in men who have 
sex with men. the majority of acute cases were born in ireland. Where risk factor information was known for 
chronic cases, the majority were born in HBV endemic countries or were asylum seekers.15
Hepatitis B infection in Europe
Although there is a decreasing trend in HBV, each year there are between 7,000 and 8,000 newly diagnosed 
cases of HBV in the EU/EEA region.16  the total percentage of people infected with HBV varies between different 
countries, with higher rates in the southern part of Europe. the country with the highest prevalence (>4%) is 
Romania followed by medium prevalence countries (>1-2%), Spain, (parts of) italy, and Greece. Countries with 
a low prevalence (<1%) include Belgium, the Czech Republic, Finland, Germany, ireland, Netherlands, Slovakia 
and Sweden.16
the most severely affected population groups are injecting drug users, sex workers, men who have sex with 
men, people living with HiV, inmates, and immigrants from high-endemic regions. in some countries, sexual 
transmission is more common than transmission through household contacts or injecting drug use.16
Maps of HBV prevalence in different population groups by country in Europe are available in the ECDC technical 
Report .7
Global distribution
the global prevalence of chronic HBV infection (based on % of population HBsAg positive) is as follows17: 
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High prevalence (≥8%): sub-Saharan Africa, South-East Asia, the Eastern Mediterranean countries, south and western 
Pacific islands, the interior of the Amazon basin and certain parts of the Caribbean. 
Moderate prevalence (2–7%): in south-central and south-west Asia, eastern and southern Europe, the Russian Federation 
and most of central and South America. 
low prevalence (<2%): Australia, New Zealand, northern and western Europe, and North America. 
Transmission risks
Several factors influence the risk of transmission of HBV infection, including the viral load of the source.
in a healthcare occupational context, the level that is regarded as “high” for a viral load differs in various regions. in America 
and ireland, HCWs who are infected with HBV but have a circulating viral burden <104 genome equivalents/ml are allowed 
to continue working unrestricted.18,19 transmission of HBV via a percutaneous route is considered unlikely at HBV DNA levels 
below 107genome equivalents/ml.20
Needlestick injuries
those who are e antigen positive generally have higher viral loads, and the transmission rate of HBV following a needlestick 
injury from a source who is e antigen positive is estimated to be between 30% and 62%.4, 18 the same injury with exposure to 
blood from a source who is e antigen negative is associated with 6-37% risk of serological evidence of HBV infection in the 
recipient.4, 18 Some patients are infected with pre-core mutant viruses. this is associated with a high viral load in the absence 
of the e antigen, and thus is also associated with a high risk of HBV transmission.18
the risk from needlestick injuries in the community is more difficult to estimate and the exact incidence of needlestick 
injuries and the transmission rate is unknown. the limited published case reports21, 22 would indicate that there is a very low 
risk of HBV transmission associated with community acquired needlestick injuries.
Other healthcare setting exposures
Spring loaded lancets have been implicated in the transmission of HBV to patients23, as have reusable sub-dermal EEG 
electrodes.24 there is a report of transmission of HBV to a patient during an endoscopic procedure, although no biopsies 
were taken, but bleeding gastric ulceration was identified. the presumed source was HBeAg positive .25
Cleveland et al report that HBV infection prevalence in dentists increases with longer duration in practice.26Although rates 
in a reference control population were not included in this report, increasing prevalence with longer duration of practice 
indicates that there is potential for transmission to dentists during their work.
Other percutaneous exposures
there are case reports documenting the transmission of HBV among butchers.27, 28 these are attributed to small hand cuts, 
and sharing knives, which can carry the virus on the handle. it is also thought that HBV can be transmitted via small cuts 
acquired in barber shops.29
Body fluid exposures
HBV DNA has been detected in body fluids apart from blood, including saliva, urine, nasopharyngeal fluid, semen, 
cervicovaginal fluids and tears.30-33. HBV transmission can occur following exposure to non-intact skin and mucous 
membranes. A case report describes transmission of HBV via broken skin, following contact with saliva and nasopharyngeal 
fluids from the source.34
Human bites
Case reports have documented HBV virus transmission via a human bite, when associated with the skin being broken.35, 36
Sexual exposures
HBsAg has been found in seminal fluid and vaginal secretions, although concentrations in these fluids are lower than in 
blood.37 the risk of transmission of HBV following sexual exposure depends on the ype of exposure, the viral load of the 
source, and the presence of sexually transmitted infections.38 the prevalence of HBV in heterosexuals is increased in those 
with multiple sexual partners38-40, and those who have markers for HiV or syphilis.41 An infection rate of 18-44.2% is seen 
in regular heterosexual partners of HBV infected patients 42-44 in addition, female commercial sex workers with a history of 
having anal intercourse had an increased risk of HBV infection.41
the risk of developing HBV infection is particularly high among men who have sex with men.37, 45  For men who have sex 
with men, the prevalence of HBV infection is increased in those who have a history of an ulcerative sexually transmitted 
infection, chlamydia, gonorrhoea, commercial sex work, or multiple partners.46 there is also a significant risk associated 
with unprotected insertive anal intercourse.47
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Prevalence of hepatitis B worldwide
Source: Centers for Disease Control and Prevention. CDC Health information for international travel 2012. New York: oxford University 
Press; 2012.
Prevalence of hepatitis B surface antigen in injecting drug users 
worldwide 
Source: Reprinted from lancet 2011;378(9791), Nelson Pk, Mathers BM, Cowie B, et al. Global epidemiology of hepatitis B and hepatitis 
C in people who inject drugs: results of systematic reviews, pages 571-83, Copyright (2011), with permission from Elsevier.
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hepatitis C virus: epidemiology and 
transmission risks
Hepatitis C infection is caused by an RNA virus that was first identified in 1989. 54 Chronic hepatitis C infection 
is a major cause of chronic liver disease and death throughout the world.55 Approximately 3% of the world’s 
population is infected with hepatitis C virus (HCV).56 Six distinct but related genotypes and multiple subtypes 
have been identified.54, 57 in western Europe genotypes 1a and 1b are most common, followed by genotypes 2 and 
3.58
Transmission
HCV is transmitted by blood and now occurs primarily through injecting drug use, and less frequently through 
sex with an infected partner, occupational exposure, and maternal-foetal transmission. in some cases no risk 
factors can be identified.54, 58 transfusion-related HCV infection is rare now since the introduction of routine 
screening of blood for HCV antibodies in the early 1990s.59
Clinical information
in general, acute HCV infection is relatively mild, with only 20-30% of infected persons developing symptoms 
or clinically evident acute infection. in most persons who become infected with HCV, viraemia persists. Antibody 
to HCV (anti-HCV) is present in acute, chronic and resolved infection. HCV RNA/HCV Ag is an indication of HCV 
viraemia.
Chronic HCV infection is marked by persistence of HCV RNA for at least 6 months after onset of infection. 
Spontaneous resolution after 6 or 12 months of infection is unusual. Between 55 and 85% of those infected 
develop chronic infection.59 Chronically infected people are at risk for progressive liver disease characterised 
by hepatocellular inflammation, hepatic fibrosis, cirrhosis and hepatocellular carcinoma (HCC). these 
complications develop only in a proportion of patients and only after many years or decades of infection. it 
has been estimated that up to 20% of chronically infected individuals will develop cirrhosis of the liver over a 
20 to 25 year period, and that, of patients with cirrhosis, approximately 3% to 4% will develop HCC per year. 
Factors that have been shown to be associated with progression of liver fibrosis include older age at infection, 
male gender, genetic factors, metabolic factors (steatosis, diabetes and obesity), co-infection with human 
immunodeficiency virus (HiV) or hepatitis B, duration of infection, and alcohol intake.59
Very effective treatment is now available, which eradicates the virus in over 50% of cases.55, 60
Prevalence of HCV infection in Ireland, Europe and the world
Ireland
A recent study has estimated that the prevalence of chronic HCV infection in ireland is 0.5-1.2% 61, similar to 
other countries in northern Europe and in line with the WHo estimate of <1%. However, it is more prevalent in 
certain sub-groups of the population, in particular injecting drug users (iDUs) and prisoners. HCV may also be 
more prevalent in immigrants to ireland from endemic countries.
Blood donors
of 257,358 first time blood donors tested by the iBtS between 1997 and 2010, 46 (0.018%) were found to be 
HCV positive (Personal communication Dr Joan o’Riordan, iBtS, November 2011).
Asylum seekers
Screening of asylum seekers in the HSE eastern region 1999-2003 found a prevalence of anti-HCV of 1.5%.14
Prisoners and injecting drug users
Studies of iDUs in prisons and iDUs attending methadone clinics, specialist addiction treatment centres and GPs 
have estimated the HCV prevalence in this population to be between 62% and 81%.62
A national cross sectional survey of irish prisoners in 1998 showed a prevalence of anti-HCV of 37% of all 
prisoners, and of 81.3% in prisoners who were injecting drug users.12
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trends in hCV in Ireland
Hepatitis C became a notifiable disease in ireland in 2004 and the number of cases notified each year since then 
has been >1,100. there were 1239 notifications in 2010. two-thirds of cases were male and most were young to 
middle-aged adults. three quarters of cases were notified from the HSE East (greater Dublin area). Where risk factor 
information was available, over three-quarters were injecting drug users.63
HCV in Europe
in Europe, HCV infection shows a significant increasing trend in reported numbers. Every year there are 27,000 to 
29,000 newly diagnosed cases in the EU/EEA.16
A recent systematic literature review of HCV prevalence in Europe, based on information from 14 countries, reported 
a prevalence range of 0.4-3.5%.7 the prevalence is higher in the southern part of Europe. Countries with high 
prevalence (more than 2%) include italy, Romania and Spain. Medium prevalence was observed in Bulgaria, France, 
Greece, and Poland. Countries with low prevalence (less than 1%) include Belgium, Germany, the Netherlands, 
Sweden, and the United kingdom.16
the most severely affected population groups are injecting drug users, haemodialysis patients, persons living 
with HiV, inmates, and immigrants from high-endemic regions. Reported numbers are likely to reflect the current 
testing and screening practices in countries rather than the real incidence of infection. the reported number is an 
underestimate of the real occurrence of HCV due to the asymptomatic nature of the infection.16
Maps of HCV prevalence in different population groups by country in Europe are available in the ECDC technical 
Report.7
Global HCV distribution
the estimated global prevalence of HCV is 2-3% .64, 65 Countries with the highest reported prevalence rates are 
located in Africa and Asia. China has a reported seroprevalence of 3.2%. one community-based survey in india 
reported an overall rate of 0.9%. indonesia’s rate is 2.1% in serosurveys of voluntary blood donors. the seroprevalence 
in Pakistan is reported to range from 2.4% to 6.5%. Egypt has the highest reported seroprevalence rate, 22%.64 Areas 
of lower prevalence include North America, northern and western Europe, and Australia.
the predominant source of new HCV infections in developed countries over the past few decades is injecting drug 
use. in developing countries, unsafe therapeutic injections and transfusions are likely to be the major modes of 
transmission.64 Anti-HCV prevalence in iDUs globally varies greatly, from 9.8% to 97.4%.66 (See map, appendix 24).
Transmission risks
Needlestick injuries
there is a wide range of reported estimates for the risk of transmission of HCV after a needlestick or sharps injury 
from a source patient – between 0 and 10%.67-69 the estimated risk from a needlestick injury from a source with 
detectable HCV RNA is 6.1% .18 the risk of developing HCV is greater after an injury with a hollow-bore needle 68, or 
deep injuries 70, compared with other injuries. Also, one study showed an 11-fold increase in transmission of HCV from 
source patients with viral load >6 log10 copies/ml, compared with source patients with viral load ≤4 log10 copies/ml 
following percutaneous exposure.70 the risk of transmission is also influenced by whether the source is co-infected 
with HiV (see section below).
in cold temperatures, HCV can survive in syringes for many days in laboratory studies.71 the clinical implications of 
this are unknown, but the risk of becoming infected with HCV from an abandoned syringe depends on the prevalence 
of HCV in the local community. there are case reports of HCV transmission from needlestick injuries in the community 
72, but as the exact incidence of injuries in the community is not known, the risk of transmission from such injuries 
cannot be accurately quantified.
Other percutaneous exposures
the risk of acquiring HCV during an operation performed by an infected surgeon is reported to be between 0 and 
3.7%. 50,73,74 in general the risk of contracting HCV following an injury from an unknown source is negligible.75
Sharps in the workplace, other than in the healthcare setting, such as razors and meat slicers have also been 
implicated in the transmission of HCV.76, 77
there is an increased incidence of HCV in those who have a tattoo, with a pooled odds ratio of 2.73 (95% Ci 2.38-3.15). 
large tattoos, and those received in non-professional locations are associated with the greatest risk.78
-72-
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Splashes/mucocutaneous exposures
Several case reports have been published describing the transmission of HCV following a splash of blood into 
the eye of the recipient.79,80 Also, transmission of HCV has occurred following splashes of infected blood onto 
broken skin.81 the exact risk associated with these exposures is unknown.
Exposure to saliva (including injuries caused by human bites)
HCV RNA has been demonstrated in saliva.82, 83 Case reports describe transmission of HCV following human 
bites, but precise details of the nature of the bites, and whether blood was present in the mouth of the 
biter, or whether skin was broken at the time of the bite, are not known.84 inoculation with saliva has caused 
transmission of the virus in experimental studies.85, 86
Studies in dentists indicate a low incidence of nosocomial transmission of HCV.87 it is also thought, however, 
that HCV can be transmitted via sharing a toothbrush with an index case.83, 88
Sexual exposures
in general, transmission of HCV via sexual contact is inefficient in stable monogamous heterosexual couples.90 
there is evidence, however, of a low rate of transmission of HCV between discordant heterosexual couples 
and a prevalence of 2-6% of anti-HCV in the non-index partner.89-91 Higher prevalence of anti-HCV has been 
observed in those with multiple sexual partners, in the absence of other risks, such as iDU or recipients of 
blood products, as further evidence of the plausibility of sexual transmission.92, 93 if a risk is present, it is likely 
to be very low, and a rate of transmission per heterosexual exposure has not been calculated.
Recent outbreaks of acute HCV among HiV-positive MSM who deny iDU suggest that the epidemiology of 
HCV transmission is changing in this population. in several European countries as well as in the United States 
and Australia, HCV has unexpectedly emerged as an Sti among HiV-positive MSM. longitudinal cohort 
studies have confirmed a marked increase in HCV incidence among HiV-positive MSM, but not HiV-negative 
MSM, after the year 2000.94 Studies in Australia, Uk, Switzerland and the Netherlands have reported an 
incidence of HCV infection ranging from 0.6 to 0.9/100 person years in HiV positive MSM who were not 
iDUs.95
Exposure to other body fluids
HCV RNA has been identified in blood, saliva82, bile96, sweat97, semen98, and cervicovaginal secretions.99 the 
infective potential of cervicovaginal secretions is questioned100, but may increase during menstruation.99
Transmission of infection following exposure to a source with HIV and HCV
the risk of developing HCV infection after simultaneous exposure to HiV and HCV is estimated at 2.8%101 (in 
this study, no one developed HiV after simultaneous exposure). 100% of patients who received an injection 
drawn from a vial contaminated with HiV and HCV developed acute HCV infection, but no one developed 
HiV.102
HiV and HCV transmission from a patient to a healthcare worker occurred after contact with the patient’s 
emesis, faeces and urine, to non-intact skin on the healthcare worker’s hands.103
A case report describes the transmission of HCV, but not HiV, via a human bite to the hand from a source co-
infected with HiV and HCV.104  Although the recipient had a wound on his hand prior to the bite, it is not known 
whether there was blood in the mouth of the source at the time of the incident. Studies have not shown an 
increased incidence of HCV RNA in saliva of co-infected patients compared to those infected with only HCV.105
the odds ratio of sexual transmission of HCV increased in women co-infected with HiV or another sexually
transmitted infection (adjusted odds ratio 3.3-3.9) or homosexual men co-infected with HiV (adjusted odds
ratio 4.1-5.7).106
there is an increased incidence of HCV-antibodies in patients who had acquired HiV via heterosexual
transmission, than in those who had developed HiV from a different exposure.107
HiV status does not seem to influence the presence of HCV in semen in men co-infected with HCV and HiV.108 
HCV RNA is detected more frequently in cervicovaginal fluid from women co-infected with HiV,
than in those not infected with HiV109, especially if HCV viremia is present, or if HiV RNA is also found in
the cervicovaginal secretions.
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Source: Centers for Disease Control and Prevention. CDC Health information for international travel 2012. New York: 
oxford University Press; 2012.
Prevalence of anti-hepatitis C among injecting drug users 
worldwide
Source:Reprinted from lancet 2011;378(9791), Nelson Pk, Mathers BM, Cowie B, et al. Global epidemiology of hepatitis B 
and hepatitis C in people who inject drugs: results of systematic reviews, pages 571-83, Copyright (2011), with permission 
from Elsevier.
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human immunodeficiency virus: epidemiology 
and transmission risks
General details
the HiV virus was discovered in 1983.117 there are currently two groups of viruses which have been isolated (HiV 
type 1 and HiV type 2), collectively known as HiV (human immunodeficiency virus). 118 in general, HiV type 2 is not 
found outside western and central Africa. HiV type 1 is identified globally. Following infection, the host’s cells 
transfer the virus to the local immune system, including t-cells, macrophages and dendritic cells. Within 10-12 
days of infection, HiV RNA can be detected in blood by PCR.
During this acute infection (also referred to as primary HiV infection, or the seroconversion illness), HiV RNA 
levels peak, before declining over subsequent weeks.119 Antibodies to HiV usually develop within 3-5 weeks 
of becoming infected. the time period between becoming infected and developing antibodies is referred to 
as the serological “window period”.118 Following seroconversion, there is an asymptomatic phase of variable 
duration.119-120 During this time, patients are well. later in the course of the infection, HiV RNA levels tend 
to drop. over the subsequent asymptomatic period, of variable duration, CD4+ lymphocyte levels gradually 
decrease. if levels of CD4+ lymphocytes drop below 200-350 cells/μl, the patient is at increased risk of 
developing opportunistic infections. 
Clinical information
the symptoms of acute HiV infection can last for between 7 and 10 days.118 the patient may complain of 
symptoms resembling the “flu”, or mononucleosis infection.119 typical symptoms include fever, maculopapular 
rash, oral ulcers, lymphadenopathy, arthralgia, pharyngitis, malaise, weight loss and myalgia. once these acute 
symptoms resolve, most patient enter an asymptomatic phase. this asymptomatic phase can last more than 10 
years.
When CD4+ lymphocyte levels drop below 200-350 cells/μl, the patient is at increased risk of developing 
opportunistic infections 121, including pneumocystis pneumonia, oesophageal candidiasis, cerebral 
toxoplasmosis, and cytomegalovirus, amongst others.122 these infections, along with cancers such as kaposi 
sarcoma, are referred to as AiDS defining conditions.
treatment for patients with HiV infection is with life-long anti-retroviral drugs, commenced ideally before the 
CD4 count falls below 350-500 cells/μl. this results in a significant reduction in the amount of virus in the 
blood, usually to undetectable levels, and allows for immune recovery.
Transmission
HiV has been isolated from semen, cervical secretions, lymphocytes, cell-free plasma, cerebrospinal fluid, tears, 
saliva, urine and breast milk.117 this does not mean, however, that these fluids all transmit infection since the 
concentration of virus in them varies considerably. Particularly infectious are semen, blood, and possibly cervical 
secretions. the commonest mode of transmission of the virus throughout the world is by sexual intercourse. 
other methods of transmission are through receipt of infected blood or blood products, donated organs, and 
semen. transmission also occurs through the sharing or reuse of contaminated needles by injecting drug users 
(iDU) or for therapeutic procedures, and from mother to child in utero and possibly at birth. the virus is also 
transmitted through breast milk. Healthcare workers (HCW) can be infected through needlestick injuries, and 
skin and mucosal exposure to infected blood or body fluids. 
Prevalence of HIV infection in Ireland, Europe and the world
Ireland
HiV became a notifiable disease in ireland in September 2011. Case based reporting of HiV cases has been in 
place since 2001. in 2010, a total of 331 newly diagnosed cases were reported in ireland, a rate of 7.8/100,000.123 
of the 331 cases, 240 were men and 89 were women. the highest proportion was attributed to MSM exposure 
(40.5%), followed by heterosexual transmission (37.2%), and iDU (6.6%). of the 331 cases, 41.1% were born in 
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ireland, 21.5% in sub-Saharan Africa and 9.7% in Central and Eastern Europe. At the time of HiV diagnosis 
8.8% were diagnosed with AiDS. 
Annual numbers of new diagnoses of HiV in ireland have fluctuated between 300 and 400 over the past 
decade. in recent years there has been a change in the predominant modes of transmission – the annual 
number of new cases among iDUs has decreased each year since 2004; the annual number of cases attributed 
to heterosexual transmission has decreased from a peak in 2003; and the number of cases in MSM has more 
than doubled since 2005.123
Blood donors
of 257,358 first time blood donors tested by the iBtS between 1997 and 2010, 13 (0.005%) were found to be 
HiV positive (Personal communication Dr Joan o’Riordan, iBtS, November 2011).
Pregnant women 
HiV screening is offered routinely to all pregnant women in ireland under a voluntary antenatal HiV testing 
programme that was introduced in 1999. Data from 19 of 20 maternity hospitals nationally in 2009-2010 
showed an uptake of screening of greater than 99%.124 the prevalence of HiV infection among pregnant 
women was 0.21% in 2009 and 0.17% in 2010. this is the lowest rate since the screening programme began.
Prisoners and injecting drug users
in 1997, 17% of a group of iDUs in the HSE eastern region, who were attending methadone clinics, tested 
positive for HiV infection.125 A cross sectional study of 307 opiate users attending 21 addiction treatment 
centres in the HSE eastern region was carried out in 2001. the prevalence of anti-HiV was 11%.13 in 2001, the 
largest tertiary centre for HiV infection in Dublin reported a five-fold increase in new HiV diagnoses in iDUs 
between 1995 and 2000.126 A study carried out among socially excluded drug users in 10 European cities in 
1998-2000 found a self-reported HiV positive prevalence of 24.6% in Dublin, the second highest of the cities.127
 
A national cross sectional survey of irish prisoners in 1998 showed a prevalence of anti-HiV of 2%. the 
prevalence was 3.5% in prisoners who were iDUs.12
Asylum seekers
Screening of asylum seekers in the HSE eastern region 2000-2003 found a prevalence of anti-HiV of 2.2%.14
HIV infection in Europe
in 2009, there were 25,917 HiV cases diagnosed in the EU/EEA region, a rate of 5.7/100,000.128 the overall 
rate for men was 8.3/100,000 and for women it was 3.2. the four countries with the highest rates were Estonia 
(30.7), latvia (12.2), the United kingdom (10.7) and Belgium (10.3). Sex between men is the predominant 
mode of transmission in EU/EEA countries (35%), followed by heterosexual transmission (24% cases, when 
cases originating from countries with generalized HiV epidemics are excluded). Five per cent of HiV cases were 
reported among iDUs. the rate of diagnosed cases of HiV has been stable since 2004. Data on transmission 
mode indicates the following trends since 2004: a decrease in the number of heterosexually acquired cases, an 
increase in MSM cases and a decrease in the number of cases among iDUs.
Global HIV distribution
At the end of 2010, an estimated 34 million people were living with HiV globally. the annual number of 
people newly infected with HiV continues to decline, although there is stark regional variation. in sub-Saharan 
Africa, where most of the people newly infected with HiV live, the incidence peaked in 1996-1998. However, 
the annual number of people newly infected with HiV has risen in the Middle East and North Africa in the 
past decade. And in Eastern Europe and Central Asia, where the incidence had slowed drastically in the early 
2000s, the incidence has been accelerating again since 2008.129
the prevalence of HiV among adults (15-49 years) by world (WHo) region is estimated to be as follows: Africa 
(4.7%), Americas (0.5%), Eastern Mediterranean (0.2%), European (0.4%), South-East Asia (0.3%), Western 
Pacific (0.1%).129
Estimates of HiV prevalence globally among those with a history of iDU vary.130 this paper by Mathers et al 
presents detailed tables of prevalence of iDU and of HiV in iDUs by world region. the largest numbers of 
injectors were found in China, the USA and Russia, where mid-estimates of HiV prevalence among injectors 
were 12%, 16% and 37% respectively (see maps, appendix 26).
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Transmission risks
Needlestick injuries
Following a needlestick injury with a needle contaminated with blood from a source known to have HiV, 
the risk of becoming infected with HiV is thought to be between 0.1% and 0.36% .18, 131-133 the risk from 
needlestick injuries in the community is more difficult to estimate and the exact incidence of needlestick 
injuries and the transmission rate is unknown. intravenous drug injections carry a higher risk, with the risk 
of HiV transmission estimated to be between 0.63% and 2.4% per injection.134 the risk from a community 
needlestick where the source is unknown is estimated to be between 0.003 and 0.05%, if the local iDU 
seropositivity is approximately 1%.48
Several factors influence the rate of transmission. in a study of occupationally associated needlestick 
injuries, seroconversion was associated with factors including whether the needle or device was visibly 
contaminated with blood (odds ratio 10, 95% Ci 4.6-23), the injury was deep (oR 15, 95% Ci 8-26), or 
if the injury was sustained by a large gauge hollow bore needle (oR 14, 95% Ci 4.9-39).132 the health of 
the source patient is also relevant. if the source patient has AiDS, the odds ratio for transmission of HiV 
is 1.9 (95%Ci 0.8-4.6). it has been demonstrated that if the source patient died within 2 months of the 
needlestick injury, the odds ratio for transmission increased to 4.8 (95% Ci 2.3-10).132
Post-exposure prophylaxis (PEP) is thought to reduce seroconversion by 81% (95% Ci 48-94%).132 
Commencing PEP early after the injury provides the greatest benefit. in animal studies, administration of 
PEP within 36 hours prevented seroconversion. in animals who received PEP at 72 hours after exposure, 
25% seroconverted. in contrast, 75% of the animals who did not receive any PEP seroconverted by 4 
weeks post exposure.135 Additionally, treatment is most effective when continued for 28 days. there are 
documented case reports of HCWs who have become infected with HiV following occupational exposure, 
despite use of PEP, which in one case was commenced within 30 minutes.136
Blood splashes
the risk of transmission associated with splash injuries is less than the risk associated with needlestick 
injuries, and HiV seroconversion following splashes of blood to intact skin has not been reported.133 the 
risk of HiV transmission associated with exposure of non-intact skin and mucous membrane exposure 
to HiV infected fluid is possible136, but the risk is very low.133 Pooled data provided an estimated risk for 
transmission of HiV via mucous membrane exposure at 0.09%, based on one seroconversion from more 
than 1000 documented exposures.131
Human bites
infection with HiV after a bite from a patient with HiV “is biologically possible, but remains unlikely”.137 
Cases of transmission have been reported in case reports, but the exact risk of transmission is unknown, 
and thought to be very low.138, 139 in the cases reported, blood was present in the mouth of the biter, and the 
skin of the recipient was broken. PEP is recommended if a patient has been bitten by someone known to be 
HiV-positive, with a high viral load, if the bite breaks the skin.140
Although there are reports of HiV transmission from a dentist who had AiDS to patients, it has never been
demonstrated that the dentist acquired HiV from any of his patients.141, 142. Cases of other dentists and 
dental health practitioners who developed HiV after presumed occupational contact are reported, but no 
evidence exists to demonstrate the exact mode of transmission.143 Given that injuries to dentists during 
procedures are common, at a reported rate of 0.9 per 1000 procedures144, and there are no documented 
transmissions of HiV to dentists from patients, the rate of transmission overall is very low.
Sexual exposures
the risk of transmission of HiV following sexual exposure depends on the type of exposure, the viral load 
of the source, and the presence of sexually transmitted infections in either the source or the recipient. if 
the index partner also has a genitourinary infection, for instance, the risk of transmission is approximately 
doubled.145 if the recipient has a genitourinary infection, the risk of acquiring HiV is also elevated.146
Heterosexual exposures
Among heterosexual monogamous couples, the risk of transmission of HiV is 0.04% to 0.07% per 
unprotected sexual act.145, 147 the risk of transmission from an index female to a male recipient (insertive 
vaginal sex) is 0.01-0.14%148, 149, and from an index male to a female recipient (receptive vaginal sex) is 
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0.081%- 0.2% per episode.149, 150 Use of a condom reduces the risk of transmission by 93%-100%.146, 147 the 
risk of transmission is greater during the initial two and a half months of infection.145, 148 the cumulative 
incidence of transmission of HiV to females in couples who practice unprotected anal intercourse is reported 
as 27.8%, compared to only 11.7% transmission to females who do not report anal intercourse.146. transmission 
is very unlikely if the source of the exposure is on antiretroviral treatment 146, 147, 151, and has a viral load <400 
copies/m.152
Men who have sex with men (MSM)
Among MSM couples engaging in unprotected anal intercourse, the estimated rate of HiV transmission for the 
receptive partner is 0.1-3% per act.149, 153 For the insertive partner, the risk of becoming infected following anal 
intercourse with a HiV positive index patient is 0.06 to 0.11%153, 154 but may be up to 0.62% (95%Ci 0.07-1.68%) 
in men who have not been circumcised.153
Orogenital exposures
the risk associated with orogenital contact cannot be accurately predicted, and is considered low, but not 
zero.155 the risk is estimated to be approximately 0% for insertive oral sex, and 0-0.04% per act for receptive 
oral sex.148
Body fluid exposure
the risk associated with exposures to non-blood stained body fluids is thought to be lower than the risk 
associated with blood exposures.18 HiV has been identified in semen, but this is reduced if the index patient is 
on treatment and blood HiV RNA is detected at <400 copies /ml.156. HiV DNA has been extracted from CSF157 
and synovial fluid.158 other fluids which it is thought could be implicated in HiV transmission are pericardial 
fluid, amniotic fluid, peritoneal fluid, human breast milk, vaginal secretions and pleural fluid. Unless there is 
visible blood present, faeces, vomitus, urine, nasal secretions, saliva, sputum, sweat and tears are not thought 
to have any infectious potential.4
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 th
at
 w
as
 g
iv
en
 to
 y
ou
. 
ke
ep
 th
e 
w
ou
nd
 c
le
an
 a
nd
 d
ry
 b
y 
ke
ep
in
g 
it 
co
ve
re
d 
w
ith
 a
 p
la
st
er
 o
r b
an
da
ge
 u
nt
il 
it 
is
 
he
al
ed
. 
if 
yo
ur
 w
ou
nd
 w
as
 c
au
se
d 
by
 a
 h
um
an
 b
ite
, 
an
 a
nt
ib
io
tic
 w
ill
 b
e 
pr
es
cr
ib
ed
 fo
r y
ou
. 
M
ak
e 
su
re
 y
ou
 fi
ni
sh
 th
e 
fu
ll 
co
ur
se
 o
f t
he
 
an
tib
io
tic
. 
if 
yo
u 
ha
ve
 a
ny
 c
on
ce
rn
s 
ab
ou
t y
ou
r w
ou
nd
 
af
te
r d
is
ch
ar
ge
, p
le
as
e 
at
te
nd
 y
ou
r o
w
n 
G
P 
fo
r f
ol
lo
w
 u
p.
 t
he
 e
m
er
ge
nc
y 
de
pa
rt
m
en
t 
w
ill
 b
e 
se
nd
in
g 
a 
le
tt
er
 to
 y
ou
r o
w
n 
do
ct
or
 
in
fo
rm
in
g 
th
em
 a
bo
ut
 y
ou
r i
nj
ur
y 
an
d 
w
ha
t 
tr
ea
tm
en
t y
ou
 re
ce
iv
ed
.
I w
as
 in
ju
re
d 
by
 a
 n
ee
dl
e 
an
d 
I k
ep
t t
he
 
ne
ed
le
 –
 c
an
 it
 b
e 
te
st
ed
 fo
r b
lo
od
 o
r 
in
fe
ct
io
ns
? 
te
st
in
g 
of
 n
ee
dl
es
 fo
r b
lo
od
 o
r i
nf
ec
tio
ns
 is
 o
f n
o 
be
ne
fit
 a
s 
it 
is
 n
ot
 v
er
y 
re
lia
bl
e 
an
d 
it 
ca
n 
be
 h
ar
d 
to
 te
st
 fo
r b
lo
od
bo
rn
e 
vi
ru
se
s.
 t
he
re
fo
re
, i
t i
s 
no
t 
re
co
m
m
en
de
d.
 
th
e 
ne
ed
le
 th
at
 y
ou
 h
av
e 
ne
ed
s 
to
 b
e 
ca
re
fu
lly
 
di
sp
os
ed
 o
f i
nt
o 
a 
sp
ec
ia
l b
in
 s
o 
th
at
 it
 w
ill
 n
ot
 
ca
us
e 
an
y 
m
or
e 
in
ju
rie
s.
 A
sk
 a
 m
em
be
r o
f s
ta
ff 
ab
ou
t s
af
e 
di
sp
os
al
 o
f t
he
 n
ee
dl
e.
 
A
m
 I 
al
lo
w
ed
 to
 b
e 
a 
bl
oo
d 
do
no
r?
 
B
as
ed
 o
n 
yo
ur
 in
ju
ry
, t
he
re
 is
 n
o 
ris
k 
th
at
 y
ou
 
w
ill
 g
et
 a
 b
lo
od
bo
rn
e 
in
fe
ct
io
n 
fr
om
 th
is
 in
ju
ry
. 
th
er
ef
or
e,
 y
ou
 c
an
 b
e 
a 
bl
oo
d 
do
no
r. 
H
ow
ev
er
, 
th
e 
iri
sh
 B
lo
od
 t
ra
ns
fu
si
on
 S
er
vi
ce
 (i
Bt
S)
 d
on
or
 
gu
id
el
in
es
 re
qu
ire
 a
 d
ef
er
ra
l p
er
io
d 
be
fo
re
 
do
na
tin
g.
 F
or
 fu
rt
he
r i
nf
or
m
at
io
n,
 c
on
ta
ct
 iB
tS
. 
Is
 th
er
e 
an
y 
ot
he
r f
ol
lo
w
-u
p 
th
at
 I 
sh
ou
ld
 k
no
w
 a
bo
ut
? 
if 
yo
u 
ar
e 
at
 ri
sk
 o
f g
et
tin
g 
an
 in
ju
ry
 w
ith
 b
lo
od
 
or
 b
od
y 
flu
id
s 
ag
ai
n,
 y
ou
 m
ay
 b
e 
ad
vi
se
d 
to
 
ge
t a
 v
ac
ci
ne
 a
ga
in
st
 h
ep
at
iti
s 
B.
 
if 
yo
u 
re
ce
iv
ed
 th
e 
1st
 d
os
e 
of
 h
ep
at
iti
s 
B
 
va
cc
in
e 
in
 th
e 
em
er
ge
nc
y 
de
pa
rt
m
en
t o
r 
oc
cu
pa
tio
na
l h
ea
lth
 d
ep
ar
tm
en
t, 
yo
u 
w
ill
 b
e 
gi
ve
n 
in
st
ru
ct
io
ns
 a
bo
ut
 w
he
n 
yo
u 
sh
ou
ld
 g
et
 
th
e 
ne
xt
 tw
o 
do
se
s 
of
 th
e 
va
cc
in
e.
 A
 h
ep
at
iti
s 
B
 v
ac
ci
na
tio
n 
ca
rd
 w
ill
 b
e 
gi
ve
n 
to
 y
ou
 a
s 
a 
re
m
in
de
r o
f w
he
n 
yo
u 
sh
ou
ld
 g
et
 th
e 
ne
xt
 
do
se
 o
f t
he
 v
ac
ci
ne
. 
‘if
 y
ou
 h
av
e 
an
y 
co
nc
er
ns
 a
bo
ut
 
yo
ur
 w
ou
nd
 a
ft
er
 d
is
ch
ar
ge
, p
le
as
e 
at
te
nd
 y
ou
r o
w
n 
G
P 
fo
r f
ol
lo
w
 u
p.
’
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W
ha
t i
s 
th
e 
ch
an
ce
 I 
w
ill
 d
ev
el
op
 
an
 in
fe
ct
io
n?
H
ep
at
it
is
 B
if 
so
m
eo
ne
 is
 e
xp
os
ed
 to
 b
lo
od
 in
fe
ct
ed
 w
ith
 
he
pa
tit
is
 B
 v
iru
s,
 e
.g
. n
ee
dl
es
tic
k 
in
ju
ry
, t
he
 
tr
an
sm
is
si
on
 ra
te
 c
an
 b
e 
as
 h
ig
h 
as
 3
0%
. F
or
 
th
is
 re
as
on
, y
ou
r h
ep
at
iti
s 
B
 im
m
un
e 
st
at
us
 w
ill
 
ha
ve
 b
ee
n 
co
ns
id
er
ed
. i
f y
ou
 a
re
 th
ou
gh
t t
o 
be
 
no
t i
m
m
un
e 
to
 h
ep
at
iti
s 
B
 in
fe
ct
io
n,
 y
ou
 w
ill
 b
e 
of
fe
re
d 
va
cc
in
at
io
n 
– 
ei
th
er
 c
om
pl
et
io
n 
of
 th
e 
co
ur
se
 if
 y
ou
 a
lr
ea
dy
 h
ad
 o
ne
 o
r t
w
o 
do
se
s,
 o
r 
th
e 
fir
st
 o
f t
hr
ee
 d
os
es
 o
f t
he
 v
ac
ci
ne
 if
 y
ou
 h
av
e 
ne
ve
r b
ee
n 
va
cc
in
at
ed
 a
ga
in
st
 h
ep
at
iti
s 
B.
 in
 
so
m
e 
ci
rc
um
st
an
ce
s,
 p
eo
pl
e 
m
ay
 a
ls
o 
be
 o
ffe
re
d 
he
pa
tit
is
 im
m
un
og
lo
bu
lin
. 
H
ep
at
it
is
 C
Fo
llo
w
in
g 
ex
po
su
re
 to
 b
lo
od
 in
fe
ct
ed
 w
ith
 
he
pa
tit
is
 C
 v
iru
s,
 e
.g
. n
ee
dl
es
tic
k 
in
ju
ry
, t
he
 ri
sk
 
of
 d
ev
el
op
in
g 
an
 in
fe
ct
io
n 
is
 a
bo
ut
 1.
8%
.
H
IV
:
o
nl
y 
ab
ou
t 0
.3
%
 o
f t
ho
se
 w
ho
 re
po
rt
 a
 
ne
ed
le
st
ic
k 
in
ju
ry
 fr
om
 a
 p
at
ie
nt
 k
no
w
n 
to
 b
e 
in
fe
ct
ed
 w
ith
 H
iV
 w
ill
 d
ev
el
op
 H
iV
. t
he
 ri
sk
 
of
 in
fe
ct
io
n 
fo
llo
w
in
g 
ex
po
su
re
 to
 a
 s
pl
as
h 
of
 
bl
oo
d 
to
 y
ou
r e
ye
 o
r i
nt
o 
yo
ur
 m
ou
th
 is
 lo
w
er
, 
ab
ou
t 0
.0
9%
. E
xp
os
ur
e 
to
 o
th
er
 b
od
y 
flu
id
s 
is
 
as
so
ci
at
ed
 w
ith
 a
n 
ev
en
 lo
w
er
 ri
sk
. t
he
re
 is
 n
o 
ris
k 
as
so
ci
at
e 
w
ith
 b
lo
od
 e
xp
os
ur
e 
to
 in
ta
ct
 s
ki
n.
 T
he
 m
an
ag
em
en
t o
f y
ou
r i
nj
ur
y 
is
 
co
ns
id
er
ed
 o
n 
an
 in
di
vi
du
al
 b
as
is
 
de
pe
nd
in
g 
on
 th
e 
na
tu
re
 
of
 th
e 
in
ju
ry
. 
If 
I d
o 
no
t k
no
w
, f
or
 e
xa
m
pl
e,
 w
ho
 
us
ed
 th
e 
ne
ed
le
 b
ef
or
e 
m
y 
in
ju
ry
 
or
 d
o 
no
t k
no
w
 w
ho
 in
ju
re
d 
or
 
as
sa
ul
te
d 
m
e,
 d
oe
s 
th
is
 c
ha
ng
e 
m
y 
tr
ea
tm
en
t?
Yo
u 
re
po
rt
ed
 a
n 
ex
po
su
re
 to
 b
lo
od
 a
nd
 b
od
y 
flu
id
s 
fr
om
 a
n 
“u
nk
no
w
n 
so
ur
ce
”. 
in
 th
is
 c
irc
um
st
an
ce
, 
it 
is
 n
ot
 p
os
si
bl
e 
to
 e
xc
lu
de
 th
e 
po
ss
ib
ili
ty
 
of
 in
fe
ct
io
n.
 t
he
 ri
sk
 th
at
 y
ou
 m
ay
 d
ev
el
op
 
an
 in
fe
ct
io
n,
 h
ow
ev
er
, i
s 
lo
w
er
 th
an
 th
e 
ris
k 
hi
gh
lig
ht
ed
 a
bo
ve
. 
W
ha
t h
ap
pe
ns
 n
ex
t?
Yo
u 
sh
ou
ld
 h
av
e 
be
en
 g
iv
en
 fo
llo
w
-u
p 
ap
po
in
tm
en
t d
at
es
, o
r a
dv
is
ed
 h
ow
 to
 a
cc
es
s 
fo
llo
w
-u
p 
ap
po
in
tm
en
ts
. F
ol
lo
w
-u
p 
ap
po
in
tm
en
ts
 
ar
e 
ne
ce
ss
ar
y 
in
 o
rd
er
 fo
r y
ou
 to
 re
ce
iv
e 
te
st
 
re
su
lt
s,
 g
et
 a
dd
iti
on
al
 b
lo
od
 te
st
s 
do
ne
 o
r r
ec
ei
ve
 
fu
rt
he
r h
ep
at
iti
s 
B
 v
ac
ci
na
tio
ns
. i
t i
s 
im
po
rt
an
t t
ha
t 
yo
u 
at
te
nd
 a
ll 
fo
llo
w
-u
p 
ap
po
in
tm
en
ts
. t
ak
e 
no
te
 
of
 fo
llo
w
-u
p 
ap
po
in
tm
en
t i
ns
tr
uc
tio
ns
 a
t t
he
 b
ac
k 
of
 th
is
 le
afl
et
. i
f y
ou
 h
av
e 
be
en
 g
iv
en
 h
ep
at
iti
s 
B
 
va
cc
in
e,
 a
 h
ep
at
iti
s 
B
 re
m
in
de
r c
ar
d 
w
ill
 b
e 
gi
ve
n 
to
 y
ou
. 
Is
 th
er
e 
an
yt
hi
ng
 I 
ne
ed
 to
 d
o 
w
hi
le
 
I w
ai
t f
or
 re
su
lt
s 
of
 th
e 
bl
oo
d 
te
st
s?
 
th
e 
fo
llo
w
-u
p 
is
 n
ot
 c
om
pl
et
e 
un
til
 3
 m
on
th
s 
af
te
r t
he
 in
ju
ry
. i
n 
th
e 
m
ea
n 
tim
e,
 if
 y
ou
 d
ev
el
op
 
sy
m
pt
om
s 
su
ch
 a
s 
fe
ve
r, 
an
y 
ra
sh
, s
or
e 
th
ro
at
, 
sw
ol
le
n 
gl
an
ds
, m
ou
th
 u
lc
er
s,
 d
ia
rr
ho
ea
, j
oi
nt
 
or
 m
us
cl
e 
pa
in
, h
ea
da
ch
es
, n
au
se
a 
or
 v
om
iti
ng
, 
re
du
ce
d 
ap
pe
tit
e,
 w
ei
gh
t l
os
s 
or
 fa
tig
ue
, p
le
as
e 
co
nt
ac
t y
ou
r d
oc
to
r a
nd
 a
rr
an
ge
 a
 re
vi
ew
 
ap
po
in
tm
en
t. 
A
m
 I 
al
lo
w
ed
 to
 b
e 
a 
bl
oo
d 
do
no
r 
w
hi
le
 I 
am
 w
ai
ti
ng
 o
n 
th
e 
re
su
lt
s?
Yo
u 
sh
ou
ld
 a
vo
id
 d
on
at
in
g 
bl
oo
d 
or
 o
th
er
 b
od
y 
flu
id
s,
 ti
ss
ue
s 
or
 o
rg
an
s,
 fo
r t
he
 d
ur
at
io
n 
of
 th
e 
fo
llo
w
-u
p 
pe
rio
d,
 to
 li
m
it 
th
e 
ris
k 
of
 p
as
si
ng
 o
n 
an
y 
po
ss
ib
le
 in
fe
ct
io
n.
 
A
re
 th
er
e 
an
y 
ot
he
r a
dd
it
io
na
l 
pr
ec
au
ti
on
s 
th
at
 I 
ne
ed
 to
 ta
ke
? 
D
ep
en
di
ng
 o
n 
th
e 
na
tu
re
 o
f y
ou
r i
nj
ur
y,
 a
dd
iti
on
al
 
pr
ec
au
tio
ns
 m
ay
 a
ls
o 
be
 n
ec
es
sa
ry
. 
• 
  P
re
gn
an
cy
 a
nd
 b
re
as
tf
ee
di
ng
 s
ho
ul
d 
be
 a
vo
id
ed
 
if 
po
ss
ib
le
. 
• 
  D
o 
no
t s
ha
re
 to
ot
hb
ru
sh
es
, r
az
or
s 
or
 n
ee
dl
es
. 
• 
  A
do
pt
 s
af
er
 s
ex
 p
ra
ct
ic
es
 i.
e.
 u
se
 a
 c
on
do
m
 fo
r 
th
e 
ne
xt
 th
re
e 
m
on
th
s.
 
• 
  T
he
re
 is
 n
o 
ne
ed
 to
 re
st
ric
t y
ou
r w
or
k 
pr
ac
tic
es
 
w
hi
le
 a
w
ai
tin
g 
th
e 
re
su
lt
s 
of
 th
es
e 
bl
oo
d 
te
st
s.
 
If 
yo
u 
ha
ve
 a
ny
 c
on
ce
rn
s 
re
ga
rd
in
g 
th
is
 a
dv
ic
e 
or
 
w
is
h 
to
 re
ce
iv
e 
co
un
se
lli
ng
, p
le
as
e 
di
sc
us
s 
th
is
 
w
it
h 
yo
ur
 d
oc
to
r. 
W
he
re
 w
ill
 I 
be
 a
tt
en
di
ng
 fo
r m
y 
ne
xt
 
ap
po
in
tm
en
t (
in
cl
ud
in
g 
co
nt
ac
t d
et
ai
ls
)?
 
W
he
n 
is
 th
is
 a
pp
oi
nt
m
en
t?
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CHECKLIST 
Testing of source person or recipient 
for hepatitis B/hepatitis C/HIV
this is a checklist for the doctor or nurse providing information to the source or 
recipient for consent prior to testing.
□   Explain why a blood test is required in this blood and/or body fluid exposure 
incident/event 
□  Discuss purpose of test as applicable 
 • Establish baseline status of recipient
 • Establish infection status of source person
 • Follow-up blood test
□  Document individual’s personal risk for hepatitis B, hepatitis C or HIV
□  Specify what blood tests are to be done
 • Hep B surface antigen ± Hep B e antigen, Hep B e antibody, Hep B viral load, 
 • Anti-HBs (if previously vaccinated and no record of post-vaccination titre)
 • Anti-HCV ± Hep C viral load
 • HIV Ag/Ab ± HIV viral load
□   Discuss advantages of testing and implications of positive test result with individual, 
covering the following:
 •  Identification of previously unknown disease and ensuring referral to infectious diseases 
specialist
 •  Protection of sexual partners
 •  Allowing informed planning for the future
 •  Possible requirement to inform insurer of a positive test result as is applicable for an 
existing policy or for a new application
 •  Applicable safe work practices including reporting to own Occupational Health Service
 •  Sharing of toothbrushes, shaving or razor blades, needles
 •  Donation of blood, body fluids or other tissues – need to disclose positive results
 •  Pregnancy and breastfeeding
□  Explain confidentiality in the use of and communication of results
□  Explain that results on source patient may have to be disclosed to recipient 
□  Ensure plan in place to obtain blood results and notify patient of results
□  Affirm that declining consent will not impact on ongoing care (if applicable)
□  Offer individual opportunity for clarification of any concerns
□   Document in presence of patient that informed consent has been given before testing
□   Inform the patient that hepatitis B, hepatitis C and HIV are notifiable diseases and 
positive results will be notified confidentially to the Medical Officer of Health
A downloadable version of this brochure can be found at www.emitoolkit.ie
t
o
o
l
k
it
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In
tr
od
uc
tio
n 
A
n 
in
ci
de
nt
 h
as
 o
cc
ur
re
d 
in
 w
hi
ch
 
an
ot
he
r p
er
so
n 
be
ca
m
e 
ex
po
se
d 
to
 
yo
ur
 b
lo
od
 o
r b
od
y 
flu
id
. B
ec
au
se
 
of
 th
e 
na
tu
re
 o
f t
he
 e
xp
os
ur
e,
 th
er
e 
is
 a
 n
ee
d 
to
 c
ar
ry
 o
ut
 a
 b
lo
od
 te
st
 
to
 c
he
ck
 if
 y
ou
 h
av
e 
ce
rt
ai
n 
vi
ru
se
s 
th
at
 c
an
 b
e 
tr
an
sm
itt
ed
 if
 p
re
se
nt
 
in
 y
ou
r b
lo
od
. t
he
se
 v
iru
se
s 
ar
e 
he
pa
tit
is
 B
, h
ep
at
iti
s 
C 
an
d 
hu
m
an
 
im
m
un
od
efi
ci
en
cy
 v
iru
s 
(H
iV
). 
 A
 
ne
ga
tiv
e 
te
st
 re
su
lt 
w
ill
 re
du
ce
 th
e 
ot
he
r p
er
so
n’
s 
an
xi
et
y 
an
d 
el
im
in
at
e 
th
e 
ne
ed
 fo
r t
he
m
 to
 u
nd
er
go
 
un
ne
ce
ss
ar
y 
tr
ea
tm
en
t.
Te
st
in
g 
fo
r t
he
 v
ir
us
es
A
 b
lo
od
 te
st
 w
ill
 b
e 
ca
rr
ie
d 
ou
t o
n 
yo
u 
in
 o
rd
er
 to
 
as
se
ss
 if
 y
ou
 a
lre
ad
y 
ha
ve
 th
es
e 
vi
ru
se
s.
 
th
e 
re
su
lt 
of
 th
is
 te
st
 w
ill
 b
e 
tr
ea
te
d 
as
 c
on
fid
en
tia
l 
an
d 
us
ed
 o
nl
y 
fo
r t
he
 p
ur
po
se
s 
of
 c
on
fir
m
in
g 
yo
ur
 
in
fe
ct
io
n 
st
at
us
 a
t t
he
 ti
m
e 
of
 th
e 
in
ci
de
nt
. i
f y
ou
r 
te
st
 is
 p
os
iti
ve
 a
nd
 th
is
 w
as
 p
re
vi
ou
sl
y 
un
kn
ow
n 
to
 
yo
u,
 th
e 
re
su
lt
s 
w
ill
 b
e 
se
nt
 c
on
fid
en
tia
lly
 to
 y
ou
r o
w
n 
do
ct
or
 w
ho
se
 n
am
e 
yo
u 
pr
ov
id
ed
. t
he
 re
su
lt
s 
of
 y
ou
r 
bl
oo
d 
te
st
 m
ay
 h
av
e 
to
 b
e 
di
sc
lo
se
d 
to
 th
e 
pe
rs
on
 w
ho
 
w
as
 e
xp
os
ed
 to
 y
ou
r b
lo
od
 o
r b
od
y 
flu
id
.
W
ha
t d
oe
s 
th
e 
bl
oo
d 
te
st
 in
vo
lv
e?
 
B
ef
or
e 
th
e 
te
st
, y
ou
 w
ill
 b
e 
pr
ov
id
ed
 w
ith
 in
fo
rm
at
io
n 
to
 a
llo
w
 y
ou
 to
 g
iv
e 
yo
ur
 in
fo
rm
ed
 c
on
se
nt
 to
 th
e 
te
st
. 
Yo
u 
w
ill
 n
ot
 b
e 
te
st
ed
 w
ith
ou
t y
ou
r g
iv
en
 c
on
se
nt
. i
t 
is
 s
im
ila
r t
o 
a 
no
rm
al
 b
lo
od
 te
st
 th
at
 y
ou
 m
ay
 h
av
e 
ha
d 
be
fo
re
. i
t s
ho
ul
d 
on
ly
 ta
ke
 a
 fe
w
 m
in
ut
es
 a
nd
 y
ou
 
w
ill
 b
e 
ad
vi
se
d 
w
he
n 
to
 e
xp
ec
t t
he
 re
su
lt
s.
 Y
ou
 h
av
e 
th
e 
rig
ht
 to
 re
fu
se
 to
 b
e 
te
st
ed
. i
f y
ou
 c
ho
os
e 
no
t t
o 
be
 
te
st
ed
, y
ou
r c
ar
e 
w
ill
 n
ot
 b
e 
af
fe
ct
ed
.
W
ha
t h
ap
pe
ns
 if
 th
e 
bl
oo
d 
te
st
 is
 
ne
ga
ti
ve
? 
th
is
 m
ea
ns
 th
at
 y
ou
 te
st
ed
 n
eg
at
iv
e 
fo
r t
he
 v
iru
se
s 
at
 
th
e 
tim
e 
of
 th
e 
bl
oo
d 
te
st
. N
o 
fu
rt
he
r t
es
tin
g 
w
ill
 b
e 
re
qu
ire
d.
W
ha
t h
ap
pe
ns
 if
 th
e 
bl
oo
d 
te
st
 is
 
po
si
ti
ve
? 
in
 th
e 
ev
en
t t
ha
t t
he
 b
lo
od
 te
st
 is
 p
os
iti
ve
 fo
r o
ne
 o
f 
th
es
e 
vi
ru
se
s 
an
d 
th
is
 w
as
 p
re
vi
ou
sl
y 
un
kn
ow
n 
to
 
yo
u,
 y
ou
 w
ill
 b
e 
re
fe
rr
ed
 to
 a
 s
pe
ci
al
is
t i
n 
in
fe
ct
io
us
 
di
se
as
es
 fo
r f
ol
lo
w
-u
p.
 Y
ou
r o
w
n 
do
ct
or
 w
ill
 re
ce
iv
e 
a 
co
nfi
de
nt
ia
l l
et
te
r o
ut
lin
in
g 
yo
ur
 re
su
lt
s.
 
 A
re
 th
er
e 
an
y 
im
pl
ic
at
io
ns
 o
f a
 
po
si
ti
ve
 te
st
?
• 
 If 
th
e 
te
st
 is
 p
os
iti
ve
 fo
r a
ny
 o
f t
he
se
 b
lo
od
bo
rn
e 
vi
ru
se
s,
 y
ou
 w
ill
 b
e 
re
fe
rr
ed
 to
 a
 s
pe
ci
al
is
t f
or
 
fo
llo
w
 u
p 
as
se
ss
m
en
t a
nd
 m
an
ag
em
en
t. 
• 
 D
ep
en
di
ng
 o
n 
th
e 
ty
pe
 o
f i
ns
ur
an
ce
 p
ol
ic
y,
 y
ou
 
m
ay
 b
e 
re
qu
ire
d 
to
 in
fo
rm
 y
ou
r i
ns
ur
er
 th
at
 y
ou
 
ha
ve
 te
st
ed
 p
os
iti
ve
 fo
r a
ny
 o
f t
he
se
 b
lo
od
bo
rn
e 
vi
ru
se
s 
w
he
re
 y
ou
 h
av
e 
an
 e
xi
st
in
g 
po
lic
y 
or
 w
he
n 
m
ak
in
g 
a 
ne
w
 a
pp
lic
at
io
n 
•  Y
ou
 w
ill
 h
av
e 
to
 in
fo
rm
 y
ou
r s
ex
ua
l p
ar
tn
er
(s
) a
nd
 
yo
u 
sh
ou
ld
 h
av
e 
be
en
 g
iv
en
 a
dv
ic
e 
re
ga
rd
in
g 
th
e 
ne
ed
 fo
r s
af
er
 s
ex
 p
ra
ct
ic
es
.
•  Y
ou
 w
ill
 n
ee
d 
to
 in
fo
rm
 re
le
va
nt
 a
ge
nc
ie
s 
if 
yo
u 
ar
e 
co
ns
id
er
in
g 
do
na
tin
g 
bl
oo
d 
pr
od
uc
ts
 o
r o
th
er
 b
od
y 
tis
su
es
.
•  Y
ou
 s
ho
ul
d 
no
t s
ha
re
 s
ha
vi
ng
 b
la
de
s 
or
 ra
zo
rs
, 
to
ot
hb
ru
sh
es
 a
nd
 n
ee
dl
es
.
•  Y
ou
 s
ho
ul
d 
ge
t e
xp
er
t a
dv
ic
e 
ab
ou
t p
re
gn
an
cy
 a
nd
 
br
ea
st
 fe
ed
in
g.
• 
 H
ep
at
iti
s 
B
, h
ep
at
iti
s 
C
 a
nd
 H
IV
 a
re
 n
ot
ifi
ab
le
 
di
se
as
es
 a
nd
 p
os
iti
ve
 re
su
lt
s 
w
ill
 b
e 
no
tifi
ed
 
co
nfi
de
nt
ia
lly
 to
 th
e 
m
ed
ic
al
 o
ffi
ce
r o
f h
ea
lth
. 
  Co
un
se
lli
ng
if 
yo
u 
ha
ve
 a
ny
 c
on
ce
rn
s 
re
ga
rd
in
g 
th
is
 a
dv
ic
e 
or
 
w
is
h 
to
 re
ce
iv
e 
co
un
se
lli
ng
, p
le
as
e 
di
sc
us
s 
th
is
 w
ith
 
yo
ur
 d
oc
to
r.
It 
is
 s
im
ila
r t
o 
a 
no
rm
al
 b
lo
od
 te
st
 th
at
 y
ou
 m
ay
 h
av
e 
ha
d 
be
fo
re
. I
t s
ho
ul
d 
on
ly
 ta
ke
 a
 fe
w
 m
in
ut
es
 a
nd
 y
ou
 w
ill
 b
e 
ad
vi
se
d 
w
he
n 
to
 e
xp
ec
t t
he
 re
su
lts
.
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H
IV
 P
EP
 m
us
t b
e 
ta
ke
n 
w
ith
in
 7
2 
ho
ur
s 
of
 y
ou
r 
ex
po
su
re
 a
s 
it 
w
ill
 n
ot
 
be
 e
ffe
ct
iv
e 
if 
ta
ke
n 
af
te
r 7
2 
ho
ur
s.
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W
h
at
 is
 H
IV
 P
EP
 t
re
at
m
en
t?
H
IV
 P
EP
 is
 a
 p
os
t-
ex
po
su
re
 p
ro
ph
yl
ac
tic
 (P
EP
) 
tr
ea
tm
en
t t
ha
t i
s 
pr
es
cr
ib
ed
 fo
r y
ou
 in
 o
rd
er
 to
 p
re
ve
nt
 
H
IV
 in
fe
ct
io
n 
fo
llo
w
in
g 
a 
hi
gh
 ri
sk
 e
xp
os
ur
e 
to
 b
lo
od
 
or
 b
od
y 
flu
id
s.
 T
he
 tr
ea
tm
en
t i
s 
fo
r 2
8 
da
ys
. I
t i
s 
ve
ry
 im
po
rt
an
t t
ha
t y
ou
 d
o 
no
t m
is
s 
an
y 
do
se
s 
an
d 
co
m
pl
et
e 
th
e 
28
 d
ay
 c
ou
rs
e.
 
Yo
u 
w
ill
 b
e 
gi
ve
n 
a 
st
ar
te
r p
ac
k 
of
 th
e 
m
ed
ic
at
io
ns
 th
at
 
yo
u 
w
ill
 n
ee
d 
to
 ta
ke
. 
In
 th
e 
st
ar
te
r p
ac
k 
th
er
e 
w
ill
 b
e 
on
ly
 e
no
ug
h 
m
ed
ic
at
io
ns
 fo
r 3
-5
 d
ay
s.
  B
ef
or
e 
th
e 
pa
ck
 h
as
 
fin
is
he
d 
yo
u 
sh
ou
ld
 h
av
e 
be
en
 s
ee
n 
by
 a
 s
pe
ci
al
is
t 
in
 in
fe
ct
io
us
 d
is
ea
se
s.
 It
 is
 v
er
y 
im
po
rt
an
t t
ha
t y
ou
 
at
te
nd
 a
ll 
ap
po
in
tm
en
ts
 th
at
 a
re
 a
rr
an
ge
d 
fo
r y
ou
. 
D
o 
I h
av
e 
to
 t
ak
e 
H
IV
 P
EP
? 
B
as
ed
 o
n 
yo
ur
 ty
pe
 o
f i
nj
ur
y 
an
d 
th
e 
po
te
nt
ia
l r
is
k 
of
 
H
IV
 b
ei
ng
 tr
an
sm
itt
ed
 to
 y
ou
 fr
om
 th
e 
so
ur
ce
 p
er
so
n/
 
ite
m
, i
t i
s 
re
co
m
m
en
de
d 
th
at
 y
ou
 s
ta
rt
 th
is
 tr
ea
tm
en
t 
im
m
ed
ia
te
ly
. 
H
IV
 P
EP
 m
us
t b
e 
ta
ke
n 
w
ith
in
 7
2 
ho
ur
s 
of
 y
ou
r 
ex
po
su
re
 a
s 
it 
w
ill
 n
ot
 b
e 
ef
fe
ct
iv
e 
if 
ta
ke
n 
af
te
r 7
2 
ho
ur
s.
 
If 
yo
u 
ar
e 
H
IV
 p
os
iti
ve
 o
n 
yo
ur
 fi
rs
t b
lo
od
 te
st
, y
ou
r 
H
IV
 P
EP
 m
ed
ic
at
io
n 
w
ill
 b
e 
re
vi
ew
ed
. 
H
ow
 lo
n
g 
w
ill
 I 
be
 o
n
 t
h
is
 
tr
ea
tm
en
t?
 
G
en
er
al
ly
 th
e 
tr
ea
tm
en
t w
ill
 la
st
 2
8 
da
ys
 a
nd
 w
ill
 
de
pe
nd
 o
n 
an
 a
ss
es
sm
en
t b
y 
a 
sp
ec
ia
lis
t i
n 
in
fe
ct
io
us
 
di
se
as
es
. Y
ou
 w
ill
 a
ls
o 
re
qu
ire
 fo
llo
w
-u
p 
bl
oo
d 
te
st
s 
ov
er
 th
e 
ne
xt
 th
re
e 
m
on
th
s.
 F
ol
lo
w
 u
p 
bl
oo
d 
te
st
s 
w
ill
 b
e 
ar
ra
ng
ed
 b
y 
th
e 
In
fe
ct
io
us
 D
is
ea
se
 C
lin
ic
. 
W
h
at
 m
ed
ic
at
io
n
s 
w
ill
 b
e 
pr
es
cr
ib
ed
?
Yo
u 
w
ill
 b
e 
pr
es
cr
ib
ed
 m
ed
ic
at
io
ns
 c
al
le
d 
tr
uv
ad
a®
 
an
d 
ka
le
tr
a®
. Y
ou
 s
ho
ul
d 
ta
ke
 o
ne
 ta
bl
et
 o
f t
ru
va
da
® 
on
ce
 a
 d
ay
 w
ith
 fo
od
. Y
ou
 s
ho
ul
d 
ta
ke
 fo
ur
 ta
bl
et
s 
of
 
ka
le
tr
a®
 o
nc
e 
a 
da
y.
 It
 is
 im
po
rt
an
t t
ha
t y
ou
 ta
ke
 y
ou
r 
ta
bl
et
s 
at
 th
e 
sa
m
e 
tim
e 
ea
ch
 d
ay
 a
nd
 d
on
’t 
m
is
s 
an
y 
do
se
s.
  S
et
 re
m
in
de
rs
 o
n 
yo
ur
 p
ho
ne
 to
 e
ns
ur
e 
th
at
 
yo
u 
ta
ke
 th
e 
m
ed
ic
at
io
n 
on
 ti
m
e.
 
A
re
 t
h
er
e 
an
y 
si
de
 e
ff
ec
ts
 t
o 
ta
ki
n
g 
th
es
e 
m
ed
ic
at
io
n
s?
Ye
s,
 th
ey
 c
an
 c
au
se
 d
ia
rr
ho
ea
, v
om
iti
ng
, t
ire
dn
es
s 
an
d 
he
ad
ac
he
s.
 Y
ou
r p
ac
k 
m
ay
 in
cl
ud
e 
ta
bl
et
s 
ca
lle
d 
do
m
pe
rid
on
e 
fo
r n
au
se
a 
an
d 
lo
pe
ra
m
id
e 
fo
r 
di
ar
rh
oe
a 
w
hi
ch
 w
ill
 h
el
p 
re
lie
ve
 s
om
e 
of
 th
e 
si
de
 
ef
fe
ct
s.
 P
ar
ac
et
am
ol
 m
ay
 a
ls
o 
be
 ta
ke
n 
to
 tr
ea
t a
ny
 
he
ad
ac
he
s 
th
at
 y
ou
 m
ay
 e
xp
er
ie
nc
e.
 It
 is
 im
po
rt
an
t 
th
at
 y
ou
 fo
llo
w
 th
e 
in
st
ru
ct
io
ns
 o
n 
th
e 
la
be
ls
. S
id
e 
ef
fe
ct
s 
us
ua
lly
 d
is
ap
pe
ar
 a
ft
er
 a
 fe
w
 d
ay
s 
bu
t i
f t
he
y 
w
or
se
n 
ta
lk
 to
 y
ou
r d
oc
to
r a
nd
 y
ou
 m
ay
 n
ee
d 
to
 ta
ke
 
tim
e 
of
f w
or
k 
or
 s
tu
dy
.
A
re
 t
h
e 
H
IV
 P
EP
 m
ed
ic
at
io
n
s 
sa
fe
 t
o 
ta
ke
 w
it
h
 m
y 
ow
n
 m
ed
ic
at
io
n
s?
 
If 
yo
u 
ar
e 
al
re
ad
y 
on
 m
ed
ic
at
io
n 
fo
r o
th
er
 m
ed
ic
al
 
co
nd
iti
on
s,
 th
e 
do
ct
or
/ 
ph
ar
m
ac
is
t w
ill
 a
dv
is
e 
yo
u 
if 
yo
ur
 o
w
n 
m
ed
ic
at
io
ns
 a
re
 s
af
e 
to
 ta
ke
 w
ith
 
th
e 
H
IV
 P
EP
 tr
ea
tm
en
t. 
H
IV
 P
EP
 c
an
 re
du
ce
 th
e 
ef
fe
ct
iv
en
es
s 
of
 th
e 
or
al
 c
on
tr
ac
ep
tiv
e 
pi
ll.
  
A
re
 t
h
er
e 
an
y 
sp
ec
ia
l p
re
ca
ut
io
n
s 
to
 b
e 
ta
ke
n
 w
h
ils
t 
I a
m
 o
n
 t
h
is
 
tr
ea
tm
en
t?
 
• 
  D
o 
no
t s
ha
re
 to
ot
hb
ru
sh
es
, r
az
or
s 
or
 n
ee
dl
es
. 
• 
  A
do
pt
 s
af
er
 s
ex
 p
ra
ct
ic
es
 i.
e.
 u
se
 a
 c
on
do
m
 fo
r t
he
 
ne
xt
 th
re
e 
m
on
th
s.
 
• 
  If
 y
ou
 a
re
 p
re
gn
an
t o
r b
re
as
tf
ee
di
ng
 y
ou
 m
us
t s
ee
k 
ad
vi
ce
 fr
om
 a
n 
ob
st
et
ric
ia
n 
or
 in
fe
ct
io
us
 d
is
ea
se
s 
sp
ec
ia
lis
t.
• 
  It
 is
 n
ot
 re
co
m
m
en
de
d 
fo
r y
ou
 to
 d
on
at
e 
bl
oo
d 
or
 
ot
he
r b
od
y 
flu
id
s 
fo
r t
he
 d
ur
at
io
n 
of
 y
ou
r t
re
at
m
en
t 
an
d 
fo
llo
w
-u
p 
ca
re
. 
 F
ol
lo
w
-u
p 
Ca
re
 
It 
is
 v
er
y 
im
po
rt
an
t t
ha
t y
ou
 a
tt
en
d 
al
l y
ou
r 
ap
po
in
tm
en
ts
. Y
ou
 s
ho
ul
d 
be
 s
ee
n 
in
 a
n 
In
fe
ct
io
us
 
D
is
ea
se
 C
lin
ic
 b
ef
or
e 
th
e 
st
ar
te
r p
ac
k 
of
 m
ed
ic
at
io
n 
ru
ns
 o
ut
. A
 re
fe
rr
al
 le
tt
er
 w
ill
 b
e 
se
nt
 to
 th
e 
in
fe
ct
io
us
 
di
se
as
es
 s
pe
ci
al
is
t e
xp
la
in
in
g 
th
e 
tr
ea
tm
en
t t
ha
t y
ou
 
re
ce
iv
ed
. I
t i
s 
us
ef
ul
 to
 ta
ke
 n
ot
e 
of
 th
e 
fo
llo
w
in
g:
 
W
he
re
 w
ill
 I 
be
 a
tt
en
di
ng
 fo
r m
y 
ne
xt
 a
pp
oi
nt
m
en
t 
(in
cl
ud
in
g 
co
nt
ac
t d
et
ai
ls
?)
 
W
he
n 
is
 th
is
 a
pp
oi
nt
m
en
t?
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at
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Co
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ra
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A
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O
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A
FL
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w
w
w
.h
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.ie
If 
yo
u 
ha
ve
 h
ad
 s
ex
ua
l 
in
te
rc
ou
rs
e 
w
ith
ou
t u
si
ng
 
co
nt
ra
ce
pt
io
n,
 a
re
 a
t 
ris
k 
of
 p
re
gn
an
cy
 d
ue
 to
 
se
xu
al
 a
ss
au
lt 
or
 th
in
k 
yo
ur
 
m
et
ho
d 
of
 c
on
tr
ac
ep
tio
n 
m
ay
 h
av
e 
fa
ile
d,
 y
ou
 m
ay
 
w
is
h 
to
 u
se
 e
m
er
ge
nc
y 
co
nt
ra
ce
pt
io
n.
 T
hi
s 
w
ill
 
us
ua
lly
 p
re
ve
nt
 p
re
gn
an
cy
. 
w
w
w
.e
m
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if 
yo
u 
ha
ve
 h
ad
 s
ex
ua
l i
nt
er
co
ur
se
 
w
ith
ou
t u
si
ng
 c
on
tr
ac
ep
tio
n,
 a
re
 
at
 ri
sk
 o
f p
re
gn
an
cy
 d
ue
 to
 s
ex
ua
l 
as
sa
ul
t o
r t
hi
nk
 y
ou
r m
et
ho
d 
of
 
co
nt
ra
ce
pt
io
n 
m
ay
 h
av
e 
fa
ile
d,
 
yo
u 
m
ay
 w
is
h 
to
 u
se
 e
m
er
ge
nc
y 
co
nt
ra
ce
pt
io
n.
 t
hi
s 
w
ill
 u
su
al
ly
 
pr
ev
en
t p
re
gn
an
cy
. 
A
 ta
bl
et
 c
on
ta
in
in
g 
a 
pr
og
es
to
ge
n 
ho
rm
on
e 
(l
ev
on
or
ge
st
re
l –
 
le
vo
ne
lle
™
) i
s 
m
os
t c
om
m
on
ly
 
us
ed
. t
hi
s 
is
 c
om
m
on
ly
 c
al
le
d 
th
e 
“m
or
ni
ng
 a
ft
er
 p
ill
”. 
it 
sh
ou
ld
 b
e 
ta
ke
n 
as
 s
oo
n 
as
 p
os
si
bl
e 
af
te
r 
un
pr
ot
ec
te
d 
se
x,
 a
nd
 id
ea
lly
 w
ith
in
 
72
 h
ou
rs
.
 N
o 
fo
rm
 o
f e
m
er
ge
nc
y 
co
nt
ra
ce
pt
io
n 
of
fe
rs
 a
 10
0%
 
gu
ar
an
te
e 
ag
ai
ns
t p
re
gn
an
cy
. 
Co
pp
er
 iU
D
 in
se
rt
io
n 
(p
ar
tic
ul
ar
ly
 
af
te
r 7
2 
ho
ur
s)
 is
 m
or
e 
ef
fe
ct
iv
e 
th
an
 le
vo
no
rg
es
tr
el
. 
H
ow
 d
oe
s 
le
vo
n
or
ge
st
re
l w
or
k?
 
le
vo
no
rg
es
tr
el
 is
 th
ou
gh
t t
o 
w
or
k 
by
 s
to
pp
in
g 
or
 d
el
ay
in
g 
an
 e
gg
 b
ei
ng
 re
le
as
ed
 fr
om
 y
ou
r o
va
rie
s 
(o
vu
la
tio
n)
. i
t m
ay
 
al
so
 p
re
ve
nt
 s
pe
rm
 fr
om
 fe
rt
ili
si
ng
 a
ny
 e
gg
 y
ou
 m
ay
 h
av
e 
al
re
ad
y 
re
le
as
ed
, o
r s
to
p 
a 
fe
rt
ili
se
d 
eg
g 
fr
om
 a
tt
ac
hi
ng
 
its
el
f t
o 
th
e 
lin
in
g 
of
 th
e 
w
om
b.
 t
he
re
fo
re
 it
 s
to
ps
 a
 
pr
eg
na
nc
y 
be
fo
re
 it
 is
 e
st
ab
lis
he
d.
 it
 d
oe
s 
no
t w
or
k 
if 
yo
u 
ar
e 
al
re
ad
y 
pr
eg
na
nt
. 
Te
ll 
yo
ur
 d
oc
to
r 
if
 a
n
y 
of
 t
h
e 
fo
llo
w
in
g 
ap
pl
y 
to
 y
ou
…
. 
• 
 Y
 ou
 a
re
 p
re
gn
an
t o
r t
hi
nk
 y
ou
 m
ay
 b
e 
pr
eg
na
nt
 
• 
  Y
ou
r p
er
io
d 
is
 la
te
 o
r y
ou
r l
as
t p
er
io
d 
w
as
 u
nu
su
al
 
• 
   Y
ou
 h
av
e 
ha
d 
un
pr
ot
ec
te
d 
se
x 
w
hi
ch
 w
as
 m
or
e 
th
an
 7
2 
ho
ur
s 
ag
o,
 a
nd
 s
in
ce
 y
ou
r l
as
t p
er
io
d 
• 
   Y
ou
 h
av
e 
a 
di
se
as
e 
of
 th
e 
sm
al
l b
ow
el
 (e
.g
. C
ro
hn
’s
 
di
se
as
e)
 th
at
 in
te
rf
er
es
 w
ith
 d
ig
es
tio
n 
of
 fo
od
 
• 
  Y
ou
 h
av
e 
be
en
 to
ld
 b
y 
yo
ur
 d
oc
to
r t
ha
t y
ou
 h
av
e 
an
 
in
to
le
ra
nc
e 
to
 s
om
e 
su
ga
rs
 
• 
 Y
ou
 h
av
e 
se
ve
re
 li
ve
r p
ro
bl
em
s 
• 
   Y
ou
 a
re
 ta
ki
ng
 m
ed
ic
at
io
n 
fo
r e
pi
le
ps
y,
 tu
be
rc
ul
os
is
 
(t
B
), 
H
iV
 in
fe
ct
io
n,
 fu
ng
al
 in
fe
ct
io
ns
 o
r h
er
ba
l r
em
ed
ie
s 
co
nt
ai
ni
ng
 S
t J
oh
n’
s 
W
or
t.
 
A
re
 t
h
er
e 
si
de
 e
ff
ec
ts
? 
B
y 
an
d 
la
rg
e,
 le
vo
no
rg
es
tr
el
 is
 w
el
l t
ol
er
at
ed
. t
he
 m
os
t 
co
m
m
on
 s
id
e 
ef
fe
ct
 is
 n
au
se
a 
an
d 
a 
sm
al
l n
um
be
r o
f 
w
om
en
 w
ill
 e
xp
er
ie
nc
e 
vo
m
iti
ng
. i
f t
he
 v
om
iti
ng
 o
cc
ur
s 
w
ith
in
 3
 h
ou
rs
 o
f t
ak
in
g 
th
e 
m
ed
ic
at
io
n 
yo
u 
sh
ou
ld
 c
on
su
lt 
yo
ur
 d
oc
to
r, 
as
 y
ou
 m
ay
 n
ee
d 
a 
se
co
nd
 d
os
e.
 
O
th
er
 s
id
e 
ef
fe
ct
s:
 Y
ou
 m
ig
ht
 h
av
e 
te
nd
er
 b
re
as
ts
, 
he
ad
ac
he
s,
 lo
w
er
 a
bd
om
in
al
 (t
um
m
y)
 p
ai
n,
 d
ia
rr
ho
ea
, 
fe
el
 d
iz
zy
 o
r f
ee
l t
ire
d 
af
te
r t
ak
in
g 
th
is
 m
ed
ic
at
io
n.
 t
he
se
 
sy
m
pt
om
s 
sh
ou
ld
 g
et
 b
et
te
r a
ft
er
 a
 fe
w
 d
ay
s.
 
Yo
u 
sh
ou
ld
 g
et
 y
ou
r n
ex
t p
er
io
d 
at
 th
e 
ex
pe
ct
ed
 ti
m
e.
 
H
ow
ev
er
, y
ou
 m
ay
 g
et
 it
 e
ar
lie
r o
r l
at
er
 th
an
 e
xp
ec
te
d.
 
Yo
u 
sh
ou
ld
 c
on
su
lt
 y
ou
r G
P
 to
 ru
le
 o
ut
 p
re
gn
an
cy
 in
 th
e 
ev
en
t t
ha
t y
ou
r n
ex
t p
er
io
d 
is
 v
er
y 
la
te
 o
r u
nu
su
al
ly
 li
gh
t. 
W
h
at
 h
ap
pe
n
s 
if
 it
 d
oe
sn
’t
 w
or
k?
 
th
er
e 
is
 n
o 
pr
oo
f t
ha
t l
ev
on
or
ge
st
re
l c
au
se
s 
an
y 
ha
rm
 to
 
a 
de
ve
lo
pi
ng
 b
ab
y.
 
in
 th
e 
ev
en
t o
f f
ai
lu
re
 o
f l
ev
on
or
ge
st
re
l t
he
re
 m
ay
 b
e 
an
 
in
cr
ea
se
d 
ris
k 
of
 e
ct
op
ic
 p
re
gn
an
cy
. 
W
h
at
 d
o 
yo
u 
do
 n
ex
t?
 
if 
yo
u 
w
er
e 
al
re
ad
y 
ta
ki
ng
 th
e 
co
nt
ra
ce
pt
iv
e 
pi
ll,
 y
ou
 c
an
 
re
st
ar
t i
t t
he
 d
ay
 a
ft
er
 ta
ki
ng
 e
m
er
ge
nc
y 
co
nt
ra
ce
pt
io
n.
 
Yo
u 
sh
ou
ld
 a
tt
en
d 
yo
ur
 G
P
 to
 d
o 
a 
pr
eg
na
nc
y 
te
st
 a
t 
th
e 
en
d 
of
 th
e 
pa
ck
et
. Y
ou
 m
us
t n
ot
 c
on
si
de
r y
ou
rs
el
f 
pr
ot
ec
te
d 
ag
ai
ns
t p
re
gn
an
cy
 fo
r t
he
 re
st
 o
f y
ou
r c
yc
le
 
fo
llo
w
in
g 
a 
do
se
 o
f l
ev
on
or
ge
st
re
l, 
pa
rt
ic
ul
ar
ly
 a
s 
it 
m
ay
 
de
la
y 
ov
ul
at
io
n.
 if
 y
ou
 w
er
e 
no
t t
ak
in
g 
th
e 
co
nt
ra
ce
pt
iv
e 
pi
ll,
 y
ou
 s
ho
ul
d 
co
ns
id
er
 u
si
ng
 a
no
th
er
 fo
rm
 o
f 
co
nt
ra
ce
pt
io
n 
fo
r t
he
 re
st
 o
f y
ou
r c
yc
le
, e
.g
. c
on
do
m
s.
W
h
at
 o
th
er
 is
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es
 s
h
ou
ld
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ou
 c
on
si
de
r?
 
H
av
in
g 
un
pr
ot
ec
te
d 
se
x 
pu
ts
 y
ou
 a
t r
is
k 
of
 c
on
tr
ac
tin
g 
se
xu
al
ly
 tr
an
sm
itt
ed
 in
fe
ct
io
ns
. Y
ou
 c
an
 d
is
cu
ss
 th
e 
ris
ks
 
of
 in
fe
ct
io
n 
an
d 
th
e 
ne
ed
 fo
r t
es
ts
 w
ith
 y
ou
r d
oc
to
r. 
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W
ha
t t
re
at
m
en
ts
 a
re
 a
va
ila
bl
e 
fo
r 
th
es
e 
in
fe
ct
io
ns
? 
if 
yo
u 
ha
ve
 n
ot
 p
re
vi
ou
sl
y 
be
en
 v
ac
ci
na
te
d 
fo
r h
ep
at
iti
s 
B
, y
ou
 m
ay
 b
e 
ad
vi
se
d 
to
 g
et
 
va
cc
in
at
ed
 a
ga
in
st
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ep
at
iti
s 
B.
 
• 
  T
he
 fi
rs
t d
os
e 
of
 th
e 
va
cc
in
e 
m
ay
 b
e 
gi
ve
n 
to
 
yo
u 
in
 th
e 
em
er
ge
nc
y 
de
pa
rt
m
en
t o
r S
At
U
. 
• 
  F
ur
th
er
 d
os
es
 o
f t
he
 v
ac
ci
ne
 w
ill
 n
ee
d 
to
 b
e 
gi
ve
n 
to
 y
ou
 b
y 
yo
ur
 o
w
n 
G
P.
• 
  Y
ou
 w
ill
 b
e 
gi
ve
n 
a 
he
pa
tit
is
 B
 v
ac
ci
na
tio
n 
ca
rd
 w
hi
ch
 w
ill
 o
ut
lin
e 
w
he
n 
yo
u 
sh
ou
ld
 g
et
 
th
e 
ne
xt
 d
os
es
 o
f t
he
 v
ac
ci
ne
.
H
IV
 P
os
t E
xp
os
ur
e 
P
ro
ph
yl
ax
is
 (P
EP
): 
Th
is
 
is
 o
nl
y 
re
co
m
m
en
de
d 
fo
r a
 s
m
al
l n
um
be
r 
of
 p
at
ie
nt
s 
an
d 
de
pe
nd
s 
on
 th
e 
ris
k 
of
 H
iV
 
tr
an
sm
is
si
on
 a
s 
a 
re
su
lt 
of
 y
ou
r s
ex
ua
l 
ex
po
su
re
. T
he
 d
oc
to
r w
ill
 a
dv
is
e 
yo
u 
if 
th
is
 
tr
ea
tm
en
t i
s 
re
qu
ire
d 
an
d 
pr
ov
id
e 
yo
u 
w
ith
 
m
or
e 
in
fo
rm
at
io
n 
ab
ou
t w
ha
t t
he
 tr
ea
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en
t i
s.
I a
m
 w
or
ri
ed
 a
bo
ut
 p
re
gn
an
cy
?
A
n 
em
er
ge
nc
y 
co
nt
ra
ce
pt
iv
e 
or
 ‘m
or
ni
ng
 a
ft
er
 p
ill
’ c
al
le
d 
Le
vo
no
rg
es
tr
el
 m
ay
 b
e 
pr
es
cr
ib
ed
 fo
r y
ou
 fo
llo
w
in
g 
a 
pr
eg
na
nc
y 
te
st
. I
t s
ho
ul
d 
be
 ta
ke
n 
w
ith
in
 7
2 
ho
ur
s.
 If
 y
ou
 
ar
e 
go
in
g 
to
 ta
ke
 th
e 
‘m
or
ni
ng
 a
ft
er
 p
ill
’, 
an
 in
fo
rm
at
io
n 
le
afl
et
 w
ill
 b
e 
gi
ve
n 
to
 y
ou
 w
hi
ch
 w
ill
 d
es
cr
ib
e 
w
ha
t i
t i
s 
an
d 
ho
w
 it
 w
or
ks
. 
A
m
 I 
al
lo
w
ed
 to
 b
e 
a 
bl
oo
d 
do
no
r?
 
Yo
u 
sh
ou
ld
 a
vo
id
 d
on
at
in
g 
bl
oo
d 
or
 o
th
er
 b
od
y 
flu
id
s 
fo
r 
th
e 
du
ra
tio
n 
of
 y
ou
r f
ol
lo
w
 u
p.
 
W
ha
t o
th
er
 fo
llo
w
-u
p 
do
 I 
ne
ed
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• 
  If
 y
ou
 a
re
 b
ei
ng
 re
fe
rr
ed
 to
 a
 s
pe
ci
al
is
t 
cl
in
ic
, y
ou
 w
ill
 e
ith
er
 b
e 
gi
ve
n 
th
ei
r c
on
ta
ct
 
de
ta
ils
 o
r g
iv
en
 in
st
ru
ct
io
ns
 w
ith
 re
ga
rd
 to
 
ap
po
in
tm
en
ts
. 
• 
  A
 re
fe
rr
al
 le
tt
er
 w
ill
 b
e 
se
nt
 to
 th
e 
sp
ec
ia
lis
t 
cl
in
ic
 e
xp
la
in
in
g 
th
e 
as
se
ss
m
en
t a
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tr
ea
tm
en
t t
ha
t y
ou
 h
av
e 
re
ce
iv
ed
. 
• 
  If
 y
ou
 h
av
e 
an
y 
co
nc
er
ns
 re
ga
rd
in
g 
th
is
 
ad
vi
ce
 o
r w
is
h 
to
 re
ce
iv
e 
co
un
se
lli
ng
, p
le
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e 
di
sc
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s 
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 w
ith
 y
ou
r d
oc
to
r.
W
he
re
 w
ill
 I 
be
 a
tt
en
di
ng
 fo
r m
y 
ne
xt
 
ap
po
in
tm
en
t (
in
cl
ud
in
g 
co
nt
ac
t d
et
ai
ls
?)
 
W
he
n 
is
 th
is
 a
pp
oi
nt
m
en
t?
H
ow
 d
o 
I k
no
w
 if
 I 
ha
ve
 o
ne
 o
f 
th
es
e 
in
fe
ct
io
ns
? 
W
ith
 y
ou
r c
on
se
nt
, a
 b
lo
od
 s
am
pl
e 
m
ay
 
be
 ta
ke
n 
in
 th
e 
Em
er
ge
nc
y 
D
ep
ar
tm
en
t 
to
 te
st
 fo
r b
lo
od
bo
rn
e 
vi
ru
se
s 
(h
ep
at
iti
s 
B
, h
ep
at
iti
s 
C
 a
nd
 H
IV
) a
nd
 s
yp
hi
lis
 to
 
ru
le
 o
ut
 a
ny
 in
fe
ct
io
n 
yo
u 
m
ay
 a
lre
ad
y 
ha
ve
. A
rr
an
ge
m
en
ts
 w
ill
 th
en
 b
e 
m
ad
e 
fo
r 
yo
u 
to
 h
av
e 
bl
oo
d 
te
st
s 
ca
rr
ie
d 
ou
t a
ga
in
 
ov
er
 th
e 
ne
xt
 fe
w
 m
on
th
s 
in
 c
as
e 
yo
u 
ha
ve
 b
ec
om
e 
in
fe
ct
ed
 a
s 
a 
re
su
lt 
of
 th
is
 
se
xu
al
 e
xp
os
ur
e.
 Y
ou
 w
ill
 th
en
 b
e 
re
fe
rr
ed
 
fo
r f
ol
lo
w
-u
p 
to
 th
e 
ne
ar
es
t S
ex
ua
lly
 
Tr
an
sm
itt
ed
 In
fe
ct
io
n 
(S
TI
)/
 G
en
ito
ur
in
ar
y 
M
ed
ic
in
e 
(G
U
M
) o
r I
nf
ec
tio
us
 D
is
ea
se
 (I
D
) 
C
lin
ic
 w
he
re
 y
ou
 w
ill
 b
e 
te
st
ed
 fo
r o
th
er
 
se
xu
al
ly
 tr
an
sm
itt
ed
 in
fe
ct
io
ns
. 
If 
yo
u 
ha
ve
 b
ee
n 
se
xu
al
ly
 a
ss
au
lte
d 
an
d 
it 
ha
s 
be
en
 re
po
rt
ed
 to
 
th
e 
G
ar
da
i, 
yo
u 
w
ill
 b
e 
re
fe
rr
ed
 to
 th
e 
ne
ar
es
t S
ex
ua
l A
ss
au
lt 
Tr
ea
tm
en
t U
ni
t (
SA
TU
) f
or
 tr
ea
tm
en
t. 
A
m
 I 
at
 ri
sk
 o
f a
n 
in
fe
ct
io
n?
 
Fo
llo
w
in
g 
an
 a
ss
es
sm
en
t a
nd
 d
ep
en
di
ng
 
on
 y
ou
r t
yp
e 
of
 s
ex
ua
l e
xp
os
ur
e,
 y
ou
 m
ay
 b
e 
at
 ri
sk
 o
f g
et
tin
g 
so
m
e 
se
xu
al
ly
 tr
an
sm
itt
ed
 
in
fe
ct
io
ns
, f
or
 e
xa
m
pl
e,
 c
hl
am
yd
ia
, s
yp
hi
lis
 
an
d 
go
no
rr
ho
ea
. Y
ou
 m
ay
 a
ls
o 
be
 a
t r
is
k 
fo
r 
bl
oo
db
or
ne
 v
iru
se
s,
 s
uc
h 
as
: h
ep
at
iti
s 
B
, 
he
pa
tit
is
 C
 a
nd
 H
iV
. 
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Private and Confidential 
Date: 
Dear Dr. , 
Re: name; address
DoB: 
Re:  Follow-up for Significant Blood /Body Fluid Exposure
the above named person was involved in a reported blood and/or body fluid exposure incident on 
___________ and attended at this service on _____________. 
this person was the: Source/Recipient of the injury (delete as appropriate).
Relevant patient clinical information attached (tick box as appropriate): 
o  If Recipient - copy of the patient management form detailing the assessment and management of 
the recipient at this service.
o  If Source - copy of the source individual’s blood test reports.
in addition, i wish to confirm the following (tick box as appropriate):
o  Patient’s GP informed
o  infectious diseases notification to Director of Public Health/MoH completed
o other __________________________________________________________________
Please do not hesitate to contact this service should you have further queries or concerns.
Yours sincerely,
Referral letter to Infectious Diseases Consultant
A downloadable version of this letter can be found at www.emitoolkit.ie
t
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Referral letter to GP or Occupational Health Department 
Private and Confidential 
Date: 
Dear Dr. , 
Re: name; address
DoB: 
Re: Follow-up for Blood /Body Fluid Exposure incident
the above named patient/employee of your organisation was involved in a reported blood and/or body 
fluid exposure incident on ___________ and attended at this service on _____________. this person was the 
recipient of the injury.
the exposure incident was considered to be:
o  Not significant
o  Significant
Please find attached a copy of the patient management form detailing their assessment and 
management at this service. 
Follow-up required - 
o  complete the course of hepatitis B vaccination and test for hepatitis B surface antibody 8 weeks after 
completion of the course of vaccination.
o  carry out a hepatitis B surface antibody test 8 weeks from today’s date.
o  wound dressing.
In addition, I wish to confirm the following – 
o  Referred to infectious Disease Service at _____________________________
o  infectious Diseases notification to Director of Public Health completed
o  other _________________________________________________________________
thank you for your cooperation in this matter and do not hesitate to contact this service should you have 
any queries or concerns.
Yours sincerely,
A downloadable version of this letter can be found at www.emitoolkit.ie
t
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Sexually Transmitted Infection/Genitourinary 
Medicine Clinics
Youth Health Service,
73 Shandon Street,
Cork City.
tel: 021-4220490/1
GMHS,
Baggot Street Clinic, 
19 Haddington Road,
Dublin 4.
tel: 01 6699553 
GUiDE Clinic,
St James’s Hospital,
James’s Street,
Dublin 8.
tel: 01 4162315/6 
Mater Hospital,
Eccles Street,
Dublin 7.
tel:  01 8032063 
louth County Hospital,
Dublin Road,
Dundalk.
tel: 086 8241847 
Waterford Regional Hospital,
Sti clinic,
Waterford.
tel: 051 842646 
South tipperary General Hospital,
Clonmel,
Co tipperary.
tel: 051 842 646  
Carlow District Hospital,
Sti clinic,
Athy Road,
Carlow.
tel: 051 842 646 
South infirmary Victoria University Hospital,
GUM clinic,
old Blackrock Road,
Cork. 
tel: 021 4966844 
Useful contact information
Health and Safety Authority
the Metropolitan Building
James Joyce Street
Dublin 1
tel: 1890 289 389
National Virus Reference Lab
UCD National Virus Reference 
laboratory 
University College Dublin 
Belfield 
Dublin 4
tel: 01 7164401
Consultants in Infectious Diseases/Genitourinary 
Medicine
Dr Busi Mooka
Mid West Regional Hospital
limerick
tel: 061 301111
Dr Catherine Fleming
University College Hospital
Newcastle
Galway
tel: 091544544
Professor Mary Horgan, 
Dr Arthur Jackson
Cork University Hospital
Wilton
Co Cork
tel: 021 454 6400
Dr Susie Clarke, 
Dr Fiona lyons, 
Prof Colm Bergin, 
Prof Fiona Mulcahy
St James’s Hospital GUiDE Dept 
James’s St 
Dublin 8
tel: 01 4162315, 01 4162316
Dr Jack lambert, 
Dr Paddy Mallon, 
Dr Gerard Sheehan
Mater Misericordiae University Hospital,
Eccles Street,
Dublin 7
tel: 01 803 2000
Professor Sam McConkey
Beaumont Hospital
Dublin 9
tel: 809 3000
Paediatric Infectious Diseases
Professor karina Butler
our lady’s Children’s Hospital
Crumlin
Dublin 12
tel: 4096100
Dr Paddy Gavin
Children’s University Hospital
temple Street
Dublin 1
tel: 8784200
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Sexually Transmitted Infection/Genitourinary 
Medicine Clinics (Continued) 
Regional Hospital,
tralee,
Co kerry.
tel: 021 4966844 
Mid Western Regional Hospital,
Sti clinic,
Dooradoyle,
limerick.
tel: 061 482382 
General Hospital,
Nenagh,
Co tipperary.
tel: 061 482382 
Ennis General Hospital,
Ennis,
Co Clare.
tel: 061 482382 
Mayo General Hospital,
Castlebar,
Co Mayo.
tel: 094 9021733 (Extn 3501) 
University Hospital Galway,
Merlin Park,
Galway. 
tel: 091 525200 
Portiuncula Hospital,
Ballinasloe,
Co Galway.
tel: 090 9648372 (Extn 676) 
Sligo General Hospital,
the Mall,
Sligo.
tel: 071 9170473 
letterkenny General Hospital,
GUiDE clinic,
letterkenny,
Co Donegal.
tel: 074 912 3715  
St Fintans Hospital,
Dublin Road,
Portlaoise.
tel: 057 936 0134 
Monaghan General Hospital,
Monaghan,
Co Monaghan.
tel: 0868241847
Sexual Assault Treatment Units (SATUs)
Dublin
Rotunda Hospital, 
Parnell Square, 
Dublin 1
01 817 1736 SAtU@rotunda.ie
out of hours: 
Phone hospital 01 8171700 ask for SAtU
Waterford
Waterford Regional Hospital, 
Dunmore Road, 
Waterford
051 84215 wrh.satu@hse.ie 
out of hours: 
Phone Hospital 051 848000 Nurse Manager on duty 
for hospital
Cork
South infirmary Victoria University Hospital (SiVUH) 
old Blackrock Rd., 
Cork.
021 4926297 
satu@sivuh.ie
out of hours: 
Phone Hospital 021 4926100 Nurse Manager on duty 
for hospital
Mullingar
Midland Regional Hospital, 
Mullingar, 
Co. Westmeath
044 9394239 /086 0409952
satu.mrhm@hse.ie
out of hours: 
Phone Hospital 044 9340221 Nurse Manager on duty 
for Hospital
Galway
Hazelwood House, 
Parkmore Rd., 
Galway
091 765751 / 087 6338118
satugalway.hsewest@hse.ie
out of hours: 
Phone 091757631 Nurse Manager on duty for Merlin 
Park Hospital
Donegal
letterkenny General Hospital 
NoWDoC Premises, 
oldtown, 
letterkenny, 
Co. Donegal
074 9104436 Bleep 777 
087 0664593 /087 0681964 
satu.letterkenny@hse.ie
out of hours: 
Phone Hospital 074 9125888 Nurse Manager on duty 
in the Emergency Dept
t
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Departments of Public Health
HSE East
Dr Steeven’s Hospital
Dublin 8
tel: 01 6352145
HSE Midlands
Area office,
Arden Road,
tullamore
Co. offaly
tel: 057 9359891
HSE North-East
Railway Street,
Navan,
Co Meath
tel: 046 9076412
HSE West
Finance Building,
Merlin Park,
Galway
tel: 091 775200
HSE North-West
iona House,
Upper Main Street,
Ballyshannon,
Co. Donegal
tel: 071 9852900
HSE South
Floor 2, Block 8,
St Finbarr’s Hospital,
Douglas Road
Cork
tel: 021 4927601
HSE South-East
HSE offices,
lacken,
Dublin Road,
kilkenny
tel: 056 7784124
HSE Mid-West
Mount kennett House,
Henry Street,
limerick
tel: 061 483337
t
o
o
l
k
it
t
o
o
l
k
it
www.emitoolkit.ie
Health Protection Surveillance Centre
25-27 Middle Gardiner Street  Dublin 1  Ireland
Tel +353 1 876 5300  Fax +353 1 856 1299  
Email hpsc@hse.ie  www.hpsc.ie
This report is also available to download  at www.emitoolkit.com
ISBN 978-0-9565622-2-7
